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 Significant evidence credentialing epigenetic changes as important 
drivers of cancer has surfaced. As a consequence, there is growing 
interest to find inhibitors to modulate the epigenome. Current FDA 
approved medications target either the DNA methylation writer protein 
DNMT1, or histone acetylation eraser protein family (HDAC). A 
longstanding interest in our lab is characterization of the 5-
methylcytosine DNA methylation (meDNA) reader protein Methyl Binding 
Domain 2 (MBD2), a member of the MBD family and Mi-2 NuRD 
repression complex. Previous reports credential MBD2 as a viable cancer 
therapeutic target in animal and cell line models. In this thesis I describe 
efforts to find small molecule inhibitors of this epigenetic target. 
 We first characterized the biochemical parameters that can affect 
MBD2 binding and selectivity for methylated DNA in vitro, determining 
salt and pH substantially contribute to the affinity and selectivity of the 
interaction. To prepare for structure aided design we crystallized the 
native and selenomethionine modified methyl binding domain 
polypeptides of MBD2 interacting with DNA. Crystals provided data to 
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~2.4Å resolution. Work is underway to complete refinement and solve the 
MBD2-MBD structure. 
 With optimal conditions we tested TR-FRET and fluorescence 
polarization high throughput screening (HTS) assays to find inhibitors of 
the MBD2-meDNA interaction. Ultimately we chose TR-FRET, with Z’ 
factors >0.7 in 384 well plates. Pilot screening with the LOPAC1280™ 
library yielded an unexpected hit, NF449, which bound MBD2 in a dose 
dependent manner by isothermal calorimetry (ITC), with Ki in the 
nanomolar range.  
 In collaboration with Scripps Florida investigators, we applied our 
HTS TR-FRET assay to the NCI-MLPCN library comprising 376,276 
compounds. Follow-up and counter-screens identified 18 MBD2 specific 
small molecules with IC50’s from 1-17µM. We applied these to a TR FRET 
assay with multiple DNA methylation reader proteins to assess 
specificity. RNA expression of cancer cell lines treated with compound 
identified two which relieve DNA methylation mediated epigenetic 
promoter repression. An intercalator competition assay and ITC 
experiment confirmed that both bind DNA, independent of methylation 
status. ChIP experiments suggested that they alter chromatin to form a 
more open state at epigenetically repressed promoters. 
 In summary we will soon solve a high resolution structure of 
MBD2-MBD bound to DNA. We also identified at least one small 
molecule which binds to MBD2 and disrupts the MBD2-meDNA 
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interaction. Two other compounds interact with DNA and somewhat 
selectively disrupt DNA methylation mediated epigenetic repression. 
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 The term epigenetics derived from the word “epigenesist,” first 
coined by Conrad Waddington in 1942. While Waddington was ahead of 
his time in his thinking on the topic, the coming decades have seen 
significant research on the levels of regulation of the genome beyond the 
genetic sequence (1, 2). This seminal leap in our thinking has drastically 
altered the way we think about genomic organization. While genetics 
provide a stable means of passing on important biological information, 
epigenetics affords cells a way to inherit important genomic information 
while remaining alterable to allow flexibility to an ever changing 
environment. Progress towards understanding these marks has only 
recently reached its full potential, as the plasticity described above 
creates a difficult “moving target” to try and research. While there are 
numerous epigenetic processes, the two best understood mechanisms 
are histone modifications and DNA methylation. I will consider these two 
mechanisms in this introduction to provide some context for the 
experiments performed in this thesis. 
 While the details surrounding the specific contributions of these 
epigenetic marks to cancer remain somewhat clouded, their importance 
for promoting cancer initiation and progression is incontrovertible(3). The 
relevance of epigenetics to cancer should not come as a surprise. 
Plasticity is inherently required for differentiation and development, as a 
single totipotent cell serves as the starting point for an entire 
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organism(4). The benefit for a cancer to hijack this pathway, to force 
dedifferentiation and uncontrolled growth, is very logical. The best 
evidence for this observation comes from monozygotic twin studies. 
Identical twins, by definition, share the same constitutional genetic 
sequence. In the extreme scenario, where genetic inheritance of defective 
genes is the sole cause of cancer, nearly 100% of identical twins should 
show concordance for developing the cancer. In reality this is not the 
case for almost any cancer; studies comparing concordance rates 
between mono- and di-zygotic twins have estimated that inherited 
genetic factors underlie approximately 20-50% of the pathogenesis of 
human cancers, but vary widely depending on the disease(5-10). The 
remaining risk is likely due to environmental factors, which can 
influence epigenetic processes. With such a large fraction of total risk 
potentially comprised of epigenetic changes it is unsurprising that this 
field has seen renewed interest in recent reports.  
 
Histone Modifications as an Epigenetic Control Mechanism 
 The first description of histone modifications appeared in 1964 in a 
paper defining the presence of methylated lysines on histone tails(11). A 
series of articles describing acetylation and phosphorylation marks, also 
on lysine, quickly followed (12, 13). Since their announcement, the 
importance of histone changes for normal and malignant processes has 
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been shown repeatedly(3, 14, 15). Despite significant progress new 
modifications are frequently reported. 
 The most basic unit of chromatin organization is the nucleosome, a 
complex comprised of four paired histone subunits (H1, H2A, H3 and 
H4)(16). 147 base pairs of DNA wrap around each nucleosome, providing 
the cell with a means of both compaction and transcription control(16). 
By marking the histone tails, which serve as a sort of flag, regions of the 
genome are labeled for dense compaction with limited access and 
expression (heterochromatin) or loose compaction for easy access of 
transcription factors (euchromatin)(17). Cancers often corrupt writer and 
eraser proteins which alters these marks, forcing the genomic landscape 
near tumor suppressors to form heterochromatin establish euchromatin 
at the regulatory regions of pro-oncogenic genes(18). These changes drive 
un-policed proliferation and dedifferentiation, both hallmarks of 
cancer(18).  
 A significant effort towards finding therapies to prevent this 
commandeering, or reverse the inappropriate histone changes has 
occurred(19). To date only 2 histone directed medications have gained 
FDA approval, and both target the eraser class of proteins known as 
histone deacetylases (HDAC)(20, 21). While these drugs clearly benefit 
patients with some human malignancies such as cutaneous T-cell 
lymphomas, a significant amount of work remains to find better and 
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more widely applicable small molecules. HDAC inhibitors and their use 
are described in more detail in chapters 3 and 4. 
 
DNA Methylation Alterations 
 The second key epigenetic mechanisms to control gene expression 
is DNA methylation(15). The first description of DNA methylation in 
eukaryotic cells appeared just prior to the discovery of histone 
modifications in the 1950’s(1,22,23). This epigenetic mark occurs at the 
5-position of cytosines (5meC), located in a CpG dinucleotide pair(1). The 
application of the mark is the responsibility of a family of DNA writer 
proteins referred to as the DNA methyltransferases (see below) and 
requires both ATP for energy and S-adenosyl-methionine (SAM) as a 
methyl donor(1). Increased frequency of the CpG sequence is often found 
at gene promoters and regulatory sequences(24). These enriched areas 
are referred to as CpG islands, and their dense methylation leads to 
heterochromatin through the actions of methylation reader proteins (see 
below)(24).  
 Histone and DNA methylation modifications are tightly linked. One 
mechanism of epigenetic inheritance from parent to daughter cells 
suggests that 5meC modifications are more “permanent,” because they 
are found at regions where heterochromatin is maintained for a longer 
period of time (25). In contrast, histone modifications are considered 
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malleable as they can be quickly removed by known enzymes(26). Recent 
models question this assumption, though, suggesting DNA methylation 
may also exhibit relatively rapid cycling under specific cell conditions 
(27). Ultimately we believe the interplay between three classes of 
proteins: readers, writers, and erasers, governs the lifecycle of DNA 
methylation and histone marks. Since the focus of this thesis is DNA 
methylation changes we will describe the readers, writers and erasers for 
this modification below, and leave the discussion of histone modifications 
for another venue. 
 
Writers of 5-Methylcytosine on DNA 
 DNA methylation writers are collectively known as the DNA 
methyltransferases (DNMTs). There are three established members, all 
capable of catalytically methylating DNA: DNMT1, DNMT3a and 
DNMT3b(28). Two other proteins share homology but lack enzymatic 
function:  DNMT2, shown to be essential for aspartate tRNA methylation 
(29), and DNMT3L, an essential DNA methylation mediator discussed 
later.  
 DNMT1 is referred to as the maintenance DNA methyltransferase. 
This protein associates with the replication fork and the histone protein 
modifier G9A and assists with maintaining the pattern of methylation to 
daughter stand DNA(30). During semi-conservative DNA replication, 
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newly replicated DNA is initially hemi-methylated immediately following 
replication, where the original strand is methylated but the newly created 
strand is not. DNMT1 converts the hemi-methylated CpG dinucleotide to 
fully methylated, thus maintaining the epigenetic information(30).  
Detailed crystallography research elucidated the enzymatic mechanism 
of DNMT1(31): The CXXC-BAH1 linker region is responsible for the 
preference of DNMT1 for hemi-methylated(31). When bound to an 
unmethylated oligonucleotide, the linker is positioned at the 5-carbon of 
the unmethylated cytosine in the active site, which sterically hinders 
enzymatic function (31, 32).  If the oligonucleotide is hemi-methylated, 
the linker cannot insert into the active site and the cytosine is optimally 
positioned for methylation.  
 Due to the essential function of DNMT1, a number of studies have 
verified its benefit as a therapeutic target. Knockout of DNMT1 in mouse 
embryonic stem cells shows a 3 fold reduction in methylation levels, 
While a Dnmt1-/- genotype in a mouse is embryonic lethal (33), mice with 
hypomorphic DNMT1 alleles display protection against intestinal 
tumorigenesis, without showing severe developmental abnormalities (33). 
This suggests that the enzyme is essential for development, but that 
some residual activity may be sufficient to sustain these developmental 
processes. Murine embryonic stem cells lacking DNMT1 contain a large 
number of hemi-methylated genomic regions (34). This suggests that 
even in the presence of other DNMTs, DNMT1 is required to convert 
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hemi-methylated DNA into a fully methylated state(35). From a targeting 
perspective, inhibiting DNMT1 can be effective for inhibition of cancer 
cell growth, but also can have toxicity to cells that proliferate and require 
maintenance of DNA methylation. 
 DNMT3a and DNMT3b are responsible for de novo DNA 
methylation, actively converting unmethylated DNA into hemi-methylated 
DNA in vivo(28). Each is expressed in a number of alternatively spliced 
constructs, but the role of each alternate construct remains to be fully 
understood (36, 37). Despite their difference in size, each DNMT3 writer 
contains a homologous C-terminal methyltransferase domain(36). 
Attempts to create DNMT3 knockout mice showed similar results as 
DNMT1: the Dnmt3a-/- genotype is lethal during the early stages of 
postnatal development (28), while Dnmt3b-/- mice are embryonic lethal, 
at a similar stage as DNMT1-/- knockouts (28). In both cases, 
significantly lower levels of genomic methylation are seen (28). Dnmt3b 
mutations have also been associated with a known human syndrome 
called immunodeficiency, centromeric instability, facial anomalies or ICF 
(28). The severe phenotypes accompanying these diseases suggest that 
targeting DNMT3’s could lead to significant toxicity. As discussed later, 
there are indeed dose limiting toxicities when using current DNMT 
inhibitors.  
DNA methyltransferase 3-like protein (DNMT3L) lacks the catalytic 
domain of other DNMT3 family members, and is structurally distinct 
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from DNMT3a and 3b despite sharing significant sequence homology(38). 
DNMT3L interacts directly with DNMT3a and unmethylated histone 
H3K4 tails via its ATRX-DNMT3-DNMT3L (ADD) domain, forming a 
tetramer of two DNMT3A molecules each bordered by one DNMT3L (38, 
39). The current functional model proposes that DNMT3L binds 
unmodified H3K4 and recruits two DNMT3A proteins which are 
positioned approximately one helical turn apart on DNA (40, 41). 
Furthermore, this reported 3L-3a-3a-3L tetramer was observed in long 
nucleoprotein filaments when combined with DNA, suggesting a 
mechanism for rapid de novo methylation(41, 42). This mechanism is 
supported by biophysical studies which show combining DNMT3L and 
DNMT3 enzymes improves de novo methylation activity up to 20 fold over 
the enzymes alone in vitro(43). This observation supports previous 
studies that DNMT3’s are most important during differentiation and 
rapid cell growth, events that occur during development. (44). 
DNMT3L is highly expressed throughout embryogenesis, where its 
expression mirrors that of DMNT3a/b and accompanies the rapid 
increase in genomic methylation observed at key steps during 
development(45). Dnmt3L-/- female mice have no specific phenotype, but 
their progeny are almost all lost during gestation, even when crossed 
with a wild type male(46). Male Dnmt3L-/- mice are sterile but otherwise 
asymptomatic(46). Interspecies conservation suggests that only animals 
with maternal imprinting patterns have a strongly conserved DNMT3L 
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sequence, suggesting that it is involved in maintaining imprinting 
patterns(40). While inhibiting DNMT3L would most likely not halt de 
novo methylation, it could lead to inefficient methyltransferase activity. 
Presumably, this would alter genomic regions that are difficult to 
methylate most effectively.  
 
DNA Readers 
5-methylcystosine marks are recognized by three major families: 
SRA domain-containing proteins, zinc finger and BTB-containing (ZBTB) 
proteins, and methyl CpG binding domain (MBD)-containing proteins 
(47). The MBD family contains seven members: MBD1, MBD2, MBD3, 
MBD4, MBD5, MBD6 and MeCP2(48). The existence of methylated-DNA 
binding proteins was first published in 1989, and followed by 
identification of the first family member, methyl CpG binding protein 2 
(MeCP2), in 1992 (49, 50). All family members contain a conserved 
methyl binding domain; despite this, it is believed that three members, 
MBD3, MBD5 and MBD6, are not involved in binding methylated DNA, 
but may be associated with various repression complexes(51). 
After identification, MeCP2 was shown to interact with Sin3A and 
indirectly with HDAC1 and HDAC2 through other complex members to 
coordinate a repressed chromatin state in the vicinity of the DNA 
methylation marks(52). This landmark discovery was the first to describe 
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a DNA methylation “reader” mechanism connecting DNA methylation and 
gene repression. MeCP2 is minimally expressed in development but is 
prevalent as cells differentiate, with expression changing concomitant 
with rising global methylation levels(53). This expression pattern is a 
common theme among proteins associated with DNA methylation, 
including DNMTs and other MBD family members. The rise of 5-
methylcytosine marks in differentiated cells requires a critical amount of 
epigenetic machinery to functionally suppress gene expression(54). 
Mutations or loss of MeCP2 in human males is lethal, and in 
females confers a particularly severe neurological disease known as Rett 
Syndrome(55). This syndrome typically presents around age 2, and leads 
to significant muscle ataxia and atrophy with growth and learning 
delays(55). Mice with Mecp2 null mutations appear to develop normally 
but after 6 weeks of age begin to display significant neurological 
deficiencies and retarded development, similar to Rett patients (56). This 
phenotype is not salvageable with increased MeCP1 levels, and is 
recapitulated in a conditional knockout of neural tissue (56). The severe 
side effects associated with MeCP2 disruption may have contributed to 
the very limited work done to find relevant inhibitors.  
MBD1 was identified as the second methyl binding domain family 
member and was initially called Protein Containing MBD 1 (PCM1) (57). 
Its detection came using a new technology at the time, online homology 
searching using EST tags, and was subsequently purified and shown to 
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cause a super shift of the MeCP1 complex when bound by an antibody 
(57). Despite initial experiments suggesting MBD1 as a member of the 
MeCP1 complex, it is now established as associating with SETDB1, 
Suv39h1 and HP1 to cause chromatin alterations and gene silencing 
independent of this complex(58).  
In addition to MBD and transcription repression domains, MBD1 
contains three CXXC zinc finger domains that are thought to bind 
specific DNA sequences(59). A brief BLAST search of these domains 
showed that two have sequences with slight alterations to the canonical 
CXXC domains found in proteins like MLL and DNMT1, but the third 
domain is almost identical and can bind unmethylated DNA(59). Further 
work suggested that it is also responsible for decreasing transcription at 
unmethylated promoter regions, an attribute no other MBD family 
member boasts(60). MBD1 may therefore repress expression using both 
epigenetic and non-epigenetic reader mechanisms. Practically, however, 
it is unclear if MBD1 uses both domains together or at all. Mbd1-/- mice 
are fertile and developmentally normal, suggesting that it is not 
absolutely required for normal cellular function and could have limited 
side effect toxicity if targeted for therapy. 
MBD2 is another DNA methylation reader protein critical for 
epigenetic repression(51). It was discovered in 1998 by Bird et al through 
homology searching and established as the third MBD family 
member(51). This ~50kDa protein is a member of the MeCP1 complex, 
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also referred to as the Mi-2/NuRD complex, where it is responsible for 
reading DNA methylation and transmitting its repressive signal to 
histone modifying proteins to form heterochromatin(61, 62).  In vitro 
binding data suggests that MBD2 in isolation is capable of binding a 
single fully methylated CpG, suggesting that its binding specificity is 
inferred from other proteins in the complex (63). MBD2 preferably binds 
fully methylated CpG’s over hemi-methylated dinucleotides and recruits 
Mi-2/NuRD complex and associated histone deacetylases HDAC1 and 
HDAC2(61). It is thought that the signaling of both MeCP2 and MBD2 
reader proteins occurs through ordering of the MBD protein structure 
upon identification of a methylated substrate((64), and Wyhs et al 
unpublished data). In solution, reader proteins sample multiple 
conformations and are relatively unorganized. Upon recognition of a 
methylated cytosine substrate, they assume a more ordered and rigid 
position, which allows MeCP1 complex members to organize in a 
conformation that promotes optimal HDAC activity for subsequent 
histone deacetylation, heterochromatin formation and gene silencing(64). 
Similar to MeCP2 and MBD1, MBD2 is not expressed in embryonic stem 
cells, but can be found in increasing abundance as the embryo 
differentiates during development(65, 66). Mbd2-/- mice are healthy and 
fertile, and no known human syndrome exists for MBD2 mutations(66). 
This suggests that targeting MBD2 for cancer therapy may have an 
attractive toxicity profile (66, 67). Apcmin/+ mice carrying homozygous 
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disruption of MBD2 alleles develop significantly fewer tumors and have 
increased survival compared to Apcmin/+ mice with wild type MBD2 
alleles(67). This suggests that targeting MBD2 with small molecules 
could be beneficial in the setting of familial adenomatous polyposis, or 
even for prevention or treatment of other neoplasms. 
Unlike MeCP2, which is a relatively small complex with only a few 
proteins, MeCP1 is quite large with at least 18 known proteins 
encompassing about 1MDa of weight (68). Optimal binding conditions for 
MeCP1 exist when multiple CpG’s are methylated in the same area, such 
as a CpG island at a promoter region (49). This is different from MeCP2, 
which is able to identify a single methylated CpG dinucleotide as 
effectively isolated as it can with its complex members (69). 
Though it contains a methyl CpG binding domain, MBD3 is unable 
to interact with methylated substrates due to a substitution of 
phenylalanine for tyrosine at the 23rd residue(70, 71). X-ray 
crystallography structures of MeCP2 and NMR structures of MBD1 and 
MBD2 suggest that this residue provides a critical water-mediated 
contact necessary for identification of methyl-cytosine(72, 73). The loss of 
a hydroxyl group at this residue suggested that MBD3 may instead bind 
hydroxymethylcytosine, but this theory has not been substantiated(74). 
Although MBD3 does not bind methylated DNA, Mbd3-/- mice are 




The endonuclease MBD4 protects the genome against spontaneous 
methyl cytosine deamination, which converts the base into 
thymidine(75). Spontaneous hydrolytic deamination occurs at the rate of 
approximately 5.8x10-13 s-1, or if one assumes 1% of the genome is 5-
methylcytosine, about 2-3 deaminations per day per cell(76). If left 
unchecked, a cell would lose not only its methylation status but be 
unable to tell which thymidine bases were once 5-methylcytosine. Such 
substitution mutations could be disastrous if left unchecked. MBD4 
preferentially binds to T-G mispairs and utilizes a c-terminal thymine 
DNA glycosylase domain to remove the inappropriate thymine base pair; 
this allows normal cell DNA repair machinery to replace it with a cytosine 
via its interactions with MLH1(77, 78). DNMT1 can then re-methylate the 
new cytosine to maintain epigenetic fidelity. In vivo modeling with Mbd4-
/- mice have a threefold increase in the rate of C to T transversions, but 
show only mild phenotypic changes during development(79). When 
Mbd4-/- mice are crossed to the spontaneous intestinal tumor model 
ApcMin/+ offspring actually show an increased tumor burden and a higher 
number of mutations per gastrointestinal cell for both tumor and normal 
tissue(79). While MBD4 does not seem to interact with methylated DNA 
like MBD2 and MeCP2, it has a clear role in maintaining DNA 
methylation and DNA sequence fidelity. 
 Similar to MBD3, MBD5 and MBD6, the two newest members of 
the MBD family, do not interact with methylated DNA (48). The MBD for 
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these proteins contains an intron dividing it in half(48). This leads to a 
nine residue deletion upstream from a beta sheet that is involved with 
methylcytosine binding in other family members. This intronic insertion, 
along with two residue alterations in another critical region of the methyl 
CpG binding domain, likely contribute to the inability of MBD5 and 
MBD6 to bind methylated DNA in vitro and in vivo (48, 80). There are no 
mouse knockout studies of MBD5 to date, but its mutations are 
associated with human neurological diseases, including seizures and 
autism (81). Similarly, MBD6 directly interacts with ATXN1L, a protein 
that has been associated with the neurological disorder spinocerebellar 
ataxia type 1(48). A good deal of work remains to decipher the purpose 
and mechanism of MBD5 and MBD6. 
 Separate from the MBD family there is another well-studied DNA 
methylation mediator: Ubiquitin-like containing PHD and RING finger 
domains 1 (UHRF1)(82). It is a multi-domain protein that interacts with 
both histone tails and methylated DNA. It contains a Tandom Tudor (TT) 
domain, shown to interact with the histone H3 in various states of 
modification (83), a Set and RING-finger Associated (SRA) domain that 
has been crystalized with a hemi-methylated DNA oligonucleotide (83), 
and a Really Interesting New Gene (RING) domain that acts as an E3 
ubiquitin ligase, having been shown to ubiquitylate DNMT1 and, 
interestingly, histone H3K23, which is thought to be necessary to 
complete DNA methylation maintenance (82, 84). UHRF1 co-localizes 
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with the replication fork complex, binding nascent hemimethylated DNA 
arising during semiconservative replication(82, 85). The affinity of UHRF1 
for hemi-methylated DNA is thought to trigger H3K23 ubiquitination, 
which then increases the affinity for DNMT1 to complex with UHRF1, 
recruiting the maintenance methylase to fully methylate the DNA (84). 
Uhrf1-/- mice are embryonic lethal at gestation day 9.5. 
  
DNA Methylation Erasers 
 Significant research into locating the erasers of DNA methylation 
has taken place over the last 5-10 years. Despite a plethora of work little 
direct evidence has surfaced. The leading theory, supported by a number 
of reports, is conversion of methyl groups to hydroxymethylcytosine, 
formylcytosine, and carboxycytosine by the TET family enzymes, and 
subsequent removal of these oxidized forms of methylcytosine by the 
nucleotide excision repair machinery(86). An excellent review on this 




 Despite evidence that DNA methylation reader proteins could act 
as effective therapeutic targets no substantial effort has been reported. 
For a number of years our lab has focused on characterization and 
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targeting of the MBD2 reader protein. Previous students focused on cell 
based screens with some success. While evaluation of these compounds 
continues to yield fruitful avenues, I chose to approach this question 
from a biochemical standpoint. During the course of my thesis work, 
described here, I design and implement a high throughput screen to 
discover small molecule inhibitors that prevent MBD2 from interacting 
with methylated DNA. Ultimately I identified two classes of inhibitors, 
one which binds MBD2 and another which binds DNA but causes 
somewhat selective chromatin changes only at methylated promoters. In 
the final chapter I spend some time discussing use of the MBD2 protein 
as a tool to precipitate genomic methylated DNA coupled with next 
generation sequencing to analyze the prostate cancer methylome. The 










Biophysical Characterization and Structural Analysis of the Methyl 






 The biophysics behind the interaction of MBD family members, 
including MBD2, and methylated DNA is not completely understood. 
Recent advances in the NMR solution structures of the methyl binding 
domains for MBD1, MBD2, and MeCP2 as well as the crystal structure of 
MeCP2-MBD and MBD4-MBD help our understanding of this 
complicated binding event. These studies support the hypothesis that 
organized water molecules, through hydrogen bonding interactions with 
as few as 2-3 residues, ultimately mediate the identification of the 
methylated cytosine on DNA. We investigated the binding specificity and 
sensitivity of the MBD2-MBD protein and determine a high resolution 
structure with x-ray crystallography. 
 Comparison of the binding sensitivity and specificity of eukaryotic 
(insect) versus bacterial recombinant MBD2-MBD protein indicated that 
the insect cell version was slightly more sensitive and selective. Using a 
fluorescence polarization based binding assay we tested numerous buffer 
conditions in vitro and found that altering salt concentrations above 
150mM decreased sensitivity, while going below 100mM decreased 
specificity. Similarly, lowering the pH led to loss of specificity, while 
higher pH led to loss of sensitivity. We combined these results to discern 
an optimal buffer for designing a high throughout assay for identification 
of small molecule inhibitors of MBD2 (chapter 3-4), and for utilizing this 
protein as a tool for methylated DNA isolation (chapter 5). 
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 We continued our work with MBD2-MBD and successfully formed 
stable crystals in complex with methylated DNA in 1.4M citrate pH 6.5. 
X-ray diffraction data were collected to ~2.4Å resolution. Molecular 
replacement failed to provide a suitable solution for phasing, and 
numerous experimental techniques were employed. Two 
selenomethionine proteins were successfully crystallized, MBD2-MBD-
R195M and MBD2-MBD-L193M, and SAD data were collected for each. 3 
selenomethionine sites were found with the L193M construct and overlay 
of the MeCP2-MBD solution with preliminary electron density maps 
suggests that protein and DNA are present. In collaboration with the lab 
of Dr. Dan Leahy, refinement and modeling is ongoing towards finding a 





 As discussed in the introduction MBD2 was discovered by Bird et 
al in 1998 through homology searches after characterization of MeCP2 
and MBD1(51). This initial report established the basic framework 
behind the biophysics of MBD2 and the MBD protein family and how 
they physically interact with methylated DNA. The first biophysics 
experiment which demonstrated MBD2 directly interacts with meDNA 
was a gel shift assay in the discovery report: in the presence of protein, 
5-methylcytosine labeled DNA shifted upward to a higher molecular 
weight (51). This was corroborated by immunofluorescence (IF) showing 
MBD2 labeled with green fluorescent protein (GFP) co-localizing to major 
satellite repeat regions known to be highly methylated in embryonic stem 
cells (51). The result led to a number of avenues of research including 
structure, the kinetics of binding, and specificity of binding related to 
DNA. Since the late 1990’s a number of publications answer some of 
these questions and we will discuss them here. 
 A bit of controversy surrounds the details for MBD2 binding 
sequence specificity and the optimal number of methylated CpG 
dinucleotides required. The initial discovery of the MeCP1 complex, 
which includes MBD2, required 12 CpG pairs for adequate binding (88). 
MeCP2 on the other hand, required only one methylated dinucleotide 
pair for interaction with DNA (88). Work in our lab indicates that when 
MBD2 is isolated from the MeCP1 complex, however, it also recognizes 
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and binds singly methylated CpG sites (63). A number of studies support 
our finding indirectly and corroborate the theory that the specificity of 
MBD2-MBD protein binding is predicated only on the basis of 5-methyl 
CpG content, and not dependent on DNA sequence. In support of this 
idea Jǿrgensen et al demonstrated that by engineering a multi MBD 
domain protein they could drastically improve the sensitivity of protein 
binding to methylated CpG’s without having to mutate the primary 
protein sequence or compromising specificity (89). Whole genome ChIP 
experiments also support this finding with the binding sites of the MBD 
domain containing family members MBD1, MBD2 and MeCP2 enriched 
at highly methylated regions more so than at any other particular 
sequence or modification (90). Interestingly, however, the sites occupied 
between the MBD’s did not overlap perfectly (90). Other reports also 
demonstrate that the different MBD family members cannot replace each 
other at particular genomic loci under all circumstances (91). A review of 
clinical evidence supports this observation: females who have mutated 
MeCP2 genes suffer from a significant neurological disorder known as 
Rett Syndrome despite having normal MBD1 and MBD2 proteins(92). 
Taken together this evidence strongly suggests that there must be a yet 
described specificity provided by either the other members of the various 
repression complexes or the MBD protein itself, and that a stochastic 
model of binding cannot alone explain all of the observations presented 
in the literature.  
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A pair of reports published during the 2000’s provide possible 
answers to this question. In one, the authors demonstrate that while 
MBD2 seems to have no sequence specificity, MeCP2 preferred A-T rich 
sequences adjacent to a methylated cytosine (91). The second reveals 
MBD1 may attain some sequence preference by utilizing a second DNA 
binding domain contained within its protein sequence, a zinc finger 
based CXXC3 domain. This extra CXXC3 domain could help identify 
particular DNA sequences, enhancing its specificity for particular loci in 
the genome(93). Despite these provocative reports, a lot of work remains 
to confirm the results for both MeCP2 and MBD1 and elicit how, if at all, 
MBD2 is targeted to particular locations on the genome. 
 Since the discovery of the MBD family a number of structural 
studies have been reported. The first work describing the mechanism by 
which MBD family members identify methylated cytosines was published 
in 1999. Through careful foot printing experiments using restriction 
enzymes and nucleosomal DNA, Chandler et al established that MeCP2 
utilizes its MBD domain to identify methylated cytosines through the 
major groove (94, 95). They also suggested that the C-terminus makes 
contact with both strands of non-nucleosome bound DNA, providing a 
plausible answer to why the protein only binds symmetrically methylated 
DNA and not single stranded DNA or RNA(95). Two reports later in the 
same year solved the NMR solution structures of the MeCP2 and MBD1 
methyl-CpG-binding domains(96, 97). They corroborate previous findings 
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that the proteins likely identify the modified DNA through its major 
groove. Both domains consist of a cluster of 4 beta sheets and one alpha 
helix. The alpha helix and DNA facing portion of the beta sheets are 
scattered with lysines and arginines, consistent with previous reports 
describing the interaction between the MBD domains and DNA to be 
independent of base sequence, but rather driven by charge interactions 
between the phosphate backbone and protein). The residues on the last 
pair of the beta sheets are predicted to form a hydrophobic pocket 
consisting of a tyrosine and isoleucine (or glutamine in MBD1) along with 
an alanine that could mediate van-der-Waal’s interactions with the 
methylated cytosine located nearby. Unlike many other transcription 
factors that bind to palindromic DNA sequences, MeCP2 and MBD1 do 
not have noticeable symmetry in their secondary or tertiary structures 
(96, 97). Furthermore, neither protein binds as a dimer, further clouding 
the question of how these domains maintain specificity and sensitivity 
alone. Regardless, these initial reports provided many insights into the 
physics of this interaction and helped guide future experiments.  
It was almost a decade later, in 2008, that the first crystal 
structure of an MBD was reported(72). The MeCP2 methyl binding 
domain was solved at 2.5Å resolution complexed with a 20bp 
symmetrically methylated CpG oligo sequence from the BDNF gene 
promoter. The crystal structure very accurately overlaid with the NMR 
model, confirming previous descriptions. Surprisingly, only 3 residues 
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directly interact with DNA bases: asp121, arg111, and arg133(72). 
Asp121, and tyr123 identify the methylated cytosine, the previous via a 
direct hydrogen bond, and the later through water mediated hydrogen 
bond. Mutations of tyr123 to phenylalanine in MeCP2, or the 
homologous tyrosine in MBD1 to Y34F, show significantly lower 
methylated cytosine affinity by gel shift assay (72). Interestingly, in wild 
type (wt) MBD3, previously established as not binding methylated 
cytosine labeled DNA, this tyrosine was already a phenylalanine (70, 71). 
MBD3-F34Y mutations regain the ability to bind 5-methylated CpG 
dinucleotides, confirming the importance of this residue and water in 
mediating this protein DNA contact(71). In MeCP2 R111 and R133 make 
hydrogen bond contact with the symmetric guanine bases associated 
with the methylated cytosines, exposing the mechanism behind the 
dinucleotide symmetry required for this binding interaction(72).  
Despite solving a higher resolution structure for MeCP2-MBD we 
are still unable to provide any context as to why there could be sequence 
specificity outside of the methylated CpG dinucleotide. This strengthens 
the argument that the methyl binding domain proteins themselves, in 
particular MBD2 and MeCP2, may not prefer a specific sequence. 
Another remarkable experiment from this work revealed that the MeCP2-
MBD T158M mutation, found in patients suffering Rett Syndrome, 
significantly lowered the affinity of MeCP2 protein to DNA in a gel shift 
assay. This result lends itself as a possible mechanism for the dramatic 
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phenotype seen in these patients, and validates the MBD domain as a 
possible target for small molecule disruption to interrupt protein 
function. 
The only other MBD x-ray crystallography structure solved to date 
is that of MBD4-MBD(98). As discussed earlier, this protein is critical for 
repairing G/T mismatches that occur as a consequence of deamination 
of a 5 methylated cytosine(77). The structure was solved complexed with 
a symmetrically methylated CpG dinucleotide as well as a meCpG/TpG 
mismatched oligo sequence. The solution shows that the MBD4-MBD 
binding pocket is extremely versatile, utilizing a number of water 
molecules to make critical contacts between the DNA and protein instead 
of direct hydrogen bonding. This allows it to conform to the many 
substrates it interacts with (C/G, T/G, meC/G etc.). Surprisingly this 
protein also binds to hydroxymethylcytosine –guanine dinucleotides, a 
result that should be investigated further. 
 Structural work on MBD2 has not been as fruitful as for MeCP2. A 
solution structure of the chicken MBD2 methyl binding domain bound to 
a methylated p-globin DNA promoter was described in 2011 to about 6Å 
resolution(99). Overlay of the MBDs between the MBD2 and MBD1 
solution and MeCP2 crystal structure support their high level of 
homology, with only minor differences noted. For example the critical 
tyrosine 34, required for methylated cytosine binding in MBD1 (Y123 in 
MeCP2), is slightly closer in MBD2, potentially allowing it to make a 
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direct hydrogen bond to the methyl group(99). MBD1 is also slightly 
rotated, allowing it to contact the DNA phosphate backbone between its 
β1 and β2 loops, where MBD2 will likely not be able to reach(99). 
MeCP2’s and MBD2’s methyl binding domains are virtually identical in 
their binding pocket. The only predicted, minor, alterations are to the 
alpha helix, with MeCP2’s being longer by 4 residues. The authors go on 
to state that for this particular promoter region MBD2 seemed to bind in 
one particular orientation on the positive strand(99). While they did not 
confirm their results with experimental data, it is intriguing to think this 
could imply strand specificity for MBD2 MBD. 
 Despite the significant amount of progress made in the past decade 
in understanding the biophysical interaction of MBDs and meDNA, a 
number of questions still loom. In this work I focused on MBD2 and 
asked how its biophysical properties change under different conditions. 
In doing so we decipher the optimal conditions for targeting MBD2 and 
using it as a tool (discussed in more detail in chapters 3, and 5). 
Interestingly the results also shed some light on ways to alter the 
protein’s specificity or sensitivity for meDNA. To better understand the 
protein, and also help us with possible structure aided design, see 
chapter 3 and 4, we set out and successfully collected x-ray diffraction 
data on an MBD2-MBD selenomethionine and wild type crystals to 
approximately 2.4Å. While this work is still on going, we’re optimistic to 




Comparison of Recombinant MBD2-MBD from Bacterial and Insect Cells  
As an eager first year graduate student I entered the Nelson lab 
and was quickly taught how to purify recombinant MBD2-MBD protein. 
We initially generated recombinant purified MBD2-MBD using a 
baculoviral/insect cell system. We expressed protein in SF9 insect cells 
through a baculoviral vector containing residues 145 to 213 of MBD2. 
Unfortunately this system left us with a relatively low yield of protein (µg 
per liter final product) and so I opted to move towards a bacterial 
expression system to improve yield. After successfully expressing MBD2-
MBD in BL21-DE3 cells, we purified recombinant protein as described in 
the methods with yields of 5-10mg/L. As a eukaryotic cell, the SF9 line 
potentially adds post translational modifications to the expressed 
protein. Previous work in our lab, the literature, and via queries with 
online prediction tools all suggest that MBD2 is phosphorylated within 
the MBD domain (Reichert et al unpublished, (100)(101)). Only one post-
translation modification to date is well investigated though: a 
methylation mark on R61 in the GR repeat domain(102). Tan et al 
demonstrate that MBD2 interacts with two arginine methyltransferases, 
PRMT1 and PRMT5, and that they methylate the R61 of MBD2 and lower 
it’s affinity for meDNA by gel shift assay. Review of the data shows that 
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while this observation holds, it is not fully corroborated by other reports 
and the difference in binding affinity is not strong.  
 To investigate whether recombinant MBD2-MBD purified from a 
eukaryotic host (potentially modified post-translationally) vs a 
prokaryotic host (not post-translationally modified) could alter binding to 
meDNA we performed a gel shift assay using MBD2-MBD made in insect 
cells, as well as our new bacterial system (Figure 2.1). We also wanted to 
determine if we could manipulate the only cysteine contained with our 
construct (C9) for other applications so N-ethylmaleimide treated protein 
was included. Interestingly, at the conditions investigated, the insect cell 
protein appeared to have similar, but higher affinity, compared to the 
bacterial protein. This supports previous reports that post translational 
modifications could impact MBD2’s ability to bind methylated 
cytosine(102). N-ethylmaleimide treatment significantly disrupted protein 
binding to methylated DNA, suggesting that use of this cysteine for 
labeling may not be ideal.  
 
MBD2-MBD Binding Under Different Physiological Conditions 
 In order to utilize MBD2-MBD as a tool for enriching methylated 
DNA (see chapter 5) and also to find optimal conditions for in vitro 
screening of small molecule inhibitors (chapter 3) we tested the ability of 
bacterially made MBD2-MBD to bind a single symmetrically methylated 
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CpG DNA under different conditions in vitro. We monitored the 
interaction using a fluorescence polarization assay with a fluorescein 
(FAM) labeled oligo. The first variable tested was salt (NaCl) 




Figure 2.1: Gel shift of recombinant MBD2-MBD from insect and bacterial cells 
with meDNA  
(A) MBD2-MBD made in either insect or bacterial cells binding to a symmetrically 
methylated hairpin oligo in an increasing dose response. (B) Increasing concentrations 





promiscuous, lowering its specificity (Figure 2.2A). Higher salt lowered 
the overall sensitivity of the protein for DNA (Figure 2.2A), as observed by 
lower total binding. The Z’ statistic determined the significance of these 
results. Comparing protein binding to unmethylated and methylated 
substrates 100-150mM NaCl was the most significant (Table 2.1). These 
results are consistent with what would be expected: as the ionic strength 
of the solution lowers the positively charged protein will seek out other 
charges, with the most abundant being the negatively charged phosphate 
backbone, leading to non-specific binding. The non-specific binding is 
clearly seen in figure 2.2A upper left panel as the low salt protein-meDNA 
interaction never fully saturates. We confirmed that the type of salt is not 
as important as the overall ionic strength by observing no differences in 
sensitivity or specificity when maintaining an optimal concentration of 
125mM salt but substituting increasing amounts of KCl in place of NaCl 
(Figure 2.3). 
 The next variable analyzed was pH, also performed using our 
fluorescence polarization assay. MBD2 was exposed to different buffers 
at pH levels ranging from 4.5-10.5 (Figure 2.4). Interestingly pH followed 
a similar trend to that observed with salt concentration. Increasing pH 
leads to a loss of sensitivity (Figure 2.4A) whereas decreasing pH lead to 
a loss of specificity (Figure 2.4B). Unsurprisingly the optimal balance 
between these effects is achieved at the physiologically relevant pH of 




Figure 2.2: MBD2-MBD and Methylated DNA binding under different salt 
concentrations  
(A) MBD2-MBD binding to singly symmetrically methylated hairpin DNA oligos 
measured by fluorescence polarization assay. Experiments were run at 50mM, 100mM, 
150mM or 200mM NaCl concentrations. (B) Difference between methylated and 
unmethylated DNA binding in vitro at various salt concentrations and 200nM or 100nM 

















Figure 2.3: MBD2-MBD binding to methylated DNA at constant ionic strength  
MBD2-MBD binding to methylated DNA (upper) and unmethylated DNA (lower) at 
constant ionic strength (125mM) but different NaCl and KCl concentrations as 




   
Figure 2.4: MBD2-MBD binding to DNA at different pH’s                                      
(A) MBD2-MBD binding to methylated DNA as measured by fluorescence 
polarization. Lower pH led to an increase in sensitivity (B) MBD2-MBD binding to 




 The final parameter queried was glycerol concentration. The 
intracellular environment is extremely rich in proteins and lipids. No 
association between MBD2 and lipids has been demonstrated, however, 
we wanted to confirm that its activity is not altered by the presence of 
detergent like materials. Addition of 4% or less glycerol did not appear to 
affect the ability of MBD2-MBD to bind methylated DNA (Figure 2.5). 
Concentrations above this level exhibited a moderate loss of sensitivity. 
 
Isothermal Calorimetry Experiments to Confirm Binding Conditions 
To confirm our results and finalize the optimal conditions for 
binding we performed isothermal calorimetry binding curves on the 
MBD2-MBD and meDNA interaction. Utilizing the same oligo and protein 
from our fluorescence polarization assay we tested low (50mM), optimal 
(125mM), and high (250mM) salt conditions (Figure 2.6A-B, Figure 2.7). 
Lower salt, as previously seen, showed nonspecific binding at higher 
protein concentrations in both hemi-methylated and unmethylated DNA 
substrates (Figure 2.8A). The nature of this interaction can be inferred by 
looking at the thermodynamics of the low salt meDNA-protein curve. The 
first binding event is entropically driven (ΔS=137), consistent with the 
MeCP2 crystal structure which describes organized water as a key 
component of the MBD protein-methylated DNA interface. The second 








Figure 2.5: MBD2-MBD binding to DNA at different glycerol concentrations  
Unmethylated and methylated DNA binding measured by fluorescence polarization 













Figure 2.6: Isothermal calorimetry binding curves of MBD2 and methylated DNA 
at low and high salt  
(A) ITC binding curve of MBD2-MBD with methylated DNA at low salt (50mM). (B) and 






Figure 2.7: Isothermal calorimetry binding curve of MBD2-MBD with methylated 
DNA at optimal salt. 









Figure 2.8: Fitted ITC curve of MBD2-MBD protein and DNA 
(A) Methylated, hemi-methylated and unmethylated DNA binding curves with MBD2-
MBD at low salt (50mM). (B) Methylated binding curve with unmethylated (background) 
heat subtracted.  
42 
 
binding curves, is more enthalpy driven, consistent with a protein 
seeking to mitigate an unmatched charge. High salt lowered sensitivity 
significantly (Figure 2.6B). The Ka for optimal conditions was  
4.48x106 M-1, similar to the value obtained from the low salt when 
unmethylated DNA binding is subtracted away from the fully methylated 
values, 1.61x106 M-1 (Figure 2.8B). Based on these results we identified 
the optimal pH (7-7.5), glycerol (4%), and salt concentration (125mM) for 
future work with the MBD2-MBD protein. 
 
Biophysical Behavior of Longer MBD2 Constructs 
 To this point only the methyl binding domain of MBD2 had been 
utilized for experiments. To determine whether other portions of the 
protein impact binding we expressed 5 larger constructs in bacterial 
cells, containing progressively more of the C-terminus (Figure 2.9A). The 
first 150 residues of MBD2 encode the GR repeat domain. This region is 
predicted to be a coiled-coiled, and its presence has made in vitro 
purification difficult in the past (Reichert and Lee et al, unpublished). As 
such we opted to remove it from all constructs. After successful 
purification and storage we tested the various proteins’ ability to bind 
fully methylated, hemimethylated and unmethylated 5-methylcytosine 





Figure 2.9: Construction, expression and purification of larger MBD2 
constructs 
(A) Layout of longer MBD2 constructs. (B) Coomassie gel on purified 




Figure 2.10: Binding curves for larger MBD2 constructs with DNA 
(A) Binding curves of longer MBD2 constructs with hairpin oligos containing a single 
symmetric CpG at with methylation states. Binding was measured using a fluorescence 
polarization assay. (B) Fitted binding curves for MBD2 constructs with fully methylated 
DNA. Approximate Kd’s are shown for each protein. 
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MBD2_G03 did not express well and thus was not included in our initial 
analysis of these proteins. It was successfully expressed and purified 
later from bacteria and had almost identical binding results to those 
presented (results not shown). The larger constructs showed similar 
disassociation constants (Kd≈50nM) compared to the MBD domain only, 
but some of the larger constructs did appear to exhibit higher affinity for 
methylated DNA (Figure 2.10). Fully methylated DNA was the preferred 
substrate for all constructs with almost no binding present in the setting 
of unmethylated DNA, and only slight binding to asymmetrically hemi-
methylated DNA (Figure 2.10A). These results suggest that the MBD 
function of MBD2 is modular, in that the domain is able to recognize and 
bind to methylated DNA in a specific manner with only some minor 
contribution to affinity from other domains or parts of the protein. 
 To characterize these proteins further we performed thermal melt 
curve and limited proteolysis experiments. Protein melt curves on each 
construct were conducted in the normal storage buffer (150mM NaCl, 
10mM Tris pH 7.4, 1mM TCEP) and showed no difference between the 
proteins, with denaturing occurring at approximately 51.5oC (Figure 
2.11A). To confirm these results and determine if a more optimal buffer 
or pH existed we repeated the thermal melt experiment under varying 
conditions using the MBD2-G01 construct (Figure 2.11B-C). Lower pH 
(between 6.0-7.0) appeared to modestly stabilize the protein, with a 2-3oC 
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shift in melting Tm. We then assessed various salts using pH values of 
5.0, 6.0 and 7.0 and found that the majority made no difference in  
 
Figure 2.11: Protein thermal melt analysis on MBD2 constructs  
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(A) Protein thermal melt raw data for all MBD2 constructs. (B) Plate setups to test 
MBD2-G01 construct with thermal melt curves. (C) Results of MBD2-G01 thermal melt 
experiment under varying pH and salt conditions Protein is most stable at lower pH and 
with high formate. 
protein stability. The exception was formate, which at concentrations of 
400mM and above seemed to help stabilize the protein, as shown by a 
dramatic 8-10oC shift in melting temperature (Figure 2.11C). 
 We next assessed our MBD2 constructs with a limited proteolysis 
experiment. Well folded proteins resist cleavage by proteases. Incubating 
the various constructs with a small amount of protease for a limited time 
should cleave only the peptide locations which are not well formed or 
stable, leaving only the domains/regions that are well packed. We 
exposed MBD constructs to subtilisin A, a serine protease with broad 
specificity, as well as trypsin, a commonly used serine protease that cuts 
after the basic residues lysine and arginine. After a 30 minute incubation 
the proteins were run on an SDS-PAGE gel and stained with Coomassie 
(Figure 2.12A) or silver stain (Figure 2.12B). Interestingly two relatively 
stable isoforms appeared in multiple proteins, indicated by arrows in the 
silver stain gel (Figure 2.12B). The larger is approximately the size of 
MBD2-G03, and the other approximately the size of MBD2-MBD. Excised 
bands sent for mass spectrometry analysis were inconclusive for the 
larger band, but confirmed the smaller one (lower arrow) as MBD2-MBD 
(results not shown).  
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 Based on these results we looked more closely at the G01 (almost 
full length) and G03 constructs to assess the feasibility of using them for 
x-ray crystallography. First we attempted large scale affinity purification  
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Figure 2.12: Limited proteolysis experiments with MBD2 constructs 
(A) Coomassie and (B) silver stain gel of limited proteolysis with subtilisin A 
and trypsin on the larger MBD2 constructs. Arrows indicate two stable forms 






Figure 2.13: Large scale affinity purification of MBD2 constructs 
(A) MBD2-G01 and (B) MBD2-G03 affinity purification with IMAC beads. The 




of the MBD2-G01 and G03 with the histidine tag tail on both proteins 
(Figure 2.13). We successfully purified both proteins but unfortunately 
MBD2-G01 became unstable during concentration and precipitated 
significantly. MBD2-G03, however, was amenable to concentrating and 
maintained purity >95% post size exclusion gel filtration purification 
(Figure 2.14A). Importantly, G03 was stable at lower concentrations of 
salt which would make screening crystal conditions easier (Figure 
2.14B). Provided the above evidence we opted to move forward with 
MBD2-MBD and MBD2-G03 for structural efforts.  
 
Crystallization of Native MBD2-MBD with Methylated DNA 
 MBD2-MBD was concentrated to ~20mg/mL (2mM) for initial 
structural work. The protein was screened by itself at 1mM using a 96 
well hanging drop vapor diffusion approach with a total of five screens. 
After a week ~80% of wells showed precipitant with no crystals present. 
Despite repeat attempts at higher concentration and alternate ratios of 
mother liquor to protein we were unable to find a suitable condition with 
protein alone. 
 Provided the previous success of other groups with crystalizing 
MBD’s with DNA we opted to add DNA to MBD2-MBD and rescreen. A 





Figure 2.14: Gel filtration purification and stability studies with MBD2-G03 
(A) Coomassie staining of MBD2-G03 gel filtration and concentration results. (B) 
Coomassie stain of MBD2-G03 dialyzed overnight into progressively lower salt 




annealed double stranded DNA sequences with overlapping A or T bases 
to allow concatemerization of adjacent strands. After approximately 5-6 
days we observed large cuboid crystals in wells containing the MBD2-
MBD with 14bp DNA sequence in a 2:1 ratio respectively. After 
optimization we achieved cuboid crystals of approximately 200µm x 
200µm x 200µm size, but only in wells with ≥1.4M citrate and pH≤7 
(Figure 2.15A). This is consistent with our thermal melt data which 
showed that MBD2-MBD is stabilized in lower pH and highly 
concentrated salts containing carboxyl functional groups (such as 
formate and citrate). Previous reports suggest that proteins crystallize 
more readily when in a stable form or condition(103). We cryoprotected 
crystals in 2.0M citrate and collected diffraction data on a local x-ray 
source (see methods for details). The crystal diffracted to approximately 
2.2Å in a P3N21 space group (Table 2.2). A single crystal was washed 
numerous times in citrate buffer and run on an SDS-PAGE gel, 
confirming it contained protein (Figure 2.15B). 
 With our collaborators we made numerous, but unsuccessful, 
attempts at solving the phase of the MBD2-MBD native crystals with the 
MeCP2-MBD crystal structure by molecular replacement (PDB accession 
number 3C2I). Heavy metal soaking was also attempted unsuccessfully, 
mostly due to human error, but also difficulties with the native crystals 





Figure 2.15: Native crystals of MBD2-MBD with 14bp 
(A) Crystals formed by MBD2-MBD with 14bp DNA in a 2:1 ratio, respectively, after 3-6 
days in 1.6M citrate pH 6.5. (B) Coomassie staining of a single crystal washed and run 












selenomethionine MBD2-MBD constructs were made as described in the 
methods. All of the endogenous methionines in MBD2-MBD are predicted 
to be in disordered regions, prompting us to mutate one into a predicted 
alpha helix. MBD2-MBD-G198M was unstable after purification and 
could not be concentrated to any appreciable level. MBD2-MBD-T200M 
did not express despite confirming by sequencing that the plasmid was 
in frame and contained the correct coding sequence. These two proteins 
were abandoned. 
 MBD2-MBD-R195M did express and we harvested crystals from 
two suitable conditions. The first was in 16-19% PEG3350, 0.2M Zinc 
Acetate and 1mM TCEP, cryoprotected in the same buffer supplemented 
with 20% glycerol. Single wavelength anomalous diffraction (SAD) data 
were collected at the advanced photon source at Argonne National 
Laboratory synchrotron but when phases were solved and initial density 
maps constructed it appeared only DNA was present. Review of our data 
suggests we accomplished phasing via a fixed zinc atom, which happens 
to contain an absorption edge very similar to selenium.  
 Repeat sparse matrix screening identified a second suitable 
condition: 30% PEG8000, 0.2M Sodium Acetate, 0.1M Bis Tris Propane 
pH 6.5. Multi wavelength anomalous diffraction (MAD) data were 
collected for selenomethionine at the advanced photon source at Argonne 
National Laboratory synchrotron (Table 2.2). Unfortunately, despite 
numerous attempts, we were unable to solve the phase with these data, 
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and suspect that the selenomethionine sites were not ordered enough to 
locate. 
 MBD2-MBD-L193M crystals were also successfully attained using 
the condition: 2.0M ammonium sulfate, 0.1M sodium acetate trihydrate 
pH 4.6. After cryopreservation SAD data were collected and processed 
(Figure 2.16A, Table 2.2). With our collaborators we successfully located 
3 selenomethionine sites with this data set and overlay of the MeCP2-
MBD solution on initial electron density maps suggests there is density 
consistent with both DNA and protein present (Figure 2.16B). Work is 





Figure 2.16: Data collection and analysis of MBD2-MBD-L193M selenomethionine 
crystals 
(A) Diffraction of MBD2-MBD-L193M selenomethionine crystals during screening at 
JHMI in preparation for a synchrotron trip. (B) Representative example of 1/3 
selenomethionine sites located in the initial electron density maps obtained from SAD 






Figure 2.17: Initial electron density maps and model with MBD2-MBD-
L193M SAD data 
(A) Electron density consistent with DNA backbone. The left and right figures are 
the same, with generic DNA modeled on the right. (B) Electron density 
consistent with protein. In the bottom panel the MeCP2 model is overlaid and 
the predicted site for the se-met labeled L193M does overlap with an identified 
selenium site. Images were kindly provided by Patrick Byrnes. 
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2.4  Discussion 
 Despite over a decade of investigation we still do not completely 
understand the mechanism behind the MBD family member interaction 
with methylated DNA. A lot of effort investigating MeCP2 has occurred, 
presumably because it was the first member identified and the only one 
with a relevant human disorder associated with its mutation. In the work 
described here we attempt to fill the gap and answer the relevant 
biophysical questions regarding MBD2’s MBD. 
 How MBD’s are targeted to the genome is an extremely relevant 
and interesting problem. Our data suggests that by changing salt and pH 
conditions the specificity and sensitivity can be drastically changed. 
Accomplishing this inside a nucleus in vivo, where MBD2 is found, is 
quite difficult and thus an unlikely mechanism. This data has assisted 
us, however, with establishing optimal conditions for using the MBD2-
MBD as a tool to enrich methylated DNA fractions in an in vitro setting. 
By increasing salt and using a slightly higher pH we’ve been able to 
improve specificity with only a moderate loss in sensitivity. 
 The differences between insect and bacterial protein binding could, 
however, suggest a mechanism by which the cell can alter MBD2 
function. The post translational modifications present from the SF9 cells 
do seem to improve binding by gel shift. While this experiment was not 
investigated further it could, along with other evidence in the literature, 
provide insight into a mechanism for controlling MBD binding(102). 
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MBD2 targeting kinases could localize to particular places in the genome 
and thereby lower the chances of MBD2 effectively binding to adjacent 
genomic locations. Clearly more work should be done in this area to 
establish the relevant post translational marks and their function. 
 The MBD2-MBD crystallography work was a large part of my 
studies of this protein. Despite numerous initial failings with the protein 
alone, complexes with methylated DNA in both our hands and others 
seem to produce diffraction worthy crystals under many different 
conditions. It is troublesome that no one to date has successfully 
crystallized an MBD family member in its entirety or with just the MBD 
protein alone. While there has yet to be a conclusive experiment 
exploring this question we speculate it may be due to the protein’s 
inherent stability/folding in solution. We suspect that, when unbound, 
MBD2, in particular the MBD, remains relatively loosely folded in its 
tertiary structure. Our gel filtration studies support this theory, as the 
protein rarely elutes in one uniform peak. In the presence of methylated 
DNA, however, MBD2 achieves a more rigid structure as favorable 
contacts emerge between the protein and DNA. This more stable form 
likely initiates enzymatic activity through the MeCP1 complex. Again gel 
filtration and other experiments lend some evidence to this idea, with 
premixed protein-meDNA constructs running at one uniform band or 
peak during purification. The limited proteolysis experiments also 
support this theory, with numerous smaller peptides appearing in a 
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short incubation time in our gels. Crystals, by their nature, require a 
rigid symmetry to form, and thus a loosely folded protein presents a 
difficult substrate to crystalize. More investigation into this area could 
help decipher the mechanism behind MBD signaling to other complex 
members and/or conditions under which an MBD may crystalize on its 
own. Such information could be helpful for structure aided design if 
suitable inhibitors are found. 
 Despite the significant effort described here there remain a number 
of unanswered questions regarding the mechanisms of MBD family 
member interaction with methylated DNA. We look forward to solving the 
MBD2-MBD crystal structure in the near future and continuing 





Comparison of Recombinant MBD2-MBD from Bacterial and Insect Cells  
A codon optimized sequence for the MBD2-MBD polypeptide was 
synthesized and cloned into the pGSE6 vector (Genscript USA Inc) for 
expression in bacteria as a C-terminal hexa-histidine tagged fusion 
protein. Briefly, BL21-DE3 cells (Agilent Technologies) were transformed 
with this construct, allowed to grow to an OD600 of 1.0, and were induced 
with 1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG, Corning Cellgro) 
overnight in a shaking incubator at 220 rpm and 20oC. Bacteria were 
lysed using a French press in equilibrium buffer containing 300 mM 
NaCl, 50 mM sodium phosphate pH 8.0, 5 mM imidazole (Sigma Aldrich), 
and a protease inhibitor cocktail (Roche USA). Lysates were centrifuged 
at 17,000xg for 30 minutes and then incubated with IMAC Nickel NTA 
beads (Bio-Rad) for 1 hour at 4oC. The beads were washed three times 
with equilibrium buffer containing 15 mM, 20 mM and 25 mM imidazole, 
respectively, and affinity purified protein was eluted in equilibrium buffer 
containing 150mM imidazole. The his-tagged protein was further purified 
by gel filtration using a Superdex g75 26/300 Column (GE Healthcare 
Life Sciences) in storage buffer (150mM NaCl, 20mM Tris pH 7.4, 1mM 
tris(2-carboxyethyl)phosphine (TCEP, P212121 LLC, Toledo, Ohio). 
Fractions containing the purified MBD2-MBD were concentrated with 
3000 MWCO Amicon® Ultra-4 Centrifugal Filter Units (Millipore) and 
flash frozen with liquid nitrogen and stored at -80oC. 
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MBD2-MBD from insect cells was made using the same primary 
sequence as the MBD2-MBD in bacterial cells. Briefly, 2-4mL of 
previously designed and produced baculovirus (T. Speed and Z. Reichert) 
was used to infect 2.2e6 SF9 cells/mL (ATCC) in a 250mL plastic flask 
(Corning) containing SF900III media (Invitrogen). Cells were incubated 
for 48 hours at 28oC and 130rpm and harvested by centrifuging at 
1000xg for 10 minutes, then snap frozen in liquid nitrogen. Protein 
purification followed the same protocol listed for the bacterial cells with 
the following exception: Lysis was performed by 3 repeated freeze (liquid 
nitrogen) thaws (42oC water bath). The lysate was then run through a 
20ga needle via a syringe 3 times. Clearing of the lysate and protein 
extraction continued as described above. 
 
Gel Shift Assay 
For the gel shift assay DNA hairpin oligo with sequence 
ATGCTCmeGTAGCACTTTTGTGCTACmeGAGCAT (IDT) was annealed by 
mixing heating to 95oC for 5 minutes, followed by rapid cooling by 
moving directly to ice until reaching room temperature. Once annealed 
oligos were labeled with P32 (Perkin Elmer) by mixing 2.5µL of 10µM oligo 
with 2.5µL of x10 T4 PNK buffer (Promega), 2.5µL of T4 Polynucleotide 
Kinase enzyme (Promega), 9µL P32 at 250µCi, and water to a total volume 
of 20µL. The mixture was incubated for 1 hour at 37oC, then at 65oC for 
20 minutes. Unbound radioactive phosphate was removed by running 
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the mixture through a G-25 gel filtration spin column (GE). The eluted 
product was diluted 1:25 to a concentration of 40nM and stored at          
-20oC. For the assay, 5µL of oligo was incubated with increasing 
concentrations of MBD2-MBD protein (from 0.1µM to 5µM) in the 
presence of x1 gel shift buffer (Promega) and water up to a total volume 
of 20µL No protein served as the negative control. This was incubated for 
30-60min at room temperature and run on a 20% TBE agarose gel 
(Invitrogen). Gels were vacuum dried for 1hour (room temperature or 
70oC) and exposed to developing film. For the NEM (Sigma Aldrich) 
treated samples the same procedure was followed, except 5mM NEM was 
added during the protein and meDNA incubation step. 
 
MBD2-MBD Binding Under Different Physiological conditions 
Fluorescence Polarization Binding Assays 
 Fluorescence polarization binding assays were performed as 
previously described(63). Briefly, MBD2-MBD protein was added in a 
dilution series to the reaction buffer containing varying levels of glycerol 
(0-14% in 2% steps), NaCl (50-200mM in 25mM steps) or buffer (adjusted 
to appropriate pH 4.5-9.5 in 1.0pH steps) along with 1 mM MgCl2, 0.5 
mM EDTA, 0.5 mM DTT, 0.2% Tween-20 up to a total working volume of 
50µL. For the pH adjusted experiments MES (Sigma Aldrich) was used 
for pH adjustments from 4.5-6.5, and Tris (Sigma Aldrich) was used for 




(unmethylated) or 5′- fluorescein - 
ATGCTCmeGTAGCACTTTTGTGCTACmeGAGCAT-3’ (methylated) were 
annealed by heating to 95oC and cooling on ice rapidly. They were then 
added to the binding reaction to a final concentration of 10nM. Binding 
assays were carried out in 96-well black half area plates (Corning) in 
triplicates. The plate was incubated at 4oC for 1 hour with gentle 
shaking. Fluorescence polarization readings were performed on a Safire2 
(Tecan) instrument with excitation at 470nm and monitoring emission at 
525nm. Anisotropy values were acquired directly from the machine 
readout and plotted relative to MBD2-MBD protein concentration and 
fitted using the open source software R version 2.12. Z’ factors were 
calculated using the equation (1):  
𝑍′ = 1 − 3 𝑥 
𝑆𝐷𝑚−𝑆𝐷𝑢
|µ𝑚−µ𝑢|
   (1) 
where SDm and µm are the standard deviation and mean anisotropy 
values respectively of protein binding to the methylated FAM labeled 
oligonucleotide, and SDu and µu are the standard deviation and mean of 
anisotropy values respectively of the protein binding to the unmethylated 
FAM labeled oligonucleotide. 
 
Isothermal Calorimetry Binding Experiments 
 For isothermal calorimetry experiments recombinant bacterial 
made MBD2-MBD was placed into an ITC buffer containing 250mM, 
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125mM or 50mM NaCl (Sigma Aldrich), 1mM MgCl2 (Sigma Aldrich), 
0.5mM EDTA (Sigma Aldrich), 0.5mM TCEP (P212121) and 10mM Tris 
pH 7.4 (Sigma Aldrich). Protein was diluted to either 10 or 20µM in a 
final volume of 2mL. For the injector, methylated hairpin DNA from the 
fluorescence polarization experiment described above was used. The 
meDNA was mixed with the same ITC buffer described above to a final 
concentration of 50 or 100µM with a final working volume of 500µL. Both 
the DNA and protein mixtures were degassed for 5 minutes before 
carefully being placed into either the syringe (meDNA) or bomb (protein) 
ensuring no bubbles were present, all per the manufacturer’s 
instructions. A MicroCal VP-ITC machine (GE) was used for all 
experiments. Data was collected using the following settings: inject 
volume 9µL, 30 total injections, time between injections 210 seconds, 
temperature 25oC, stirring speed 270rpm, and a 10µCal/sec baseline 
heat. Data was analyzed and fitted using the Origin® software provided 
by MicroCal, utilizing a chi squared statistic to determine optimal fitting 
parameters for a 1 site or 2 site binding event.  
For comparing MBD2-MBD affinity to different DNA substrates the 
process was the same, but only 50mM NaCl was used. For these 
experiments the protein as diluted to 60µM in 500µL working volume 
and placed in the syringe, while the appropriate DNA (either fully, hemi 
or unmethylated) was diluted to 5µM in 2mL working volume and placed 




Biophysical Behavior of Longer MBD2 Constructs 
Purification of MBD2 Longer Constructs 
 Larger MBD2 constructs were purified following the similar 
methods listed above under the comparison of bacterial and insect 
protein section for MBD2-MBD from bacteria. Expression constructs 
were PCR amplified following the recommended protocol in the Fail Safe 
product manual (Epicentre) from a bacterially codon optimized vector 
made by GenScript (New Jersey) (Table 2.3). The PCR products were topo 
cloned following recommended protocols into a p-EXP-5CT vector 
(Invitrogen) containing a C-terminal hexa-histidine tag. These plasmids 
were transfected into BL21-DE3 cells (Agilent Technologies) and the 
bacteria allowed to grow to an OD600 of 1.0 in Terrific Broth (Corning-
Cellgro). A total of 20mL of bacteria for each construct was induced with 
1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG, Corning Cellgro) and 
grown overnight in a shaking incubator at 220 rpm and 20oC. The 
protein was purified using the Talon 20mL Single Step Purification kit 










Table 2.3: Primers used to create MBD2 longer constructs.  






was then concentrated in a 15mL volume 10,000 MWCO Amicon® Ultra-
4 Centrifugal Filter Units (Millipore) and stored in storage buffer (150mM 
NaCl, 10mM Tris pH 7.4, 1mM TCEP). Protein was flash frozen in liquid 
nitrogen and stored at -80oC.  
 
Fluorescence Polarization Binding Curves of MBD2 Constructs 
 Fluorescence polarization binding curves were performed as 
previously described in the comparison of bacteria and insect MBD2-
MBD section. The larger constructs were substituted in place of MBD2-
MBD in the appropriate wells. The assay buffer contained 4% glycerol, 
1mM MgCl2, 0.5mM EDTA, 0.5mM DTT, 125mM NaCl, 10mM Tris HCl 
(pH 7.4), 0.2% Tween-20 (all from Sigma Aldrich) with a final working 
volume of 20µL. Oligos were hairpins with identical base pair sequences, 
methylation status being their only difference:  
Methylated ATGCTmeCGTAGCACTTTTGTGCTAmeCGAGCAT  
Hemi-methylated ATGCTmeCGTAGCACTTTTGTGCTACGAGCAT 
Unmethylated ATGCTCGTAGCACTTTTGTGCTACGAGCAT 
Primers were annealed prior to use by heating to 95oC and then rapidly 
cooled on ice to room temperature. Oligos were used a final 
concentration of 10nM in the assay. Protein was assayed from 2000nM 
in a 4 fold decreasing fashion to about 0.12nM. Black 96 well half area 
plates (Corning) were used for all assays. Readings were performed using 
a Safire2 (Tecan) instrument with excitation at 470nm and monitoring 
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emission at 525nm. Anisotropy values were acquired directly from the 
machine readout and plotted relative to MBD2-MBD protein 
concentration and fitted using the open source software R version 2.12. 
 
Thermal Melt Analysis of MBD2 Constructs 
 Thermal melt curves were performed in 96 well PCR plates (Bio-
Rad) in a total working volume of 20µL. Approximately 2.5µg of protein 
was added to each well in a buffer containing 10x Sybr Orange (Life 
Technologies), and 50mM NaCl and 10mM Tris pH 7.4. Proteins were 
heated on a CFX96 real time PCR machine (Bio-Rad) from 25oC to 95oC 
in 0.5oC steps with a 5 second hold at each step. Analysis and heatmaps 
were created using Matlab® and software/protocols described online in 
an open source website developed by Johns Hopkins School of Medicine 
researchers ((103), http://www.hotproteins.com/). 
 For assessing protein stability in pH and salt buffers the same final 
concentrations of material described above was used, but was added in 
2µL to each well (added at 10x concentration). The remaining 18µL of the 
working volume consisted of the buffer or salt being tested at the 
described concentration (Figure 2.11B). Heating and reading was 
performed as described above. 
 
Limited Proteolysis Experiments 
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 Previous work (not described) tested protease concentrations of 
10ng, 1ng, and 0.1ng to determine the optimal concentration for the 
MBD2 protein. The optimized protocol used 10µg of protein construct 
added to a 12 well strip tube (USA Scientific). This was diluted with 
100mM NaCl, 20mM Tris pH 8.0 and 1mM β-Mercaptoethanol (Sigma 
Aldrich) to a final volume of 16µL. 0.1ng of TrypLE (Cellgro) or subtilisin 
A (Sigma Aldrich) was added to each well and mixed with pipetting at a 
final working volume of 20µL. Samples were incubated at 37oC for 30 
minutes. 6µL x4 LDS loading buffer with SDS (Invitrogen) was quickly 
added to each well and then heated to 95oC to stop protease activity. 
Samples were run on a SDS-PAGE gel (Invitrogen) and visualized using 
SimplyBlue™ (Invitrogen) or silver staining (Bio-Rad) following 
manufacturer instructions. Bands were excised using a straight razor 
and stored in 1.5mL Eppendorf tubes. They were then submitted to the 
Johns Hopkins Mass Spectrometry Core facility for analysis. 
 
Large Batch Purification of MBD2 Constructs 
 Batch purification of MBD2-G01 and MBD2-G03 constructs was 
performed as previously described in the Comparison of Recombinant 
MBD2-MBD from Bacterial and Insect Cells for MBD2-MBD. The only 
deviation from this protocol was use of a 10,000MWCO concentration 
column in place of the 3000MWCO column described. Proteins were 




Dialysis Experiment on MBD2-G03 
 Same day purified MBD2-G03 protein was used for this 
experiment. 500µg of protein (approximately 10µL) was added to 490uL 
of high salt buffer (250mM NaCl, 20mM Tris pH 7.4, 1mM TCEP). Five 
100µL aliquots were placed into separate 3000MWCO dialysis cassettes 
(Thermo Scientific-Pierce Net) after they were pre-soaked in buffer for 5 
minutes. Protein was dialyzed overnight at 4oC with gentle mixing by stir 
bar in 500mL of one of 5 buffers (NaCl at 50mM, 100mM, 150mM, 
200mM or 250mM) with 20mM Tris pH 7.4 and 1mM TCEP. Samples 
were removed the next morning and centrifuged at 17,000xg in a 
microcentifuge at 4oC. Supernatant was removed and mixed with x4 LDS 
loading buffer and loaded onto an SDS-PAGE gel (Invitrogen). Gels were 
visualized by SimplyBlue® staining. 
 
Crystallization of native MBD2-MBD with methylated DNA 
MBD2-MBD Crystallization  
MBD2-MBD was purified as previously described and concentrated 
to ~20mg/mL (2mM).  Initial crystallization conditions were identified 
using Sparse Matrix Screening with commercially available screens 
(Crystal Screen I (Hampton), Crystal Screen II (Hampton), SaltRx 
(Hampton), PEGs Suite Screen (Qiagen) and Protein Complex Suite 
(Qiagen)). Hanging drop vapor diffusion experiments were assembled by 
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mixing 1mM  protein (50mM NaCl, 1mM TCEP, 10mM Tris pH 7.4) in a 
2:1 ratio with well solution using a Mosquito® liquid handling robot (TTP 
Labtech) in 96 clear well plates (Corning) with plate covers (Hampton).  
 
MBD2-MBD with Methylated DNA Crystallization 
 Three protein:DNA complexes, differing in the length of the DNA 
duplex,  were screened for crystallization.  Double stranded DNA 
sequences of 12bp, 14bp and 20bp length and either a T or A single base 
overhang at either end to assist in crystal lattice formation (Table 2.4).  
To form complex for crystallization, the DNA was resuspended at 4mM in 
ddI water and then annealed by heating to 95oC for 3 minutes and then 
cooling by 1oC per 2 minutes to a final temperature of 25oC.  Annealed 
DNA duplex was mixed in a 2:1 molar ratio to 1mM protein (50mM NaCl, 
1mM TCEP, 10mM Tris pH 7.4) and the complex was isolated on an 
analytical gel filtration complex (analytical Superdex G75). Crystallization 
conditions were then determined using sparse matrix screening as 











Table 2.4: DNA Sequences used for crystal condition screening. 





specific for screening DNA containing complexes. 
 Crystals of MBD2-MBD and 14bp DNA were obtained in 1.5M 
sodium citrate pH 6.5 and further optimized by grid-screening in 24 well 
hanging drop plates. Crystals were obtained by mixing 1µL of complex 
with 1µL of well solution containing citrate between 0.8-2.0M at 6.0 to 
8.0 pH. Trays were stored at 25oC and cuboid crystals approximately 
200x200x200µm in size formed in 2-5 days. 
 Crystals were cryostabilized by direct transfer to 2M Citrate pH 6.5 
and flash frozen in liquid nitrogen. Data were collected using a Rigaku 
FR-E x-ray generator (Copper-Kα=1.54Å) with a Saturn 944+ CCD 
detector and processed with HKL2000(104). With two collaborators from 
the Leahy lab we attempted molecular replacement phasing with 
Phaser(105). A series of heavy metal soaks were performed and data was 
processed using Shelx(106), Solve(107) and Resolve(108) to identify 
isomorphous or anomalous signal; however, ultimately, no heavy metal 
soaks were successful in phasing the protein:DNA complex.  
 
MBD2-MBD Selenomethionine Crystallization 
Single point mutations (L193M, R195M, G198M or T200M) were 
cloned into MBD2-MBD using Quick Change Lightening kit (Agilent 
Technologies) to aid in phase determination.  Selenomethionine 
substituted protein was expressed and purified as wild-type with the 
following exceptions.  An overnight-culture of BL21(DE3) cells 
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transformed with MBD2-MBD variants were used to inoculate 1L of 
minimal media from the M9 SeMET High-yield Media Kit (Medicillon). 
Cells were grown at 37oC until an OD600 of 1.0 and induced as described 
previously. Upon induction, an amino acid mixture and seleno-
methionine slurry were added per manufacturer’s instructions to inhibit 
methionine synthesis and promote selenomethionine incorporation.  
Cells were grown for 16 hours at 16-20oC and harvested.   Protein 
purification proceeded as described previously except 1mM TCEP was 
added to all purification buffers.  
 Complexes between selenomethionine incorporated MBD2-MBD-
R195M crystals were obtained mixing 1mM protein (100mM NaCl, 10mM 
Tris pH 7.4, 1mM TCEP) with 1mM 14bp methylated DNA under 
conditions 28%-32% PEG8000, 0.2M NaOAc, 0.1M Bis Tris Propane pH 
6.5 in hanging drop vapor diffusion 24 well plates. Crystals appeared 
approximately 2-3 days after trays were assembled and stored at 25oC 
and were frozen with cryopreservative consisting of 42% PEG8000 or 
35% PEG8000/15% Glycerol, 2mM MgCl2, 1mM TCEP, 0.2M NaOAc, 
0.1M Bis Tris Phosphate pH 6.5 and stored in liquid nitrogen. SAD data 
for this mutant was collected on beam line 23-ID-D-GM/CA at the 
advanced photon source at Argonne National Laboratory with significant 
help from Jacqueline McCabe and Professor Dan Leahy. 
Complexes between selenomethionine incorporated MBD2-MBD-
L193M crystals were obtained mixing 1mM protein (100mM NaCl, 10mM 
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Tris pH 7.4, 1mM TCEP) with 1mM 14bp methylated DNA under 
conditions 2M ammonium sulfate and 0.1M Na Acetate trihydrate, pH 
4.6 in hanging drop vapor diffusion 24 well plates. Crystals 
approximately 40x40x40µm in size appeared approximately 3-5 days 
after trays were assembled and stored at 25oC and were frozen with 
cryopreservative consisting of the same condition above supplemented 
with 20% glycerol and stored in liquid nitrogen. SAD data for this mutant 
were collected on beam line 7-2 at the advanced photon source at 
Argonne National Laboratory with significant help from Pat Byrnes and 
Professors Dan Leahy and Scott Bailey.   
 
X-ray Crystallographic Data Collection and Structure Determination 
Data were collected at beam line 23-ID-D-GM/CA or 7.2 at the 
Stanford Synchrotron Radiation Light Source (12658.96 eV = 0.9794Å) 
and processed with HKL2000(104)(R195M protein) or XDS(109)(L193M 
protein). Initial heavy atom sites were identified using ShelxC/D(106). 
Single-wavelength anomalous dispersion (SAD) phases were calculated in 
SOLVE(107). A single-round of density modification in RESOLVE (108) 





 I would like to make a very special acknowledgement to Dr. Dan 
Leahy and my collaborators in his lab. Apart from serving on my 
committee, Dr. Leahy spent hours of his time discussing and explaining 
the foreign language that is crystallography to an overzealous and 
completely naïve graduate student. Without his unending patience 
through numerous crystal structures, including solving both lysozyme 
and B-form DNA accidentally, we would never have gotten anywhere near 
where we are now. I truly felt like a member of his lab every moment I 
was in the Hunterian building, thank you! And to my collaborators in 
Dan’s lab I leave you these thoughts:  
I started as a second year graduate student, wide eyed and bushy 
tailed, with Dr. Ping Liu as my mentor. Ping’s hard work and teachings 
are best described in a story: she was kind enough to entrust her only 
daughter to my care while she ran my experiments in lab. It was 
probably mostly because she didn’t want to get pink eye (which her 
daughter had at the time) but I really think it was because she didn’t 
trust me to do just about anything in the lab; a wise decision in my 
opinion. Through the course of a year I slowly gained Ping’s trust and 
she taught me all the basics behind setting up trays, shooting crystals, 
collecting data and crossing your fingers and hoping for good diffraction. 
On top of laying the groundwork for my understanding of this field and 
for all the future structure work with this protein we collected a native 
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MBD2-MBD data set July of 2010. My first data set, I’ll never forget the 
excitement. We did go on to solve one structure together over 
Thanksgiving of 2010, thank you Mr. Lysozyme!  
Jackie McCabe, my lab wife. I can’t think of anyone who I enjoy 
arguing with more, except of course my real wife. Hopefully if Sarah 
reads this she won’t be too jealous. I’ve never met anyone more 
meticulous and unrelenting than Jackie. No matter how well I thought I 
had done or thought out an experiment/problem, Jackie was always 
there to show me where the MBD2 herpes project could improve and why 
what I did wasn’t great, or oftentimes even above average. For her 
countless hours shooting xtals, collecting and ultimately processing data 
thank you! We’ll always share the zinc based DNA structure we solved 
together. 
And to Pat Byrnes, my current collaborator. While he lacks Ping’s 
height, or Jackie’s meticulousness, Pat makes up for in charming looks 
and thoroughness. Right when the MBD2_MBD project was in a spiraling 
mess Pat stepped in and valiantly improved the outlook of the project, no 
small task. For your many mutants, including the one that ultimately 
will solve this structure, and very late odd hours, thank you! 
And finally the dynamic married duo Dr. Jennifer Kavran and Dr. 
Scott Bailey. I thought it was very fitting that at the end of the day Scott 
is the one that shot the seleno-met xtal that provided us with our 
electron density map and Jennifer will be the one that solves it (or holds 
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someone’s hand doing so). While most of the time they looked upon me 
with pity because of my lack of crystallography charm (and certainly 
theory) they spent hours of uncompensated time providing guidance and 
expertise. I will probably never get a chance to repay them for their 
efforts, so until the next fantasy football game or dinner out thank you! I 
will certainly be wearing your gift at my defense. And for the record, Ping 
told me to put that lysate directly on the column… 
 This work was supported by funding from the Prostate Cancer 
Foundation, the Patrick C. Walsh Prostate Cancer Research Fund, 
Department of Defense Prostate Cancer Research Program Pre-doctoral 










Development of a High Throughput Screening Assay for Discovery of 






Methylated DNA binding proteins such as Methyl-CpG Binding 
Domain Protein 2 (MBD2) can transduce DNA methylation alterations 
into a repressive signal by recruiting transcriptional co-repressor 
complexes. Interfering with MBD2 could lead to re-activation of tumor 
suppressor genes and therefore represents an attractive strategy for 
epigenetic therapy. We developed and compared fluorescence polarization 
(FP) and time resolved fluorescence resonance energy transfer (TR-FRET)-
based high-throughput screening (HTS) assays to identify small molecule 
inhibitors of the interaction between the methyl binding domain of MBD2 
(MBD2-MBD) and methylated DNA. The TR-FRET assay (Z’ factor = 0.58) 
emerged as a superior screening strategy compared to FP (Z’ factor = 
0.08) when evaluated in a HTS 384 well plate format. Using TR-FRET we 
screened the Sigma® LOPAC library for MBD2-MBD inhibitors and 
identified 4 compounds that also validated in a dose response series. 
This included two known DNA intercalators (mitoxantrone and 
idarubicin) amongst two other inhibitory compounds (NF449, and 
aurintricarboxylic acid). All four compounds also inhibited the binding of 
SP-1, a transcription factor with a GC-rich binding sequence, to a 
methylated oligonucleotide demonstrating that the activity was 
nonspecific. Our results provide proof-of-principle for using TR-FRET-





Epigenetic silencing of tumor suppressor genes via DNA 
hypermethylation has been established as a common hallmark of 
oncogenesis(111) . The methylation of CpG dinucleotides, particularly at 
gene promoters and regulatory regions, has been shown to induce 
epigenetic gene silencing via the recruitment of methyl-binding domain 
(MBD) proteins such as MBD2, Methyl-CpG Binding Domain Protein 1 
(MBD1) and Methyl-CpG Binding Protein 2 (MeCP2) and their associated 
chromatin remodeling/co-repressor complexes such as Mi2-NuRD(112). 
These complexes are capable of remodeling the local chromatin and 
preventing the transcriptional machinery from gaining access to DNA, 
leading to transcriptional repression(113). Recent pharmacological 
interventions for reversal of epigenetic gene silencing in cancer have 
focused on inhibiting DNA methyltransferases (DNMTs), which establish 
the DNA methylation marks, and histone deacetylases (HDACs), which 
are part of transcriptional repressive complexes that signal chromatin 
compaction via removal of acetylation modifications on histone tails(114). 
Importantly, such efforts have led to FDA approval of two DNMT 
inhibitors and two HDAC inhibitors for myelodysplastic syndrome and 
cutaneous T-cell lymphoma respectively(115).  
However, there has been little effort in developing inhibitors of the 
methyl binding domain class of proteins, despite the findings from 
several recent reports credentialing these proteins, particularly the 
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MBD2 protein, as anti-cancer drug development targets(116). At the 
molecular level, RNAi-mediated depletion of MBD2 led to re-expression of 
epigenetically silenced tumor suppressor genes with promoter CpG 
methylation(117). In vivo, genetic disruption of Mbd2 in Apcmin mice, 
which are prone to developing dozens of intestinal tumors within 4 – 6 
months of age(118), led to remarkably reduced tumor formation and 
increased survival(67). Interestingly, while mice carrying homozygous 
disruption of Dnmt1 alleles show embryonic lethality, mice with 
homozygous Mbd2 disruption have a normal life span, size and 
reproductive potential, suggesting a favorable toxicity profile for targeting 
MBD2. Taken together, these observations suggest that MBD2 has 
potential as an anti-cancer drug development target(116). 
 Development of MBD2 antagonists as molecular probes of 
epigenetic mechanisms and as anti-cancer epigenetic drugs would be 
greatly aided by the availability of a suitable high-throughput screening 
assay. Here we describe the development of a modified time-resolved 
fluorescence resonance energy transfer (TR-FRET)(119) assay for 
measuring MBD2-MBD binding to methylated DNA (Figure 3.1). TR-
FRET utilizes the long-lived fluorescence of lanthanide metals to monitor 
fluorescence resonance energy transfer after a time delay, when auto 
fluorescent signal has decayed significantly. This translates into a robust 
signal-to-noise ratio when measuring the binding of two ligands. The TR-
FRET assay was highly amenable to high-throughput screening of small 
86 
 
molecule libraries and showed significantly superior performance 
compared to a fluorescence polarization(120) based assay format. We 
used this TR-FRET screening approach in a pilot screen of 1,280 highly 
studied compounds, identifying small molecules capable of inhibiting 






Figure 3.18: Overview of TR-FRET and Fluorescence Polarization MBD2-MBD DNA-
binding assays.  
(A) TR-FRET overview: MBD2-MBD protein containing a hexa-histidine tag is mixed 
with FAM-labeled DNA and terbium-labeled anti-penta-His antibody (Tb-Ab). The 
MBD2-MBD-Tb-Ab-bound complex is excited with a pulse of 332nm laser light and 
emission is monitored at 485nm and 515nm (result of FRET) after a 50 µsec delay. The 
ratio of the 515nm and 485nm emission intensity provides a measure of the extent of 
binding. (B) Fluorescence polarization assay overview: MBD2-MBD is incubated with 
FAM-labeled DNA. The reaction is excited with plane-polarized light, and the extent of 
polarization of the emitted light is measured using parallel and perpendicular 




TR FRET and Fluorescence Polarization Assay Validation 
We developed both TR-FRET and FP based assays to measure the 
binding of MBD2-MBD to methylated DNA, and evaluated each of these 
assays for use in high-throughput screening for inhibitors capable of 
disrupting this binding (Figure 3.2). Both assays showed strong 
preferential binding of MBD2-MBD to methylated DNA (EC50 of 86nM 
and 42.7nM, respectively) compared to unmethylated DNA (EC50 >> 1µM) 
as expected (Figure 3.2A,B) (63). Using these experiments, we determined 
the optimal concentrations of MBD2-MBD, labeled-oligo, and other assay 
components for each assay (see methods). Using a series of four controls 
(n = 32 replicates of each), we evaluated the performance of both assays 
for use in high throughput chemical compound screening, as determined 
by calculating the Z’ factor (Figure 3.2C,D). The TR-FRET assay showed 
significantly better signal-to-noise ratios (Z’ factor = 0.59) compared to 
that of the FP assay (Z’ Factor = 0.08). As expected, the negative control 
(unlabeled unmethylated oligonucleotide) did not significantly disrupt 
binding of MBD2-MBD in either assay. Additionally, both assays 
measured significant DNA binding inhibition by a competitive inhibitor 
positive control (excess unlabeled methylated oligonucleotide). The TR 








Figure 3.2: Performance of TR-FRET and FP MBD2-MBD DNA binding assays.  
 
(A,B) The binding curves of MBD2-MBD to methylated and unmethylated DNA 
substrates was measured using the TR-FRET (A), and FP (B) assays. (C,D) Performance 
of the TR-FRET (C) and FP (D) assays with control treatments in 384 well format using 
25nM labeled substrate oligonucleotides. Lane 1 (DMSO vehicle control) and Lane 3 
(excess unlabeled unmethylated DNA) are negative inhibitor controls; Lane 2 is a 
positive inhibitor control, consisting of excess fluorophore free methylated DNA. Lane 4 
is an assay negative control, showing lack of binding with FAM labeled unmethylated 




Pilot screen of LOPAC1280 TM compounds for inhibition of MBD2-MBD 
binding to methylated DNA 
To assay inhibitors of MBD2_MB2 binding a methylated 
oligonucleotide, we used the 1280-compound Library of 
Pharmacologically Active Compounds (LOPAC™) (Sigma Aldrich®). This 
library consists of a variety of drug and drug-like compounds with well-
studied mechanisms, as well as molecules from larger chemical 
compound libraries. Test compounds from the LOPAC™ were added to 
our optimized TR-FRET assay at a final concentration of 20µM. The 
compounds were assayed across four 384 well plates with each plate 
containing positive and negative controls (Figure 3.3A). The TR-FRET 
signal from most compounds followed a normal distribution centered 
around the median of the negative control. Z and Z’ factors were 
calculated for each plate (Figure 3.3B); Z’ factors for each plate were 
0.69, 0.73, 0.73 and 0.55 respectively. As expected, Z factor scores for 
each plate were lower than their respective Z’ score but all were above 
0.5. The LOPAC™ screen replicated the sensitivity of the initial validation 
and also Identified ten compounds that significantly inhibited MBD2-
MBD binding to methylated DNA after correction for multiple hypothesis 




Figure 3.3: Screening of LOPAC1280™ library with the MBD2-MBD TR FRET assay.  
 
(A) TR FRET ratios for each compound were normalized to the plate median and plate 
standard deviation to obtain a standardized Z-score that was plotted for each 
compound. Open circles represent compounds with significant binding inhibition. The 
dotted line represents the Z-score cutoff corresponding to a Bonferroni adjusted p-value 
< 0.05. Each of the four plates contained 16 replicates of four controls, including two 
inhibitor controls and two assay controls (see box plots). Those primary hit compounds 
(open circles) that were confirmed through dose-response analysis (see Figure 3.4) are 
labeled. (B) Z’ and Z factors for the screen data were calculated for each plate according 
to equation (1) as described in Materials and Methods. In all cases Z’ was greater than Z 




Table 3.1: Significant hits from the Sigma® LOPAC1280™ screen  
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Dose response of hits for inhibition of MBD2-MBD binding to methylated 
DNA 
To validate the “hits” observed on the LOPAC™ screen, we assayed 
each compound in a dose-response (Figure 3.4, Table 1). A suramin 
analog, Reactive blue 2, emerged as a “hit” from the primary screen but 
was excluded from the secondary analysis because its coloration and 
light absorption could interfere with the assay. Of the remaining 9 
compounds, four compounds (mitoxantrone, idarubicin, 
aurintricarboxylic acid, and NF449) showed a sigmoidal dose-response 
for inhibition of MBD2-MBD binding to methylated DNA, while five 
compounds (6-Hydroxy-DL-DOPA, Carbetapentane citrate, Dephostatin, 
Me-3,4-dephostatin, and L-CCG-I) failed to show appreciable inhibition 
in the dose range tested (Figure 3.4, Table 1).  Mitoxantrone and 
idarubicin, are known DNA intercalators (121, 122), and 
aurintricarboxylic acid is known to polymerize in water and can inhibit 
many macromolecular protein-nucleic acid interactions (123). These 
three compounds would be expected to nonspecifically inhibit DNA-
protein interactions. Interestingly, a suramin analog, NF449, known to 
inhibit P2X1 receptors with picomolar potency and high selectivity 
compared to P2X2 receptors (124), also emerged as a dose-response 
validated inhibitor of the MBD2-MBD interaction with methylated DNA, 










Figure 3.4: Dose response curves with significant hits 
 
The 9 hit compounds from the primary screen were tested with the TR-FRET 
assay using a 4-fold dose response series from 1.2nM to 20µM (4 replicates 
each). Controls are shown as red open circles. Four of the 9 compounds showed 
a potency for inhibition of MBD2-MBD binding to DNA within the dose range 





Counter screen with the DNA Transcription factor SP-1 
To assess the specificity of the four verified hit compounds for 
inhibiting binding of MBD2-MBD to methylated DNA, we developed a 
counter screen (Figure 3.5A) using the transcription factor SP-1 to 
identify those hits that would also inhibit binding of an unrelated protein 
to DNA or some other components of the assay. The transcription factor 
SP1 has been shown to localize to GC rich regions in the human genome, 
including promoter CpG islands where MBD2 can be found (117). 
However, SP-1 has no known specificity for methylated DNA, which we 
verified (EC50 = 22nM for both methylated and unmethylated DNA 
(Figure 3.5B) (125). We then tested MBD2-MBD inhibitors from the 
LOPAC™ for cross-inhibition of SP-1. All four hit compounds inhibited 
SP-1 in a dose-response manner (Figure 3.5C), suggesting that these 
compounds are unlikely to be selective inhibitors of MBD2-MBD binding 







Figure 3.5: Counter-screen with DNA transcription factor SP1 to assess 
specificity of identified hit compounds.  
 
(A) Overview of TR-FRET assay for measurement of SP-1 binding to DNA. (B) 
Transcription factor SP-1 binding to methylated and unmethylated 
oligonucleotides in the TR FRET assay. There appears to be no dependence of 
the methylation status on protein-DNA binding. (C) All 4 compounds showing a 
dose-responsive inhibition of MBD2-DNA binding were also capable of inhibiting 
SP1-DNA binding in a dose-dependent manner. 
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3.4  Discussion 
 We have developed a robust, high throughput, TR-FRET based 
assay for screening small molecule libraries for inhibitors of MBD2_MBD 
protein binding methylated DNA. Compared to a fluorescence 
polarization based approach, our TR-FRET assay provides a better 
signal-to-noise ratio, resulting in improved Z’ factors under optimized 
screening conditions. We used this assay to analyze the 1280 compound 
LOPAC™ library to identify small molecules capable of inhibiting the 
interaction of MBD2-MBD with methylated DNA. Of the initial 9 hits, 
four showed a robust sigmoidal inhibitory dose-response. Three of these 
four compounds, mitoxantrone, idarubicin, and aurintricarboxylic acid, 
would be expected to inhibit MBD2-MBD binding to methylated DNA 
given that each  are known to inhibit multiple DNA-protein interactions. 
This was confirmed by our counter-screen which showed that these 
compounds also prevented binding of SP1 to DNA with similar potency. 
However, the ability of NF449 to inhibit MBD2-MBD binding to 
methylated DNA was not anticipated. 
NF449 is a suramin analog which can inhibit the P2X1 receptor 
with sub-nanomolar potency  (126, 127). The P2X family form homo or 
heterotrimeric complexes on the surface of many cell types, forming ATP-
gated cation channels (128) that have been implicated in multiple 
cellular processes (129). The mechanism of inhibition features ionic 
interactions between the 8 sulfonic acid groups on NF449 with positively 
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charged basic amino acids at the base of a cysteine-rich loop on P2X 
family members (127). The selectivity of NF449 to P2X1 compared to 
other P2X and P2Y members is thought to arise through a second 
favorable contact between the compound and lysine 138 near the ATP 
binding pocket (127). NF449 has also been shown to inhibit other 
proteins, including the G protein alpha subunit (130) and FGFR3 (131). 
In each case, the number and orientation of the negatively charged 
sulfonic acid groups on NF449 were thought to be critical for inhibition. 
We speculate that NF449 may similarly inhibit MBD2: the negatively 
charged sulfonic acids on NF449 may disrupt the binding of positively 
charged basic residues on the MBD2 surface with the negatively charged 
phosphate backbone of DNA (99). A similar mechanism may also be 
responsible for the observed disruption of SP1 binding to DNA by NF449 
in our counter screen. Additionally, the previous work examining the 
inhibition of FGFR3 by NF449 suggested that the compound may be 
capable of interacting with the intracellular tyrosine kinase domain of 
FGFR3 (131). NF449 may therefore be available in the intracellular space 
for activity. If this proposed intracellular bioavailability is confirmed, 
then NF449, or its derivatives, may have promise as pharmacological 
probes for studying MBD2 function in cells. Additionally, in future work, 
it may be possible to find NF449 derivatives that are capable of 
selectively inhibiting MBD2 and not other DNA binding proteins, 
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analogous to the selectivity of NF449 for P2X1 compared to other P2X 
receptors (127). 
These data demonstrate the utility of our TR-FRET based MBD2 
methylated-DNA binding assay and coupled counter screen to identify 
and test the specificity and activity of small molecules. This TR-FRET 
based primary screening and counter-screening assay should be easily 
adaptable to more extensive small molecule libraries in order to discover 






 A codon optimized sequence for the MBD2-MBD polypeptide was 
synthesized and cloned into the pGSE6 vector (Genscript USA Inc) for 
expression in bacteria as a C-terminal hexa-histidine tagged fusion 
protein. Briefly, BL21 DE3 cells (Agilent Technologies) were transformed 
with this construct, allowed to grow to an OD600 of 1.0, and were induced 
with 1mM Isopropyl β-D-1-thiogalactopyranoside (IPTG, Corning Cellgro) 
overnight in a shaking incubator at 220 rpm and 20oC. Bacteria were 
lysed using a French press in equilibrium buffer containing 300 mM 
NaCl, 50 mM sodium phosphate pH 8.0, 5 mM imidazole (Sigma Aldrich), 
and a protease inhibitor cocktail (Roche USA). Lysates were centrifuged 
at 17,000xg for 30 minutes and then incubated with IMAC Nickel NTA 
beads (Bio-Rad) for 1 hour at 4oC. The beads were washed three times 
with equilibrium buffer containing 15 mM, 20 mM and 25 mM imidazole, 
respectively, and affinity purified protein was eluted in equilibrium buffer 
containing 150mM imidazole. The his-tagged protein was further purified 
by gel filtration using a Superdex g75 26/300 Column (GE Healthcare 
Life Sciences) in storage buffer (150mM NaCl, 20mM Tris pH 7.4, 1mM 
tris(2-carboxyethyl)phosphine (TCEP, P212121 LLC, Toledo, Ohio). 
Fractions containing the purified MBD2-MBD were concentrated with 
3000 MWCO Amicon® Ultra-4 Centrifugal Filter Units (Millipore) and 




Fluorescence Polarization Assay 
Fluorescence polarization binding assays were performed as previously 
described (117). Briefly, MBD2-MBD protein was added in a dilution 
series to the reaction buffer containing 4% glycerol, 1 mM MgCl2, 0.5 
mM EDTA, 0.5 mM DTT, 125 mM NaCl, 10 mM Tris–HCl (pH 7.4), 0.2% 
Tween-20 up to a total working volume of 20µL. Hairpin-forming 
oligonucleotides with the sequence 5′-fluorescein (FAM)-
ATGCTCGTAGCACTTTTGTGCTACGAGCAT-3′ (unmethylated) or 5′- 
fluorescein - ATGCTCmeGTAGCACTTTTGTGCTACmeGAGCAT-3’ 
(methylated) were annealed by heating to 95oC and cooling on ice rapidly. 
They were then added to the binding reaction to a final concentration of 
10nM. Binding assays were carried out in 384-well black, flat-bottom 
plates (Corning) in quadruplicate replicates. The plate was incubated at 
4oC for 1 hour with gentle shaking. Fluorescence polarization readings 
were performed on a Safire2 (Tecan) instrument with excitation at 470nm 
and monitoring emission at 525nm. Anisotropy values were acquired and 
plotted relative to MBD2-MBD protein concentration and fitted using the 
open source software R version 2.12.1 (132). The optimal conditions of 
10nM oligonucleotide and 200nM MBD2 protein were used for the high 
throughput assay. Positive and negative inhibitor controls consisted of 
5µM of hairpin oligonucleotides (either methylated or unmethylated) with 
the same sequence described above but without a FAM label, and were 
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analyzed in 32 replicates each. Z’ factors were calculated using the 
equation (1):  
𝑍′ = 1 − 3 𝑥 
𝑆𝐷𝑚−𝑆𝐷𝑢
|µ𝑚−µ𝑢|
   (1) 
where SDm and µm are the standard deviation and mean anisotropy 
values respectively of protein binding to the methylated FAM labeled 
oligonucleotide, and SDu and µu are the standard deviation and mean of 
anisotropy values respectively of the protein binding to the unmethylated 
FAM labeled oligonucleotide (133). 
 
Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) 
TR-FRET assays were performed in 384-well black low volume plates 
(Greiner Bio One) with a total working volume of 20µL. MBD2-MBD 
protein at 25nM was added to the same buffer as described above for 
fluorescence polarization. The FAM-labeled oligonucleotides described 
above were added in a dilution series and LanthaScreen® Elite Tb-anti-
His-Tag Terbium-labeled antibody (Life Technologies) was added to a 
final concentration of 5nM. The plate was incubated at 4oC with gentle 
shaking for 1 hour. The plates were read on a Safire2 (Tecan) instrument 
with excitation at 332nm and emission read at 485nm (to read FAM 
emission) and 515 nm (to read Terbium FRET emission) after a delay of 
50 µsec and a total integrated read time of 400 µsec. The ratio of the 515 
nm and 485 nm readings was used to assess the degree of FRET, which 
is proportional to the amount of total binding. The ratio from a control 
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sample containing no protein was subtracted from the other data and the 
binding curves plotted relative to total DNA concentration. Curve fitting 
was performed using the open source software R version 2.12.1. The 
optimal conditions were determined to be 30nM oligonucleotide and 
25nM MBD2 protein. Positive and negative inhibitor controls consisted of 
5µM of oligonucleotide (either methylated or unmethylated) with the 
same sequence described above but without a FAM label, and were 
analyzed in 32 replicates. Z’ factors were calculated in the same manner 
listed above. 
 
LOPAC1280 TM Screen 
The 1280 compound Library of Pharmacologically Active Compounds 
(LOPAC)™ (Sigma-Aldrich) was screened using the TR-FRET assay 
described above with optimized conditions in 384-well low volume plates 
(Greiner Bio-One) in a reaction volume of 20µL. A final concentration of 
20µM in 10% dimethyl sulfoxide (DMSO) was used for each compound. 
Four controls were used on each plate with 16 replicates for each control: 
1) a 10% DMSO vehicle control, 2) 5µM of unlabeled, methylated 
oligonucleotide described above as a competitive inhibitor positive 
control, 3) unmethylated, FAM-labeled oligonucleotide described above as 
a technical control, and 4) a second technical control in which no MBD2-
MBD protein was added. Plates were incubated for 1 hour at 4oC and 
read using the Safire2 (Tecan) and the conditions listed above. The 
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emission ratios were calculated as described above and were adjusted 
based on the median plate value for each plate. For each compound i on 





where xi,j is the TR-FRET signal for each compound, Xj is the median 
plate TR-FRET signal across all compounds on that plate, and sigma is 
the standard deviation across all compounds on plate j. The two-sided p-
value associated with the Z-score was calculated assuming a normal 
distribution and was subjected to Bonferroni correction. Compounds 
with Bonferroni adjusted p-value < 0.05 were considered significant hits. 
The Z’ factor was calculated for each plate separately using equation (1).  
Additionally, a Z-factor was calculated for each plate according to 
equation (1), except that SDm and mean µm represent the standard 
deviation and mean ratio values respectively for all compounds on each 
plate.  
 All compounds that significantly inhibited protein binding in the 
LOPAC screen were tested in a dose-response series (1nM to 20µM) using 
the TR FRET assay. Also included were a negative vehicle control (DMSO 
only) and a positive inhibitor control using 5µM unlabeled methylated 
oligonucleotide. Curve fitting was performed using the open source 
software R version 2.12.1. 
 
Counter screen with the Transcription Factor SP-1 
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We adapted the TR-FRET assay for assessment of recombinant Hexa-His-
tagged SP1 protein binding to the unmethylated hairpin oligonucleotide 
described above. The assay was performed using 10nM of the DNA 
binding transcription factor SP1 (Abcam), 100nM FAM-labeled 
oligonucleotide, and compounds in a dose response from 1nM to 20µM, 
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Chapter 4  
 
High Throughput Screen to Discover Small Molecule Inhibitors of 





4.1  Abstract 
 In the past two decades a significant effort towards discovering 
small molecule inhibitors of epigenetic proteins has occurred. Despite 
mounting evidence that epigenetic alterations are not only stably selected 
but also drivers of many cancers only 4 drugs have received FDA 
approval. These medications target either the DNA 5-methylcytosine 
writer protein DNMT1 or the histone eraser protein family known as 
HDAC’s. In this work we use a high throughput screening approach to 
find small molecule inhibitors of the DNA methylation reader protein 
MBD2, a novel epigenetic target. 
In collaboration with the Scripps Institute® we utilized a TR FRET 
based assay (chapter 3) to screen the NIH’s MLPCN small molecule 
library consisting of 370,276 compounds. We found 1,149 compounds 
(0.31%) able to significantly disrupt MBD2-MBD from binding 
methylated DNA (meDNA). The assay performed as expected with a 
Z’=0.84±0.01 and Z=0.79±0.10. Of the primary screen active compounds 
271 validated in triplicates at a single dose. We employed a counter 
screen using another methyl cytosine reader protein, UHRF1, also in a 
TR FRET based assay, to find nonspecific DNA-protein disruptors. 
Comparing the counter screen and secondary screen we classified 48 
compounds as both significant binding disruptors and as being MBD2 
specific. 46 of the active compounds were subjected to a dose response 
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with our UHRF1-SRA and MBD2-MBD TR FRET assays, identifying 18 as 
both MBD2-specific and having an IC50≤10µM.  
MCF7 and LNCaP cancer cell lines were subjected to 17 of the 18 
active compounds found by our screen in both a single and dose 
response series. This treatment resulted in 6 compounds causing 
significant re-expression of epigenetically silenced genes. All but one of 
these small molecules also caused luciferase expression on a plasmid 
containing a fully methylated GSTP1 promoter driving luciferase.  
Biophysical analysis showed that none of the 17 active compounds 
altered the melting temperature of MBD2-MBD protein to a significant 
extent in a thermal melt assay. A DNA intercalator competition assay 
revealed that all but 3 of the original 17 hit compounds significantly 
displaced Sybr® green from DNA, suggesting the majority of our hits 
interact with DNA in a methylation and protein independent manner. 
Only 2 of the compounds were capable of relieving epigenetic repression 
in our cell based assays. The binding specificity and IC50 results were 
confirmed by isothermal calorimetry experiments. Interestingly NF449, a 
small molecule identified in the LOPAC1280™ screening efforts, bound 
MBD2 protein in a specific and dose responsive manner by ITC.  
We investigated the mechanism of action for the two most 
biologically active compounds, KCC-120 and KCC-111, by performing 
ChIP experiments on MCF7 cells. Interestingly, at methylated and 
unexpressed promoters both compounds caused a shift towards a more 
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open chromatin state with increases in H3K4 trimethylation and H3K9 
acetylation and loss of H3K27 and H3K9 trimethylation. These changes 
were not observed at unexpressed but unmethylated promoters or highly 
active promoters. Some loss of MBD2 at methylated promoters was also 
observed, providing a possible explanation for this observation.  
The HTS and follow-up experiments ultimately identified three 
possible MBD2-MBD interacting compounds: KCC-127 and 131, which 
were inactive in the ITC, protein melt curve or DNA intercalator assays, 
and NF449, which shows micromolar affinity to MBD2 in vitro. Two DNA 
interacting compounds, KCC-111 and 120, significantly relieve epigenetic 
repression and do so by causing chromatin changes and possibly 
disrupting MBD2 binding. Work is ongoing to determine whether KCC-
131 and 127 are targeting MBD2 and if NF449 has biological activity. 
Through these efforts we’ve identified lead compounds for interruption of 
a novel epigenetic target. 
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4.2  Introduction 
It is well established that epigenetics plays an important role in a 
number of neoplastic malignancies (134-137). A significant effort, 
particularly over the past decade, to find novel small molecule inhibitors 
of key epigenetic proteins has thus emerged. To date, medications 
targeting the epigenetic writer protein DNMT1 and eraser HDAC proteins 
have won FDA approval, all with hematopoietic indications (19). Because 
of these successes the majority of work in epigenetic therapy has been 
spent investigating novel DNMT and HDAC inhibitors. Other targets have 
recently entered the field and are of intense interest. For example 
bromodomain and extra terminal (BET) and bromodomain containing 
proteins have become extremely popular targets due to recent evidence 
that their inhibition significantly hinders proliferation and aggressiveness 
in numerous cancer models(138). We will briefly discuss the key 
epigenetic targets and the efforts towards inhibiting them for therapeutic 
efficacy. 
The first epigenetic protein targeted by small molecules was the 
DNA methylation writer protein DNMT1, with azacytidine winning FDA 
approval for all subtypes of myelodysplastic syndrome (MDS) in 
2004(139). Azacytidine, in three clinical trials run by the Cancer and 
Leukemia Group B (CALGB), improved life expectancy relative to 
supportive care, but did not change the overall conversion rate to acute 
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myeloid leukemia (AML), the most lethal outcome for this disease. 
Azacytidine is a cytidine mimic and is incorporated into both DNA and 
RNA, disrupting translation machinery as well as causing 
hypomethylation and replication fork collapse (139, 140). A number of 
second generation DNMT1 inhibitors are in development (i.e. zebularine) 
or are already FDA approved (i.e. decitabine) and remove the RNA 
incorporation seen with azacytidine(141). This significantly lowers 
unwanted side effects and toxicity(141). The mechanism of action for this 
class of inhibitors is complicated. The cell death caused by DNA 
replication collapse seen in the setting of high levels of azacytidine is 
easily understood, as most chemotherapeutics act in a similar manner. 
The epigenetic mechanism of action is a bit less clear. In an ideal setting 
DNMT1 inhibition relieves DNA methylation based silencing of a tumor 
suppressor gene, such as p16, allowing it to resume normal function and 
cause apoptosis or senescence(142). While evidence exists that this 
occurs, increases in reactive oxygen species and the major chromatin 
structure changes that occur with DNMT1 inhibition may also contribute 
to the therapeutic effect (142-144). The ultimate mechanism behind the 
pharmacodynamics is likely a combination of these processes, but that 
remains to be proven. A recent crystal structure of DNMT1 bound to DNA 
has rekindled interest in this target and a number of groups have begun 
efforts at structure aided design to find novel non cytidine mimicking 
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small molecules(145). Significant interest remains in finding novel 
DNMT1 inhibitors with less toxicity and greater efficacy. 
The second class of proteins currently targeted in the clinic is the 
histone deacetylase family. In 2006 the FDA approved vorinostat, a pan-
HDAC inhibitor and the first non-DNMT1 epigenetic targeting agent 
certified for patient use. Vorinostat approval occurred following an open 
label trial which demonstrated significant delay in progression time in 
patients with cutaneous T-cell lymphoma (CTCL) pretreated with the 
medication(20). Quality of life scores also significantly improved under 
this therapy regimen. Since vorinostat’s approval, only romidepsin, also 
for CTCL, has made it past clinical trials as an HDAC inhibitor(21). Both 
of these agents are pan inhibitors, targeting numerous classes of 
HDAC’s. Interestingly, despite targeting different HDAC classes, the 
mechanism of action for both vorinostat and romidepsin are the same, 
involving abrogation of a key zinc metal and the enzymatic active site 
(142, 146). Similar to DNMT1 inhibitors, the mechanism behind the 
therapeutic index is multifaceted: dependent upon up regulation of 
tumor suppressors, silencing of anti-apoptotic genes, increased levels of 
reactive oxygen species, and anti-angiogenic factors(146). A significant 
amount of work remains to be done to fully understand the ideal HDAC 
classes or histone eraser proteins to target, as well as find more potent 
inhibitors of this class of proteins (147, 148). 
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More recently, a wave of enthusiasm for targeting another 
epigenetic reader protein has swept through the scientific community. 
Similar to methylated DNA, acetyl histone modifications are read by a 
large family of reader proteins that assist with enforcing the chromatin 
state. The domain responsible for identifying this epigenetic mark and 
mediating downstream gene expression is known as the 
bromodomain(149). The human genome contains 42 genes that encode 
for at least one of 61 bromodomains(150). These proteins often hold 
additional classes of histone reading domains, such as HAT or PHD 
domains(151). Bromodomains themselves have no enzymatic activity and 
rely on recruiting complex members or positioning other domains in the 
same protein to promote gene expression(150). Much of the excitement 
behind this class of proteins stems from the specificity provided by their 
structures(152). Though the binding pocket of all bromodomains is 
hydrophobic and well conserved, the entry into the pocket contains 
numerous unique residues which make it possible to design protein 
specific inhibitors (153-155). Recently, two groups successfully targeted 
BET containing bromodomain family members, BRD4 and BET151, with 
nanomolar affinity(156, 157). Interestingly, BRD4 inhibition shows 
significant anti-proliferative and anti-anchorage independent growth 
effects in a number of different cancer cell models in vitro and in vivo 
(158, 159). Clearly the bar is set high for these novel inhibitors as they 
enter more complicated animal trials and early clinical trials.  
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While the brief discussion here hardly covers the complete scope of 
epigenetic proteins under investigation as targets for therapy it is clear 
that a significant effort is underway. A large body of work on targeting 
the writer DNMT1, histone reader BET/bromodomain and histone eraser 
HDAC exists. Little of these efforts, however, have focused on DNA 
methylation readers. In the previous two chapters we describe an 
exhaustive effort to find optimal conditions and methods for a high 
throughput amenable screen to identify small molecule inhibitors of the 
methylated DNA reader protein MBD2 (110). We now apply our optimal 
assay to the National Institutes of Health (NIH) Molecular Libraries Probe 
Production Centers Network (MLPCN) small molecule screen of ~370,000 
compounds. Four small molecules are identified as effectively disrupting 
the MBD2-meDNA interaction with micromolar affinity. We go on to show 
at least 2 of these compounds have biological activity, causing gene re-





Primary Screen To Find MBD2(MBD)-meDNA Interaction Inhibitors 
The MBD2-methylated DNA TR FRET assay described in chapter 3 
was provided to The Scripps Research Institute® in Florida. With some 
optimization they further miniaturized the assay from 384 to 1536 well 
plate format. The assay was then subjected to the entire MLPCN screen 
comprising 370,276 compounds, as described in the methods. The 
screen deemed 1,149 compounds (0.31%) as significant MBD2-meDNA 
interaction inhibitors: with significance defined as loss of FRET signal >3 
standard deviations from the median (dotted red line Figure 4.1 A and B). 
The Z’ factor for the primary screen was calculated at 0.84±0.01 and 
Z=0.79±0.10.  
Only 1,036 of the compounds from the primary screen were 
available for further work. Each was screened at a single dose in 
triplicate to identify false positives from the primary screen. Only 271 of 
the 1,036 compounds (26.2%) in this second screen validated as 
significant inhibitors of the MBD2-meDNA interaction (Figure 4.2A). The 
Z’ factor for the secondary screening was 0.89±0.03 (Z=0.27±0.00). We 
expected the Z factor statistic in the secondary screen to be low, as all of 
the compounds had already been vetted in the primary effort and were 




Figure 4.1: Primary screen results for the MBD2-meDNA TR FRET high 
throughput screen.  
(A) Summary of all experiments and resulting active compounds for each step of 
the MLPCN screen. (B) Results of the single dose single well primary screen for 





Figure 4.2: Summary of secondary screening results.  
(A) Results of the secondary screening, single dose in triplicate, on the 1036 
active compounds identified in the primary screen. Compounds are plotted 
relative to their inhibition of MBD2 (y axis) and UHRF1 (x-axis). Compounds 
which only significantly inhibit MBD2 are labeled in blue. (B) Venn diagram of 
secondary screen results. 
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our counter screen data as both a query for nonspecific inhibitors of 
MBD2-MBD and also interesting small molecules themselves we opted to 
use the SRA (methylated DNA reading) domain of UHRF1 protein in place 
of SP-1, the transcription factor used during assay development. We 
applied the 1,036 compounds from the MBD2-MBD primary screening 
effort in triplicate to a TR-FRET based assay using UHRF1-SRA and 
hemi-methylated DNA. The results showed that only 48 of the 271 small 
molecules that significantly inhibited MBD2-MBD after the triplicate 
screening were selective (Figure 4.2 A and B). The UHRF1-SRA TR FRET 
screen performed well with a Z’=0.79±0.10. The Z factor was 0.06±0.13, 
providing a good statistical confirmation of what is obvious in the results: 
that the majority of inhibitors from the MBD2-MBD screening are non-
specific protein-DNA interaction disruptors. 
 
Dose Response Series on Potential MBD2-MBD Inhibitors 
Of the 48 MBD2-meDNA specific active compounds identified by 
the secondary screen we obtained 46 for further work. We then subjected 
each to the MBD2 and UHRF1 TR FRET assay in a dose response in 
triplicate. This experiment identified 18 compounds as both MBD2 
specific and also having an IC50 below 10µM (Table 5.1). A more detailed 




Table 4.1: Summary of dose response on 17 active compounds identified in the 








Table 4.1 Continued: Summary of dose response on 17 active compounds 





difference in their inhibition of UHRF1-SRA and MBD2-MBD, with only 5 
having a ratio of their UHRF1 IC50 to MBD2 IC50 > 5. To this point we 
had only queried the specificity of these compounds with one non MBD2 
methylation reader protein, UHRF1-SRA. To further investigate the 
specificity with other proteins we expressed, purified and tested multiple 
MBD family members and verified the recombinantly made protein 
preferentially bound methylated DNA (Figure 4.3). We then applied our 
TR FRET assay using MBD1-MBD, MeCP2-MBD, MBD2-MBD, UHRF1-
SRA and transcription factor SP-1 to the 17 available compounds 
validated in the high throughput dose response screen (Figure 4.4). The 
results placed compounds into one of three categories: MBD selective 
(Figure 4.4 top panel, 7 total), MBD2 and MeCP2 selective (Figure 4.4 
middle panel, 3 total), or non-selective (Figure 4.4 bottom panel, 7 total). 
All active compounds had IC50’s in the micromolar range, confirming 
previous dose response data obtained from the Scripps Institute (Table 
4.1 and Figure 4.4). 
 
Epigenetically Silenced Gene Re-expression Potential of MBD2 Active 
Compounds 
 To lower the likelihood of a false negative we included all 17 







Figure 4.3: TR-FRET binding curves for MBD family members to DNA.  
MBD family members were expressed in bacterial cells and recombinant protein 




Figure 4.4: Dose response curves for MBD family members with HTS active 
compounds.  
All 17 active small molecule inhibitors identified by the HTS screen were added to MBD 
family members in a dose response series to assay specificity. Results binned small 
molecules into one of three categories: MBD specific (upper group), MeCP2 and MBD2 
specific (middle group) or non-specific (lower group). 
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examination of biological activity, regardless of their selectivity when 
tested against the other MBD family members. We began by evaluating 
the compounds’ abilities to re-express known DNA methylation silenced 
genes: GSTP1 in MCF7 cells (breast cancer) as well as GSTP1 and PTGS2 
in LNCaP cells (prostate cancer). Compounds were evaluated at a single 
dose for 48 hours (Figure 4.5A). A total of 6 compounds relieved 
epigenetic silencing in at least 2 of the 3 genes tested (black arrows 
Figure 4.5A).  
 To confirm these results HEK293 cells containing M.SssI treated 
GSTP1 promoter (fully methylated) driving a luciferase reporter gene were 
exposed to compound (Figure 4.5B, Table 4.2). An unmethylated CMV 
driven renilla served as a transfection and viability control. 
Encouragingly, 5 out of 6 of the compounds which re-expressed 
endogenously silenced genes also showed significant luciferase 
expression at a minimum of 2 concentrations (black arrows Figure 4.5B). 
KCC-107 was unable to cause gene re-expression in the reporter assay 
despite causing endogenous gene re-expression. KCC-134 and 112 also 
relieved epigenetic repression in both experiments but had very similar 
family members already represented (KCC-102 and KCC-117 
respectively). As such these compounds were not tested further. 
 To validate these findings we selected the 6 compounds that 




Figure 4.5: Gene re-expression potential of small molecules identified by high 
throughput screening.  
(A) RNA transcript levels of endogenously methylated genes GSTP1 and PTGS2 
measured by real time PCR following a 48 hour treatment of LNCaP or MCF7 cells at a 
single dose. Compounds indicated by the arrow had significant re-expression in at least 
2 genes. (B) Firefly luciferase levels relative to a CMV-renilla control of HEK293 cells 
treated with a dose escalation series of small molecule inhibitors identified by the HTS. 
Luciferase expression was driven by a fully methylated GSTP1 promoter. Arrows 
indicate compounds which relieve epigenetic repression of the luciferase promoter at a 
minimum of two concentrations. 
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Table 4.2: Flow cytometry results of HTS active compounds with a methylated 
GSTP1 promoter driving GFP.  
Percentage of cells with expression of a fully methylated GSTP1 promoter driving GFP 
The first column lists cells that also had expression of a CMV driven renilla while the 
second describes cells that were GFP (methylated promoter) positive but not RFP 
(unmethylated CMV promoter) positive. The final column is the combination of columns 
1 and 2. 
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4.5), and also included 3 more small molecules which showed either 
MBD2/MeCP2 selectivity in the TR FRET MBD family screen (KCC-127 
and KCC-116) or had family members that showed gene re-expression 
and also had slight activity themselves (KCC-102). We treated MCF7 cells 
for 48 hours in a dose response series and assessed expression levels of 
a number of genes previously established as epigenetically repressed, 
and sensitive to MBD2 knock down(160). KCC-120 and KCC-111 showed 
clear dose response re-expression of multiple epigenetically silenced 
genes, with expression levels 1-2 logs higher than DMSO treated cells 
(Figure 4.6). 
 
Biophysical Interactions of Active Compounds with meDNA and MBD2 
Protein 
 After establishing 2 of our 17 compounds as capable of relieving 
epigenetic repression in relevant cancer models we sought to confirm 
whether they were binding meDNA or MBD2-MBD protein. In an effort to 
prevent missing a possible protein binding small molecule we tested all 
17 TR FRET based active compounds, not just those with biological 
activity, using a DNA intercalator competition assay. Briefly, either fully 
methylated or unmethylated plasmid DNA containing the GSTP1 
promoter was pre-incubated with SYBR® green reagent and then 
incubated with increasing concentrations of small molecule for 1 hour. 
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Compounds which interact with DNA, either through minor groove or 
intercalation mechanisms, should disrupt SYBR® green binding to DNA 
and will result in a loss of fluorescence signal (see methods for details). 
Surprisingly, despite incorporating a counter screen to eliminate DNA 
binding molecules, the majority of active small molecules disrupted 
SYBR® green binding to DNA, suggesting they were interacting with DNA 
(Figure 4.7). Only 4 compounds, KCC-131, KCC-127, KCC-101 and KCC-
107, did not interact with DNA. Both KCC-120 and KCC-111, the two 
biologically active small molecules from our in vivo gene expression 
studies, significantly disrupted SYBR® green binding to DNA. No 
difference was observed between the methylated and unmethylated 
plasmid results, suggesting the compounds were not sensitive to DNA 
methylation status.  
 To verify that the protein was not targeted by our small molecules 
we performed a protein thermal melt curve analysis. When interacting 
with small molecules many proteins resist melting, causing a shift in 
their calculated melt temperature(103). For a nanomolar or micromolar 
small molecule a Tm shift of approximately 5-10oC or 2-5oC, respectively, 
is expected (156, 161). None of the compounds found by our screen 
changed the thermal melting temperature of the MBD2-MBD protein 
(Table 4.3). As a control, and alternate path of investigation, we included 




Figure 4.6: Dose response series re-expression of endogenously methylated 
genes in MCF7 cells  
RNA expression levels of genes known to be sensitive to MBD2 siRNA 
knockdown after escalating dose treatment for 48 hours with small molecules 







Figure 4.7: DNA intercalator completion assay on HTS active compounds 
(A) Fluorescence measured with 50µM small molecule and 10x Sybr® green 
mixed with plasmid DNA. Dotted line represents DMSO control. Ethidium 
bromide (EtBr) served as a positive control. Compounds were run in triplicate 
and are sorted by median fluorescence intensity. (B) Fluorescence results of 




      
 
 
Table 4.3: Protein thermal melt temperatures with MBD2 and small 





our TR FRET assay pilot screen, and some of its family members (see 
chapter 3). Interestingly this family did cause a 1oC shift in melting 
temperature, suggesting they could specifically bind MBD2. 
 
Isothermal Calorimetry Analysis of MBD2-meDNA Active Compounds 
 To obtain more information about the biophysics of our novel 
MBD2-meDNA disrupting small molecules we performed isothermal 
calorimetry (ITC) measurements. We focused experiments on compounds 
KCC-120 and KCC-111 (able to relieve epigenetic repression in vivo), and 
KCC-127, KCC-131, KCC-101 and KCC-107 (not positive in our SYBR 
green displacement assay) and NF449 (positive hit from our pilot 
LOPAC1280™ screen). KCC-102 was also included as a control. Both 
biologically active compounds, KCC-120 and 111, show strong binding to 
methylated DNA with Kd of ~40-50µM and 36µM respectively (Figure 4.8 
and 4.9). This confirms the results of the DNA intercalator assay, 
implicating both of these compounds as DNA binding small molecules. 
KCC-101 and KCC-102 display significant heat release, comparable to 
that observed with KCC-111 and 120, when injected into methylated 
DNA (Figure 4.10 and 4.11). Though their curves did not follow a 
sigmoidal shape the background readings, compound into buffer, were 
<0.05µcal/sec on multiple replicates. Despite not observing saturable 





Figure 4.8: Isothermal calorimetry experiment with KCC-120  





Figure 4.9: Isothermal calorimetry experiment with KCC-111 






Figure 4.10: Isothermal calorimetry experiment with KCC-101  
Small molecule injected into methylated DNA. Curve never saturates but 
significant heat release is present. Background (compound into buffer) showed 





Figure 4.11: Isothermal calorimetry experiment with KCC-102  
Small molecule injected into methylated DNA. Curve never saturates but 
significant heat release is present. Background (compound into buffer) showed 





Figure 4.12: Isothermal calorimetry experiment with KCC-107  
KCC-107 injected into MBD2 protein (upper panel) or methylated DNA (lower 
panel). Experiments were replicated at multiple temperatures and 




Figure 4.13: Isothermal calorimetry experiment with KCC-116  
KCC-116 injected into MBD2 protein (upper panel) or methylated DNA (lower 
panel). Experiments were replicated at multiple temperatures and 
concentrations with similar results. 
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.   
Figure 4.14: Isothermal calorimetry experiment with KCC-131  
KCC-131 injected into MBD2 protein (upper panel) or methylated DNA (lower 
panel). Experiments were replicated at multiple temperatures and 






Figure 4.15: Isothermal calorimetry experiment with KCC-127  
Methylated DNA injected into KCC-127. Experiments were replicated at multiple 
temperatures and concentrations with similar results. KCC-127 was insoluble at 




(Figure 4.7) make it highly likely that both of these compounds bind 
DNA. 
 KCC-107, KCC-116 and KCC-131 do not appear to bind either 
MBD2 protein or DNA in our ITC experiments (Figure 4.12-14). Similarly 
KCC-127 also does not appear to bind DNA (Figure 4.15). KCC-127 and  
107 have strong optical effects at the wavelengths our TR FRET assay is 
read, which could explain why the assay identified them as active hits. 
KCC-116 and KCC-131, however, do not appear to have strong optical 
effects nor bind to either DNA or MBD2 protein in our ITC experiments. 
They may still interact with one of the two components in our assay but 
do so in such a weak manner, Kd > 40µM, that our thermal melt and ITC 
assays do not have the required sensitivity to measure them accurately. 
Interestingly, NF449 binds to MBD2-MBD protein in a dose dependent 
and saturable manner (Figure 4.16). The binding kinetics appear 
complicated, and suggest that there are two binding sites with Kd’s of 
~1.5µM and  ~10µM, with the stronger interaction consistent with our 
pilot TR FRET results.  Because of the complex nature of this binding, 
however, we had a difficult time fitting the results and thus we may be 
underestimating the Kd of this interaction. Control experiments of NF449 
into methylated hairpin DNA or buffer demonstrate no appreciable 
binding or heat release, confirming this appears to be a protein specific 





Figure 4.16: Isothermal calorimetry experiment with NF449 and MBD2-MBD  
NF449 injected into MBD2 protein. Experiment was replicated with similar results 
suggesting two binding events occurring. The Kd of each is calculated at ~1.5µM and 
~10µM with the lower of the two consistent with the TR FRET results. 
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Figure 4.17: Isothermal calorimetry control experiments with NF449 
NF449 injected into methylated DNA (upper) or buffer (lower) panel. Experiments were 
replicated with similar results. 
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Growth Curves With KCC Compounds 
 To make an initial assessment of the toxicity of these compounds 
we evaluated MCF7 breast cancer growth curves in the presence or 
absence of inhibitor. All of the compounds, except KCC-116 and 135, 
shown to interact with DNA by our previous work were quite toxic, with 
IC50’s below 2µM (Figure 4.18A). The compounds which did not interact 
with DNA also did not appear to be toxic (Figure 4.18B). KCC-131 
minimally interfered with cell growth at concentrations up to 50µM, with 
MCF7 growth areas at approximately 64.4% of control (Figure 4.19). 
Further work on KCC-107 and 116 suggested that though they did not 
appear to inhibit cell growth in this experiment, they did have significant 
toxicity at 50µM with 18.5% and 0.3% growth area relative to control 
respectively (Figure 4.19). 
  
Chromatin Immunoprecipitation (ChIP) of Histone Modifications at 
Epigenetically Silenced Regions 
 With evidence that our two biologically active small molecules, 
KCC-120 and KCC-111, bind DNA we sought to show that the 
mechanism of this effect was by relief of epigenetic repression and not a 
simpler reason, such as steric hindrance. ChIP was performed with 
antibodies targeting a number of histone modifications as well as MBD2 





Figure 4.18: MCF7 growth curves in the presence of HTS assay active 
compounds  
(A) Growth curves with compounds that interact with DNA based on the DNA 
intercalator experiment. All appear to be toxic at low micromolar concentration. 
(B) Growth curves with compounds that were inactive in our ITC and DNA 




















(1) Epigenetically silenced with a methylated promoter and low expression. 
(2) Unmethylated promoter with low expression. 
(3) Unmethylated promoter with high expression.  
Unfortunately, due to technical issues, the RNA polymerase II 
precipitation universally showed little enrichment and the results were 
not included in the analysis.  
Interestingly, genes with methylated promoters and low RNA 
expression showed histone changes consistent with a move towards a 
more open chromatin state (Figures 4.20 and 4.21). This included 
increases in histone H3K4 trimethylation and H3K9 acetylation marks 
associated with losses of H3K9 and H3K27 trimethylation. Genes with 
semi methylated or unmethylated promoters and low RNA expression 
displayed histone changes inconsistent with a change in the overall 
chromatin status, or shifted slightly towards a closed chromatin state 
(Figure 4.22 and 4.23). Likewise, genes with high expression, GAPDH 
and ESR1, exhibited states consistent with euchromatin in control 
samples, extremely enriched for H3K4 trimethylation and H3K9 
acetylation, with little change after treatment with either compound 
(Figure 4.24). Surprisingly, the literature describes the gene MTAP as 
having low expression, but the chromatin state in our analysis is more 
consistent with genes of high expression. This discordance should be 
investigated further.  
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A summary view of the changes for all genes indicates that KCC-
111 and KCC-120 effectively alter the histone code at methylated 
promoters, creating a more open chromatin state, while causing little 
effect at non methylated but silent or highly expressed promoter regions 
(Table 4.4). MBD2 ChIP, also shown here, may hint at a possible 
explanation for the mechanism behind this observation. In treated cells 
MBD2 levels appear lower at promoter regions, implying the compounds 
may selectively interfere with epigenetic machinery while allowing 
transcription factors and polymerases to access the site. These results, 
particularly those with the MBD2 protein, need to be repeated to confirm 





Figure 4.20: ChIP results of epigenetically controlled genes treated with KCC-120 
and 111 
Fraction of input for genes with methylated promoters and low RNA expression. RNA 
polymerase and MBD2 precipitations had universally low results. Bar plots on left and 




Figure 4.21 ChIP results of epigenetically controlled promoters treated with KCC-
120 and 111 cont… 
Fraction of input for genes with methylated promoters and low RNA expression. RNA 
polymerase and MBD2 precipitations had universally low results. Bar plots on left and 





Figure 4.22: ChIP results of non-epigenetically controlled genes treated with KCC-
120 and 111  
Fraction of input for genes with semi (RAR Alpha) or unmethylated (TWIST_3) promoters 
and low RNA expression. RNA polymerase and MBD2 precipitations had universally low 
results. Bar plots on left and right for each gene are the same data plotted with different 
y axis scales. TWIST_3 primer set is 1000bp downstream of the first primer set (figure 




Figure 4.23: ChIP results of non-epigenetically controlled genes treated with KCC-
120 and 111 cont...  
Fraction of input for genes with unmethylated promoters and low RNA expression. RNA 
polymerase and MBD2 precipitations had universally low results. Bar plots on left and 
right for each gene are the same data plotted with different y axis scales. MTAP results 
are consistent with a gene that is highly expressed, contradictory to what is published 





Figure 4.24: ChIP results of highly expressed genes with KCC-120 and 111  
Fraction of input for genes with unmethylated promoters and high RNA expression. 
RNA polymerase and MBD2 precipitations had universally low results. Bar plots on left 
and right for each gene are the same data plotted with different y axis scales. Both 





Table 4.4: Summary of chromatin mark changes based on ChIP analysis of MCF7 




A key focus of our lab for a number of years now has been 
identification of novel small molecules to target the epigenetic reader 
protein MBD2. Previous students and fellows focused on cell based re-
expression approaches, similar to the luciferase assay utilized in the 
work described here with the GSTP1 promoter. These methods are very 
effective at finding biologically active compounds, as hits from cell based 
screens must permeate the cell and cause a gene re-expression to be 
found. Unfortunately, finding the target of such small molecules is not 
always trivial, as they could be disrupting any protein in the silencing 
pathway. If one considers that the Mi-2 NuRD complex alone contains at 
least 18 identified components, and these proteins can interact with 
others directly or indirectly, the network of possible targets becomes 
quite large. 
In this work we take an orthogonal approach and choose the 
target, in this case MBD2, and then determine which small molecules 
which inhibit MBD2 in vitro have biological consequences. After a 
rigorous effort we uncovered 2 compounds capable of relieving epigenetic 
repression. To our surprise they targeted DNA and not the protein, and 
were not specific for DNA methylation status. While toxic to all cells 
above 25µM, below this the compounds seem to induce histone changes 
which confer a more open chromatin state at only methylated gene 
promoters. The fact that the activity of these compounds is focused 
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towards methylated promoters, but not unmethylated or highly 
expressed promoters, suggests that their mechanism is likely due to 
disruption of epigenetic repression machinery. This observation also 
rules out nonspecific steric hindrance as a mechanism, as the increased 
RNA expression levels at these locations is consistent with the notion 
that transcription factors and RNA polymerases are still accessing the 
gene.  
These results, coupled with the evidence they relieve epigenetic 
repression and induce gene expression, suggest that KCC-120 and 111 
could hold value as epigenetic targeting agents. A cursory review of the 
literature shows small molecule interaction with DNA is not a novel 
epigenetic target mechanism. All current DNMT1 inhibitors are 
nucleoside mimics, and other groups continue to develop DNA targeting 
agents to disrupt other important cancer related proteins (141, 162). 
Whether the compounds identified in this screen are viable as potential 
drug candidates will require a significant effort to establish safety and 
tolerable toxicity profiles in both cell based and animal models. 
Three other compounds we investigated, KCC-131, KCC-107 and 
KCC-127, remain somewhat difficult to judge. Both clearly inhibit our TR 
FRET based screen, disrupting meDNA-MBD2 interaction. None of the 
follow-up experiments presented here, however, explain the mechanism 
behind the disruption. Since none showed biological activity it would be 
easy to waive them off as false positives. But if one considers the 
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numerous potential reasons why a small molecule may not access its site 
of action in a cell based screen they are harder to dismiss. The evidence 
here suggests that they are likely weakly bound to either DNA or protein. 
Parsing out which will require more sensitive techniques, such as surface 
plasmon resonance or some other novel technology. While this may seem 
like a fruitless venture, even weakly bound small molecules can be 
curated into useful inhibitors in the age of structure aided design. With 
the crystal structure of MBD2-MBD likely to be solved by our 
collaborators in the near future, further investigation into these 
compounds is warranted. 
One of the most surprising outcomes of this effort were the results 
of NF449. This small molecule, identified in our LOPAC1280™ screen, is 
not really that small, weighing in at 1505 Daltons. A brief search on 
pubchem shows it as a frequent hit on many small molecule screens, 32 
hits on 174 total assays or 18.4%, particularly those utilizing DNA 
binding proteins or cell surface receptors (163, 164). The eight negative 
charges it contains likely contribute to this finding, allowing NF449 to 
make numerous favorable interactions with positively charged side 
chains on a protein’s surface. Despite literature suggesting its activity is 
relatively non-specific, we observed reproducible, dose dependent binding 
by ITC and TR FRET assays to MBD2-MBD. We can infer, then, that the 
small molecule binds in a specific manner at a targeted site(s).  
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Very surprisingly, a look at the structure of NF449 shows it 
contains numerous carboxyl like structures. When this is considered 
with the increased melting stability of MBD2 in the presence of formate, 
and that the first condition which yielded diffraction worthy crystals was 
citrate, both carboxyl group containing salts, it should not be surprising 
that a carboxyl like moiety is present in an inhibitor. Given its size and 
nanomolar IC50 for MBD2, it is doubtful the entire NF449 molecule is 
interacting with the protein. It would be interesting, however, to 
determine which part of it is contacting MBD2. This information could 
allow for design of a more specific small molecule. Condition screening 
for co-crystallization of MBD2 and NF449 should also be considered, 
since carboxyl groups have made favorable conditions for previous 
crystallography attempts. This is an especially attractive opportunity as 
co-crystallization of MBD2 and NF449 would allow for structure aided 
design, and supply a DNA free structure of the protein: two birds with 
one stone made of x-rays. 
Despite not discovering an immediately attractive nanomolar small 
molecule inhibitor for MBD2 our HTS effort yielded numerous interesting 
compounds to follow up. With both DNA and protein targeting 
compounds the future is bright for finding a novel class of epigenetic 
reader protein disruptors.  
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4.5  Methods 
Primary Screening for MBD2(MBD)-meDNA Interaction Inhibitors 
 The TR FRET assay was performed as described in chapter 3, 
under the Time Resolved Fluorescence Resonance Energy Transfer (TR-
FRET) heading. The primary screen was run using 4.4µM inhibitor in 
10% DMSO in 1536 well plates with a working volume of 5µL. All plates 
were run by The Scripps Research Institute® in Florida.  
 
UHRF1_SRA protein Purification 
A codon-optimized sequence of the SRA domain of UHRF1 was 
synthesized in a pUC19 plasmid (GenScript USA Inc), and cloned into the 
HIS-tag containing vector pEXP-CT (life Technologies). This vector was 
then transformed into BL-21 Gold cells (Agilent) and cultured at 37C and 
220rpm in an orbital shaker to log phase (OD600 of 1.0) in Terrific Broth 
media. Cultures were then induced for protein expression using 1mM 
Isopropyl β-D-1-thiogalactopyranoside (IPTG, Corning Cellgro) at 24C 
overnight. Bacterial cultures were harvested by centrifugation at 3,000 x 
g for 15 minutes at 4C. Isolated bacterial cells were resuspended in an 
equilibrium buffer consisting of 300 mM NaCl, 50 mM sodium phosphate 
pH 8.0, 5 mM imidazole (Sigma Aldrich), and a protease inhibitor cocktail 
(Roche USA). Lysis was performed by adding 0.75mg/mL lysozyme 
followed by incubation for 30 minutes at room temperature. Additionally, 
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the bacteria mixture was sonicated three times (Sonic Dismembrator 
Model 100, Thermo Fisher Scientific, Waltham, MA) for 10 seconds 
followed by 30 seconds on ice. The mixture was centrifuged at 10,000 x g 
for 30 minutes to remove non-soluble components. IMAC Nickel NTA 
beads (Bio-Rad) beads were prepared by washing with deionized water 
followed by equilibrium buffer. The bacterial supernatant was mixed with 
washed beads and incubated at 4C for 1 hour. The beads were collected 
on a filter column and washed with 5 solutions of increasing imidazole 
concentration (15, 20, 25, 30, 45 mM). The beads were then eluted in 
equilibrium buffer containing 250 mM imidazole and incubated at 4C for 
20 minutes. The eluent was collected by gravity flow and dialyzed into a 
protein storage buffer containing 125mM NaCl, 20 mM Tris pH 7.4, and 
10 mM 2-mercapto ethanol using the Slide-A-Lyzer system (Pierce).  
 
TR-FRET assay for UHRF1_SRA binding to methylated DNA 
TR-FRET assays were performed in an optimized buffer (4% 
glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 125 mM NaCl, 10 
mM Tris HCl, and 0.2% Tween-20) in non-binding, flat-bottom 384-well 
plates (Corning) at a total volume of 20µL. To make a master mix, 
UHRF1_SRA protein was added at 125nM and terbium-labeled antibody 
was added at 5nM (life Technologies). For binding verification 
experiments, FAM-labeled oligonucleotides were added in a dilution 
series, and the reaction mixture was incubated at 4C with shaking for 1 
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hour.  FRET measurements were made on a SpetraMax M5 (Molecular 
Devices), using a excitation of 332 nm and emission read at 515 nm with 
a 50µsec delay and 400µsec integration.  
 
Dose Response Series on Potential MBD2-MBD Inhibitors 
 Dose response curves on the 46 available compounds were 
performed using the TR FRET assay described above in the primary 
screen. Experiments were performed in 1536 well plates and a working 
volume of 5µL. Compounds were run in triplicate from ~10nM to 100µM. 
The assay, data collection and fitting was performed in collaboration with 
The Scripps Research Institute® in Florida. 
 Recombinant protein for MBD family members as made in BL21-
DE3 cells (Agilent). Bacterial codon optimized DNA sequence was 
obtained in a pUC19 vector (GenScript) and cloned into a pEXP-5CT C- 
terminal his tag labeled bacterial expression vector per manufacturer’s 
instructions (Life Technologies). All proteins were expressed in 1L of 
terrific broth (Corning-Cellgro) with 1mM IPTG overnight at 20oC as 
previously described(110). Protein was purified using affinity purification 
as previously described(110) and concentrated to ~100µM (~1mg/mL). 
SP-1 protein (ab82236) was purchased from Abcam and resuspended to 
5µM in 150mM NaCl, 10mM Tris, 1mM TCEP and stored at -80oC. 
 Dose response curves for the MBD family members MBD1-MBD, 
MeCP2-MBD, SP1, MBD2-MBD and UHRF1-SRA were performed in 384 
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well plates as previously described(110) with the following changes: Dose 
response concentrations began at 2000nM and proceeded in a 4 fold 
dilution to 0.12nM in quadruplicates. SP-1, MBD1-MBD and MeCP2-
MBD protein were used at 10nM, MBD2-MBD protein at 25nM, and 
UHRF1-SRA protein at 125nM final concentration in a working volume of 
20µL. 
 
Epigenetically Silenced Gene Re-expression Potential of MBD2 Active 
Compounds 
Endogenous Gene Expression Analysis 
 MCF-7 cells (ATCC) were grown in MEM media (Life Technologies) 
with 10% fetal bovine serum (Gemini Biosciences). LNCaP cells (ATCC) 
were grown in RPMI media (Life Technologies) with 10% fetal bovine 
serum (Gemini Biosciences). Cells were dosed with either 50µM (MCF7) 
or 20µM (LNCaP) of each compound in 0.5% DMSO (Sigma Aldrich) for 
48 hours. Cells were harvested and RNA was extracted via an RNeasy kit 
(Qiagen). RNA was converted to cDNA with the High Capacity cDNA Kit 
(Applied Biosystems) and real time PCR was performed on the 
epigenetically silenced gene Glutathione S Transferase Pi 1 (GSTP1) 
using the primers 5′-GGGACCCTCCAGAAGAGC and 5′-
ACTCACTGGTGGCGAAGACT, and Cox 2 (PTGS2) as previously 
described(63) on a CFX 96 machine (Bio-Rad). Graphs were constructed 
in excel (Microsoft). 
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 Dose response expression was obtained on MCF7 cells cultured as 
described above. Cells were treated for 48 hours with 25µM, 12.5µM, 
6.3µM, or 3.1µM compound. RNA was extracted and real time PCR 
performed as described above. Primers used for this assay included: 
DAPK1: Forward 5’-CTCACGGCATTTCTTCACAA-3’, reverse 5’-
TGGTGAGGCGTGACAGTTTA-3’. 
KLK10: Forward 5’- CCGTTGAAGAGCGAGACCT-3’, reverse 5’- 
CTGCTGATGGCGCAACT-3’. 
 
Luciferase Expression Analysis 
 A ~400bp GSTP1 promoter driving luciferase in plasmid pGL3 
(Promega) was acquired from previous lab members. A CMV promoter 
driving renilla was obtained from Promega. 200ng of the pGL3 plasmid 
and 50ng of the CMV-renilla plasmid were transfected into HEK293 
(ATCC) cells grown in DMEM (Life Technologies) with 10% FBS (Gemini 
Biosciences) using MegaTran 1.0 (OriGene) per manufacturer’s 
instructions in 24-well culture plates (Corning) with biological duplicates. 
8 hours after transfection cells were treated with compound at 50µM, 
20µM, or 5µM. The next morning the media was replaced and 
compounds reapplied. After 48hrs total exposure to small molecule cells 
were lysed and read for luciferase using a Dual-Luciferase® Reporter 
Assay (Promega) following manufacturer’s instructions. P-values were 
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Biophysical Interactions of Active Compounds with meDNA and MBD2 
Protein 
DNA Intercalator Competition Assay 
 The GSTP1 promoter was PCR amplified from the pGL3 (Promega) 
plasmid used for the luciferase expression experiment described above. 
PCR was performed with Platinum™ Taq (Life Technologies) per the 
manufacturer’s instructions with forward primer 
GGGACCCTCCAGAAGAGC and reverse primer 
AGTGCCGTTAGCGGCTTTC, at 58oC annealing temperature and with 40 
cycles. PCR product was run on a 1% agarose gel and purified with a Gel 
Purification Kit (Qiagen). 10ng of eluted product was cloned into a topo 
2.1 vector (Life Technologies) per manufacturer’s instructions. This new 
plasmid was used untreated (unmethylated) or treated with M.Sssi 
enzyme (New England Biolabs) per manufacturer’s instructions 
(methylated). Methylation was confirmed by digesting the M.Sssi plasmid 
with HhaI (New England Biolabs) and HpaII (New England Biolabs) 
restriction enzymes per manufacturer’s instructions. 
 For the intercalator experiment, 100ng of plasmid (either 
methylated or unmethylated) was mixed with 10x Sybr® Reagent (Bio-
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Rad). Compound was added at 500µM, 50µM, 5µM or 0.5µM in a final 
working volume of 20µL in 384 black well low volume plates (Corning). 
Triplicates were performed for each dose. Plates were incubated at room 
temperature with gentle shaking and read on a Spectramax™ M5 plate 
reader with excitation at 488nm and emission read at 520nm. Data was 
analyzed using the open source software R version 3.0.2 (165). 
  
Isothermal Calorimetry Analysis of MBD2-meDNA Active Compounds 
 MBD2-MBD protein, purified as described earlier, was dialyzed 
overnight in 3mL 3000MWCO dialysis cassettes (Thermo Scientific-Pierce 
Net) after they were pre-soaked in buffer for 5 minutes. Protein was 
dialyzed overnight at 4oC with gentle mixing by stir bar in 500mL of ITC 
buffer (125mM NaCl, 1mM MgCl2, 0.5mM EDTA, 0.5mM TCEP, 10mM 
Tris pH 7.4, all from Sigma Aldrich). The following day protein was 
concentration was verified by NanoDrop(Thermo Scientific) to be 0.5-
1mM and flash frozen in liquid nitrogen for storage. For ITC experiments 
the calorimeter was loaded with 2mL of either 50µM MBD2-MBD in 5% 
DMSO or 30µM singly symmetrically methylated hairpin oligo 
(ATGCTmeCGTAGCACTTTTGTGCTAmeCGAGCAT) (IDT, HPLC purified) in 
5% DMSO, depending on whether protein or DNA was being tested. The 
syringe was loaded with compound at 5% DMSO as indicated in table 
4.5, varying between 750µM and 1.5mM. Data was analyzed and fitted 
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using the Origin® software provided by MicroCal, utilizing a chi squared 
statistic to determine optimal fitting curves.  
 
Chromatin Immunoprecipitation (ChIP) of Histone Modifications at 
Epigenetically Silenced Regions 
 ChIP experiments were performed on MCF7 cells (ATCC) at passage 











Table 4.5: Setup for isothermal calorimetry experiments with HTS active 
compounds 
Unless compound was insoluble at high concentration, small molecule was 






10% fetal bovine serum (Gemini Biosciences). Compounds were diluted 
in DMSO to 10mM and eight T-175 flasks (Sarstedt) of cells were treated 
with 15µM KCC-111 (in 0.5% DMSO), 20µM KCC-120 (in 0.5% DMSO) or 
0.5% DMSO (control) for 24 hours in a 37oC incubator and 5% CO2. After 
24 hours cells were washed with PBS (CellGro) and fixed with 20mL of 
freshly mixed 1% formaldehyde (Sigma Aldrich) in PBS for 10 minutes at 
room temperature on a shaker. Fixation was stopped by adding 1mL of 
2.5M glycine and incubating for 5 minutes on a shaker at room 
temperature. The formaldehyde/glycine mixture was aspirated and cells 
were washed with 10mL cold PBS, scraped into 5mL of cold PBS, and 
centrifuged at 1000xg to pellet. Supernatant was removed and pellets 
were resuspended in 8mL of cold PBS, aliquoted equally into 8 Eppendorf 
tubes (USA Scientific), re-pelleted as described above and flash frozen in 
liquid nitrogen and stored at -80oC. ChIP was performed by the 
wonderful Lord Esopi following the protocol listed below, kindly provided 
by Dr. Michael “the Haff” Haffner. Buffers for the protocol below can be 
found in table 4.6. 
 
ChIP PROTOCOL(166): 
1. Defrost cell pellets on ice. 
2. Lyse cell pellet in Lysis Buffer supplemented with protease inhibitor. 
Use 350μl for per T175 flask of 80% confluent LAPC4 or LNCaP. 
3. Sonicate to a fragment size of 300 – 800bp using the Covaris 
sonicator in NGSC. 
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4. Set aside 10μl of the sonicated sample material, label as “input” and 
freeze at -20°C. 
5. Dilute the remaining sample with dilution supplemented with 1 X 
Roche protease inhibitor cocktail EDTA free buffer 1:4. 
6. Prepare Dynabeads protein G (Life technologies) by washing 60 
μl/sample of resuspended bead solution twice with PBS supplemented 
with BSA (5mg/ml). Use a magnetic rack for all wash steps. 
7. Pre-clear samples by incubation the diluted sheared material with 30 
μl bead for 1 h on a spinning wheel in the cold room. 
8. Apply tubes to the magnetic rack, let beads precipitate and transfer 
samples in new pre-chilled tubes.  Discard beads. 
9. Add 5µg of appropriate antibody listed below to the sample and 
incubate over-night in the cold room. 
 MDB2: Bethyl A301-633A 
 H3K27 trimethyl: Millipore 07-449 
 H3K4 trimethyl: Abcam ab-8580 
 H3K9 trimethyl: ab-8898 
 H3K9 acetyl: Millipore 07-352 
 RNA Pol II: Covance MMS-126R-500  
10. Block 30 μl of beads for each sample by incubating in PBS BSA 
(5mg/ml) supplemented with 100 μg/sample of yeast tRNA over-night 
in the cold room. 
11. Next day, add 30 μl of blocked bead solution to the samples and 
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incubate for 4 h. 
12. Apply tubes for 30 sec to magnet to precipitate bead bound 
immunocomplexes. 
13. Sequentially wash beads for 10 min on ice each with TSE1, TSE2, 
TSE3 and TE (pH. 8.0). 
14. After the final wash step, re-suspend beads in 100 µl freshly prepared 
IP Elution Buffer. Vortex to mix and transfer bead mixture into strip 
tubes. 
15. Incubate at 56°C for 15 min, vortex every 5 min, to elute the 
chromatin from the beads. 
16. Collect the supernatant, which contains the DNA. Repeat this step 
again by eluting with another vol. of 100 μl IP Elution Buffer for 15 
min. 
17. Incubate the supernatant containing the DNA at 65°C for 8 h to 
complete the reversal of the formaldehyde cross-links. 
18. Do not forget to de-crosslink the input faction 
19. After de-crosslinking, add 8 µl of RNaseA (10 mg/ml) to each sample 
and mix by inverting tube several times and incubate at 37°C for 2 
hours. 
20. Add 4 µl of Proteinase K (20 mg/ml) to each sample and mix by 
inverting tube several times and incubate at 56°C for 2 hours. 
21. Purify DNA using a Qiagen PCR purification kit, elute sample with 




After extraction real time PCR was performed in duplicates to determine 
enrichment. Briefly, wells were mixed with 10µL of IQ™ Sybr® Green 
Master Mix (Bio Rad), 2µL eluted DNA, forward and reverse primers to a 
final concentration of 400nM (IDT), and water up to a final volume of 
20µL. Primers used for this analysis are listed in table 4.7. Analysis was 
performed on results in excel (Microsoft) using a pseudo ΔΔCq analysis: 
Cq values for each treatment were compared to both their total input 
fraction and DMSO to determine a fraction of input. Results were plotted 
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Chapter 5  
 
Investigation of Whole Genome Methylation Patterns as a Risk 






 Recent evidence suggests that a significant fraction of men with 
prostate cancer undergo unnecessary and life altering therapy. Accurate 
prognosis with pathology is possible if good sampling of the tumor is 
accomplished. This is limited, however, by lack of suitable radiographic 
methods for targeting biopsies. Here we describe an investigation to 
determine whether DNA methylation could assist with Gleason scoring or 
act as an independent predictor of prognosis. 
 We determined whole genome methylation levels using Illumina 
450K Methylation Microarrays and a novel MBD2-MBD protein based 
methylated DNA enrichment technique coupled with next generation 
sequencing. Following a thorough pathology re-review and quality 
control, we obtained 72 samples for this analysis and binned them into 
four groups: normal prostate, low grade (Gleason score ≤6), high grade 
(Gleason score ≥8) and metastasis. Comparing peaks of methylation 
determined by our novel MBD-Seq method and the microarray beta 
values, we found a strong correlation between the two platforms. 
 We next used the microarray beta values to determine the utility of 
DNA methylation marks for predicting Gleason score. After removing 
probes with CpG densities <0.025 and one sample which had its tumor 
and normal samples switched, we calculated the standard deviation 
across all samples for each probe. The top 300, 1000 and 20,000 (5%) of 
total probes based on standard deviation all showed nice separation 
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between low grade and normal prostate tissue versus high grade and 
metastasis by principle components analysis.  
 We queried the top 5% most variable probes for hypermethylated 
regions in only high grade and metastatic samples with a sensitivity of 
≥0.25, and specificity ≥0.9. This yielded 72 probes, 53 genes, which 
comprised a possible biomarker panel predicting Gleason score. 
Visualization of the probes and samples by heat map and application of a 
Tukey Honest Significant Difference and ANOVA statistic showed that the 
panel could significantly predict Gleason score/tumor stage based on 
methylation values with very significant p-values <2.2e-16. Gene 
ontology analysis did not yield any enriched gene signatures. The panel 
performed best when differentiating between metastatic and primary 
cancer or normal prostate tissue, with a difference in methylation levels 
>31%. 
 Here we describe application of a methylated DNA enrichment 
technique and confirm that it can accurately determine methylation 
levels when compared to established methylation microarray technology. 
We also show that DNA methylation could serve as a useful biomarker to 
assist with Gleason scoring and may even act as an independent, or 





Despite many advances prostate cancer remains one the chief 
causes of cancer related morbidity and mortality for men today. Yet, 
autopsy studies have shown that a significant fraction of men will 
ultimately die with but not from the disease. Therefore, a major 
controversy has arisen regarding the potential overtreatment of prostate 
cancer with some studies suggesting that under current clinical 
practices, it is necessary to treat between 5 to 45 men with potentially 
harmful medical procedures in order to prevent a single death from 
prostate cancer(167-170). The heterogeneity of the disease is quite 
remarkable considering that some men will die of recurrent disease 
despite aggressive treatment including surgery or radiation while others 
live with the disease for decades without major morbidity. This 
complexity highlights the need to develop biomarkers that can 
distinguish the men with aggressive disease in order to prevent 
subjecting men with indolent forms of cancer to unnecessary treatments 
that carry potentially life-altering side-effects, such as incontinence and 
impotence(171).  
The greatest utility for prognostic biomarkers occurs in the period 
of initial screening and diagnosis. In this setting molecular biomarkers 
could assist with both the diagnosis of cancer as well as the 
identification of those most likely to behave aggressively. This dual 
approach would help efficiently and correctly allocate aggressive 
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treatment options, such as prostatectomy or radiation therapy, to 
patients with aggressive forms of the disease while saving conservative 
approaches, such as watchful waiting, for those with more indolent 
disease. 
Gleason score is an extremely effective histopathological biomarker 
for assessing the aggressiveness of prostate cancer in the biopsy setting. 
However, it is limited by several factors. First, Gleason score must be 
assessed in tissue specimens and thus cannot be used in the initial 
screening or diagnostic setting until after a biopsy has been completed. 
Since prostate biopsies are done without radiographic guidance with 
respect to tumor location, sampling issues can prevent proper 
assessment of Gleason score. This has been demonstrated by the fact 
that a significant portion of men are “up-graded” with higher Gleason 
scores when they have their radical prostatectomies(172). Second, 
Gleason scores are a somewhat subjective measure, and much literature 
has shown that there is significant inter-observer variability in the 
assessment of Gleason score even by expert pathologists(172). We 
hypothesize that DNA methylation changes associated with Gleason 
grade can be exploited to help reduce the variability associated with 
Gleason scoring for more robust prostate cancer risk stratification. 
The progressive acquisition of somatic genome alterations is a 
defining feature of all human cancers, including prostate cancer. It is 
well established that genetic alterations such as somatic mutations, 
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amplifications, translocations, and deletions are central to the 
development and progression of the disease (173). More recently, 
research has implicated epigenetic processes, such as alterations in DNA 
methylation patterns, as major driving forces of prostate cancer initiation 
and progression (134, 135). Epigenetic changes such as cytosine 
methylation or histone tail modification can activate proto-oncogenes or 
turn off tumor suppressors (134, 174). These changes ultimately yield 
phenotypes resembling those seen with genomic landscape changes: 
either up-regulation of an oncogene or repression of a tumor suppressor 
(175, 176). For prostate cancer, DNA cytosine hypermethylation, capable 
of stably silencing gene expression, appears to occur in multiple waves 
(134). A large initial wave of CpG island hypermethylation takes place 
very early during prostate carcinogenesis; even arising at the stage of 
prostate precursor lesions and is maintained throughout disease 
progression (134). These early CpG island hypermethylation changes are 
already under large-scale clinical and translational development as 
biomarkers for prostate cancer screening and diagnosis.  
Our laboratory and others have also collected preliminary evidence 
suggesting that there are subsequent waves of CpG island 
hypermethylation in prostate cancer (134). These changes may make 
excellent biomarkers for risk stratification as they should correlate with 
disease progression. Presumably these epigenetic alterations also play a 
role in driving disease evolution and should therefore be directly 
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associated with disease severity or aggressiveness (e.g., cancer grade and 
stage) and/or chance of recurrence after treatment depending on which 
changes are present in a particular cancer. Another potentially valuable 
outcome to understanding which genes are driving progression is 
identification of novel genes for targeted therapy. While this is not the 
primary focus of the project it would be an important discovery and 
could lead to new treatments.  
Our lab has developed a novel technology called qMBD-Seq for 
observing genome-wide DNA methylation patterns (the methylome) at 
extremely high resolution (approaching 100bp). In preliminary studies, 
our group and others, using parallel approaches, applied this technology 
to analyze genome-wide DNA methylation patterns in a set of prostate 
cancer cell lines (177),(178). Comparing LNCaP prostate cancer cells to 
normal prostate epithelial cells (PrEC) we found the genes GSTP1 and 
PTGS2 clearly show an increase in methylation in their respective 
promoter regions for LNCaP but not PrEC. This is an expected result as 
both have been widely shown to be hypermethylated in LNCaP cells and 
in prostate cancer cells in human tissues, but almost never methylated 
in PrEC’s or normal prostate tissues (179, 180). This analysis also 
yielded >400 novel genes with hypermethylated promoter regions. 
Bisulfite sequencing performed on some of these regions confirmed the 
results observed in the qMBD-Seq analysis. This illustrates the high 
accuracy and resolution of the method.  
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In this work we compare the methylation patterns found with our 
novel MBD-Seq approach to the well-established Illumina 450K 
Methylation microarray to further confirm the accuracy of our novel 
sequencing method. We then establish that the patterns obtained with 
the 450K array can differentiate between highly aggressive and more 
indolent prostate cancers as a tool to assist with accurate Gleason 




5.3  Results 
Sample Acquisition and Quality Control 
Samples for this project were acquired from three sources, all 
within the Johns Hopkins School of Medicine or Hospital, and consisted 
of organ donor normal, primary and metastasis samples. All material was 
re-reviewed by a single expert uropathologist to confirm both Gleason 
score and other pathology (see methods). Once confirmed by pathology, 
samples underwent a rigorous three step quality control metric before 
being added to the study. First they were analyzed by NanoDrop to 
establish their purity spectroscopically. One sample had an 
OD260/280<1.75 and was rejected. The second step was accurate 
quantitation of double stranded DNA concentration by a fluorescence dye 
assay (Qubit). Numerous samples showed a discrepancy between their 
fluorescence dye and NanoDrop concentration due to impurities 
unaccounted for by the NanoDrop assay. Additional material was 
requisitioned for these samples to ensure enough DNA was available for 
both sequencing and microarray analysis. Unfortunately there was not 
enough metastatic material available to request more and those samples 
were utilized for MBD-Seq only. In the final QC check each sample was 
run on an agarose gel and imaged with ethidium bromide. This served as 
a second verification of DNA quality and also provided an estimate of the 
average DNA size for each sample. All samples, with the exception of 
185 
 
metastasis 19332, contained high quality DNA of average size > 10kb 
(Figure 5.1). Since we acquired only a limited number of metastatic 
samples, and more were difficult to obtain, we opted to include 19332 in 
our study. 
In total 62 samples were collected for sequencing (Table 5.1). Of 
the 22 normal samples, 7 originated from organ donors and the other 15 
from matched normals from primary tissue collected for the study. For 
450K methylation array analysis all 33 primary and normal samples 
were used, but there was only enough material from two metastasis 
samples (19329, 19332). The remaining microarray samples, 9 
metastasis and 5 normals, were previously run on this array by other 
members of the lab and the data was recycled for this project (135, 181). 
 
Library Preparation and Sequencing 
For whole methylome analysis samples were submitted for MBD-
Seq next generation sequencing analysis and processed as described in 
the methods. Briefly, the MBD-Seq approach was developed in our lab 
and utilizes the methylated DNA specific binding properties of the MBD2-
MBD protein fixed to a bead to precipitate methylated DNA from a 
genomic fraction. It is similar to the approach described by Lee et al in 
2010(178). Once methylated DNA fractions are bound to the protein, 




Figure 5.1: Representative agarose gel of samples acquired for MBD-Seq 















protein by denaturation. The eluted product is then submitted for next 
generation sequencing library preparation (see methods). Un-enriched 
genomic DNA, taken prior to methylation specific precipitation, serves as 
a reference for each sample. Fully methylated lambda phage DNA was 
also spiked into each sample at a constant concentration. This was 
intended to serve as an internal standard to assess enrichment efficiency 
and to develop methods to measure the degree of methylation at each 
loci, simplifying inter sample comparison. 
Despite our rigorous QC the initial two batches of samples, 
comprising 8 specimens, showed inconsistent DNA size distributions 
during library preparation when evaluated by Bioanalyzer. After an 
exhaustive investigation we suspect the samples may have contained 
some contaminant that was interfering with linker ligation or nick 
translation. All future samples were pre-treated with a repeat column 
purification to remove the contaminant post pathology review but pre 
QC. We encountered no further obstacles related to DNA quality. 
450K Illumina Microarray analysis was performed on all of the 
normal and primary tissue as well as 2 of the metastatic samples. Raw 
data was obtained by submitting samples to the Sidney Kimmel 
Microarray Core Facility, but processed and analyzed by our group. As 
discussed above, previously acquired raw data was also included to 




Processing of MBD-Seq Raw Data 
MBD-Seq data was processed and aligned to the hg18 genome as 
described in the methods. Post alignment analysis of the lambda phage 
sequences, which we intended to use as an internal standard for 
quantifying the level of methylation across the genome, showed fairly 
variable levels of spike-in. This was especially reflected in the enriched 
fractions (Figure 5.2). This unanticipated result complicated our initial 
approach for determining differentially methylated regions. A number of 
alternative strategies are being pursued to facilitate semi-quantitative 
differential methylation analysis. 
 
Processing and QC of Illumina 450K Methylation Array Data 
In parallel with the sequencing efforts we analyzed the methylation 
status of these same samples on the well-established Illumina 450K DNA 
Methylation Microarray. After obtaining raw fluorescence values, the data 
was normalized and processed as described in the methods using the 
Bioconductor–minfi Data package for R(182). Briefly, the probe type and 
color spaces were preprocessed and subset quantile normalization was 
performed to obtain beta values (fraction methylated) for each probe. The 




Figure 5.2: Representative methylated lambda phage sequencing results 
Number of reads that align to lambda phage are plotted relative to their CpG 
density. (A) Example of a sample which does not appear to have sufficient reads 




provided by the core facility suggesting that our workflow was working as 
intended (Figure 5.3).  
 We opted to move forward with the Minfi analysis beta values as 
they incorporated more rigorous normalization and our control gene 
results more closely matched expected trends. Quality assessment plots 
suggest our sample results are of high quality, following expected trends 
in the distribution of methylation/beta values (Figure 5.4). A cursory 
look at gene promoters previously established as methylated in prostate 
cancer (GSTP1, PTGS2 and APC (not shown)), confirms high beta values 
for all probes in these genes in the cancer samples (Figure 5.5). 
Furthermore, genes with CpG islands and high expression, such as 
GAPDH, displayed lower beta values.  
 We next wanted to confirm that all samples were behaving as 
expected. Principle components analysis (PCA) and multidimensional 
scaling plots (MDS), measuring the distance between sample methylation 
statuses by observing total variability between samples, suggested that 
tumor normal pair 6058 may have been switched (Figure 5.6). The 
Normal for this sample clusters with low grade tumors and the tumor 
clusters with normal samples. To ensure our analysis incorporated only 
high quality data we opted to remove this sample from all analyses. 
Another sample with abnormal results by PCA was 7155. While the 











Figure 5.3: Comparison of core facility and Minfi package beta values 




Figure 5.4: Quality control plots for Minfi package beta values  
(A) Distribution of beta values for all samples. Note that the majority of values 
follow previously reported distributions and are very low (<0.2) or very high 




Figure 5.5: Beta values for representative probes of three control genes 
GSTP1 and PTGS2 are known to have methylated promoters in prostate cancer 
and show increased methylation (beta value) with disease progression. GAPDH is 






Figure 5.6: Principle components analysis with all 450K microarray probes 
Sample 6058 and 7155 are highlighted to show abnormal clustering results. 




normal as switched, like 6058, and we decided to include it in our 
analysis. 
 
Comparison of MBD-Seq and 450K Microarray Data 
A key question entering this project was how the next generation 
sequencing based methylome analysis would compare with an 
established method, in this experiment the 450K Methylation Microarray. 
To answer this question we took the peaks identified by MACs calls in 
our sequencing data that overlapped (>1bp) with regions that contain a 
probe for our 450K methylation microarray and placed them in one of 
three bins: no peak (or p-value < 10-5), low confidence (10-5 < p-value < 
10-10), or high confidence (p-value > 10-10). To evaluate between sample 
groups the bins were formed individually for normal, low grade, and high 
grade samples. The 2 metastatic samples analyzed on both the 
microarray and sequencing platforms were incorporated into the high 
grade group. Comparison of the sequencing p-value bins and microarray 
beta values showed significant correlation (Figure 5.7). A histogram 
(Figure 5.8) confirmed that only a limited number of probes do not 
correlate well with sequencing. While the value of the Pearson correlation 
comparing p-values to fraction methylated is not relevant, it’s 
significance supports our hypothesis that the regions identified by 










Figure 5.8: Comparison of methyl-sequencing peak p-values and microarray 
data 
histogram showing correlation of sequencing peaks with microarray beta values 
for the same samples. Note for (A) surface plots in each column are the same, 













Table 5.2: Pearson coefficients comparing sequencing peak confidences 




Initial Analysis of the 450K Methylation Microarray Data Across All 
Samples. 
Having established that our microarray data was both high quality 
and significantly correlated to our sequencing data we set out to 
determine whether a panel of methylation marks which could assist with 
risk stratification in a Gleason dependent or independent manner. After 
removing one sample pair which was likely inverted (6058 normal and 
tumor) we removed all probes with a CpG density within a 300bp window 
around the probe location of less than 2.5% (Figure 5.9A). This was to 
avoid regions where the methylation status is likely influenced by a very 
limited number of CpG base pairs. This left us with approximately 
311,000 probes. In a sample independent manner we sorted the probes 
based on their standard deviation (Figure 5.9B). We then isolated the top 
1000 or 5% (about 20,000 probes) most variable probes, based on 
standard deviation, for our analysis. We hypothesized these regions 
would provide the best signature for differentiating tissue types. 
We began by comparing the 5% most variable probes by principle 
components analysis (Figure 5.10A). Interestingly, considering just the 
most variable component, PC1, nicely separated the majority of high 
grade and metastatic samples from low grades and metastasis (Figure 





Figure 5.9: CpG density and standard deviation of probes used for finding 
biomarker panel 
(A) Histogram displaying the fraction of total sequence that is a CpG 
dinucleotide after removing sequences with density <0.025. (B) Histogram 
showing standard deviation for all probes with CpG density>0.025 across all 




Figure 5.10: Initial evaluation of the 5% most variable microarray probes 
(A) Principle components analysis and (B) hierarchical clustering of 5% most 
variable probes based on beta value standard deviation across all samples. 
Hierarchical clustering yielded 4 groups, with group 1 comprised only of normal 
tissue, and group 2 comprised of metastatic and high grade tumors, all likely to 
have a poor outcome. 
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and found they created four clusters of samples. The first is enriched for 
normal samples and clusters the farthest from the other three groups. 
This is unsurprising as it would be expected for normal tissue to contain 
similar methylation patterns, likely organized to maximize the function of 
prostate tissue. Group two was the second most unique identified, and 
contained exclusively metastatic and high grade tumors. This was 
extremely exciting as the outcome of patients with these tumors is often 
poor. We also observed that all metastasis with multiple samples from 
the same patient clustered together. A previous report using similar 
samples had the same finding of clonal maintenance across metastases, 
supplying some confidence that our analysis is sound(135). 
 Before attempting to identify a biomarker panel we wanted to query 
whether smaller groups of probes could distinguish between our Gleason 
scores. For this question we created heat maps of the top 1000 (Figure 
5.11) and top 300 (Figure 5.12) most variable probes by standard 
deviation. Similar to the previous results with 20,000 probes, these maps 
clearly organized samples into a group containing predominantly normal 
prostate tissue, and another containing metastatic and high grade 
samples. A number of tumors now appear with the normal group, 
though, and closer analysis revealed that these tumors cluster with their 
respective matched normal tissue. Despite attempting to control for 
tumor content during pathology review, we suspect these cancers have 






Figure 5.11: Heat map of the 1000 most variable microarray probes  




Figure 5.12: Heat map of the 300 most variable microarray probes  




leading to this mal-clustering. Another possibility is that these tumors 
have relatively few DNA methylation alterations compared to their 
matched normal tissue. Another interesting, but expected, observation is 
that the majority of probes selected by our analysis (which is largely 
restricted to regions with high CpG density) appear to gain methylation 
(increase their beta value). Previous reports have established that 
hypermethylation at specific gene promoters is better maintained than 
hypomethylation(135). 
 
Identification of a DNA Methylation Biomarker Panel to Assist with 
Gleason Scoring 
 Confident that our analysis method could identify probes that 
differentiate our samples based on Gleason Score we attempted to 
identify a small panel of markers which could serve as a biomarker for 
Gleason grade. We first approached our question by using simple ANOVA 
comparisons between each probe and all four sample groups. 
Unfortunately this yielded probes which had very stable beta values, but 
not necessarily significantly different in magnitude between groups.  To 
avoid this we returned to our 5% most variable probes and queried them 
in this simple manner: we calculated sensitivities for each probe, looking 
at high grade + metastasis vs. low grade tumors and vice versa. We 
eliminated all probes with sensitivities <0.25. We then calculated a 
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specificity for each probe, and excluded any which was <0.9. 
Interestingly, there were no probes that showed higher beta values for 
low grade samples with the sensitivity and specificity cutoffs we 
employed. Comparing high grade + metastasis to low grade, however, 
yielded 72 probes from 53 unique genes (Table 5.3). A boxplot of beta 
values for all 72 probes based on their sample type shows a significant 
relationship between increasing beta value and Gleason score/tissue 
stage (Figure 5.13A). Principle components analysis on the probes 
identifying these differentially methylated regions (DMRs) clearly 
distinguish metastatic and high grade samples from normal and low 
grades (Figure 5.13B). The one normal tissue outlier, indicated by an 
arrow, belongs to sample 7155 which was flagged earlier as possibly 
switched with its tumor (Figure 5.13B). 
 We next constructed a heat map to further investigate the 
properties of this panel. The heat map separated samples into 2 groups 
(Figure 5.14). The first group is comprised of all metastatic and high 
grade samples, similar to group 2 in our previous heat maps with the 
1,000 and 20,000 most variable probes. The second group for this panel 
contains the remaining samples but accurately sub clusters them based 
on Gleason score with only a couple exceptions (Figure 5.14). To obtain a 
better idea of the biological functions of these genes we performed GSEA 
analysis and found that there was no significant enrichment for any 
pathways or families (data not shown). Analysis of the probes themselves 
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show that the majority locate to CpG islands, with only 14% found in 
gene bodies or intergenic regions (Figure 5.15 A and B). This data is 
supported by the short distances to transcription start sites for each of 
these probes (Figure 5.15C). Since the 450K methylation microarray is 
enriched for probes at promoter regions these results were not 
unexpected. We applied both the Tukey Honest Significant Difference 
and analysis of variance (ANOVA) statistics to confirm the significance of 
our panel, observing p-values of <2.2e16 for the differences in 















Figure 5.13: Initial Analysis of Gleason score differentiating DNA methylation 
biomarker panel  
Initial Analysis of novel DNA methylation biomarker panel distinguishing prostate 
cancer samples based on Gleason score and stage. (A) Boxplot describing beta values 
based on samples and (B) principle components analysis across all 72 probes that 
identify the differentially methylated regions of this panel. The arrow in (B) indicates 






Figure 5.14: Heatmap of 72 probes comprising the Gleason score DNA 
methylation biomarker panel  
Heatmap of all probes in our DNA methylation biomarker panel for 




Figure 5.15: Summary of probe locations in Gleason score DNA methylation 
biomarker panel  
Summary of novel Gleason score differentiating methylation biomarker panel 
probe locations. (A) Pie chart and (B) bar graph describing probe locations. (C) 
Histogram showing distance to transcription start site. The majority of probes 








Figure 5.16: Statistical tests comparing sample groups based on Gleason score 
biomarker panel 
Summary of statistical tests confirming significance of beta value differences observed 






 Since the discovery of PSA in 1979 by Wang et al, and its 
entry into the clinic in the mid 1990’s, the field of urology has benefited 
from one of the best biomarkers ever discovered for cancer diagnosis 
(183). With thorough pathology and staging, accurate prognosis often 
follows diagnosis (184). Unfortunately pathology is always limited by how 
well the biopsy actually samples the tumor. Since no good radiological 
methods for guiding biopsies currently exist, the only direction the 
needle is receiving is luck. To investigate a solution to this problem we 
analyzed DNA methylation levels in prostate cancer and normal tissues 
to show that they could serve as an accurate biomarker to assist with 
Gleason scoring.  
 Application of a novel technology requires a thoughtful and 
meticulous approach to avoid missing biases or misleading results. Here 
we carefully compare methylation levels derived from a microarray and 
sequencing platform from 69 samples to show that our MBD-Seq 
approach is both accurate and reproducible. Highly significant 
correlations between the data, as measured by Pearson coefficients of 
>0.5, provide statistical evidence that our methods are highly correlated 
and thus serve to independently cross-validate each other. The MBD-Seq 
method is especially exciting because of its unbiased approach. Unlike 
microarrays, which are limited by probe locations that are enriched at 
CpG islands and promoters, and bisulfite sequencing, hindered by 
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conversion rate efficiencies and high cost, MBD-Seq provides a bias free 
approach to analyzing the entire methylome. Bioinformatic efforts are 
ongoing to identify differentially methylated regions with these data. 
In the meanwhile, we have gone forward with using the Infinium 
450K microarray data. We initiated this work by removing almost 25% of 
the probes in the array because of low CpG densities. These regions 
contained less than 8 CpG’s within a 300bp window of the CpG that was 
queried. These regions concerned us because they were not 
representative of regions where CpG methylation is likely to have a 
significant impact on transcript levels. Removing them helped us enrich 
our discovery set for regions which likely had biological consequences as 
a result of their methylations status.  
Based on the problems observed with simple ANOVA comparisons 
we used the opposite methodology, and only considered probes with the 
high variability across all samples. After applying some stringent cutoffs 
to specificity we identified a small, 72 probe, panel that could distinguish 
between normal prostate, low grade, high grade, and metastatic samples. 
Despite comparing high grade and metastasis to low grade and vice 
versa, we found only probes with methylation that increased with 
grade/stage were significant. This is also apparent in our heat maps of 
the 72, 300 and 1000 most variable probes (Figures 5.14, 5.11 and 5.12). 
This finding is supported by recent evidence that hypermethylated 
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regions are better conserved in disease progression than hypomethylated 
ones (135, 136, 177).  
 Another interesting observation is detected when looking at the 
confidence intervals and statistical testing (Figure 5.16). Despite 
designing this experiment to find biomarkers that distinguish between 
Gleason scores/stage we achieved a panel which strongly separates 
metastatic samples compared to primary and normal tissue (Figure 5.14 
and 5.16). It is unclear why this occurred, but it would be interesting to 
investigate the genes identified in the biomarker panel more closely to 
determine what biological benefit they may offer a metastatic cell. Such 
an analysis could yield a novel therapeutic target to prevent or slow 
transition to the metastatic state. Another tantalizing observation is 
found with the clustering of high grade tumors, which form two groups: 
one associated with metastasis and another with low grade tumors. It 
would be interesting to determine if the high grades that cluster closer to 
low grade and normal prostate tissue are the patients who end up with 
less disease burden and better outcome despite poor pathological 
prognosis. This clustering could also be explained by stromal 
contamination, and further work will be necessary to investigate both of 
these possibilities. 
 In summary, we show that DNA methylation could be used to 
assist with Gleason scoring and tumor staging and may in fact be an 
independent predictor of risk. We also demonstrate that our novel 
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sequencing method, MBD-Seq, accurately measures whole genome 
methylation levels when compared to current gold standard techniques, 
and offers a bias free view of the methylome. Future students will 
continue work with the MBD-Seq results so that it can be used as a 
discovery set to form a methylation based biomarker panel to help with 
prostate cancer risk stratification. 
  




Sample Acquisition and Quality Control 
All primary fresh frozen samples were from patients treated at 
Johns Hopkins Hospital undergoing radical prostatectomy procedure. 
Collection was done by The Prostate Cancer Biorepository Network 
(PCBN) using pre-established protocols to minimize experiment error due 
to storage or handling(185). Metastasis samples were obtained through 
the Project to Eliminate Lethal Prostate Cancer (PELICAN) rapid autopsy 
program as previously described(186). For all primary samples H&E was 
reviewed by a single expert pathologist to confirm Gleason Grade (either 
6 or >7), percentage of tumor (>70%), absence of cribriform or other 
significant inflammatory markers, or the presence of tumor in normal 
samples. Once this was confirmed 50-100 20µm slices were taken and 
the last slice was also reviewed by the same pathologist to confirm that 
the pathology had not changed while removing material from the block. 
DNA and RNA were extracted from these slices using a DNeasy (Qiagen) 
or RNeasy (Qiagen) kits. Samples were quantitated by NanoDrop (Thermo 
Scientific) and quality was confirmed by assessment with real time PCR 
using primers for ribosomal component 18S and beta globin (BioRad). 
5µg of material was provided for this study. The DNA was requantified by 
NanoDrop. Double stranded DNA concentration was determined using a 
fluorescence based Qubit® assay following manufacturer’s instructions 
(Life Technologies). 100ng of each sample was run on a 2% agarose gel to 
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determine average size and quality. Samples that required re-purification 
due to possible contamination were run through a DNeasy kit (Qiagen) 
per manufacturer’s instructions and eluted into 100µL of elution buffer. 
 
Library Preparation and Sequencing 
 Library preparation for next generation sequencing with ABI 5400 
sequencers (Applied Biosystems) was performed per manufacturer’s 
instructions with the following changes(187). 1-2 µg of DNA was 
sonicated to a modal size of ~150-250bp, and end-repaired using the 
NEBNext SOLiD DNA library preparation kit end-repair module following 
the manufacturer's protocol (New England Biolabs). After column-
purification (using the Qiagen PCR purification kit), SOLiD P1 and P2 
adapters lacking 5' phosphate groups (Life Technologies) were ligated 
using the NEBNext adapter ligation module and column-purified, and 
subjected to isothermal nick-translation by treating with Platinum Taq 
polymerase to remove the nick. The resulting library was divided into two 
fractions, a total input fraction, and an enriched methylated fraction. The 
enriched methylated fraction was then subjected to affinity enrichment of 
methylated DNA fragments by using recombinant C-terminal 6xHis-
tagged MBD2-MBD polypeptides immobilized on magnetic beads, similar 
to previously described methods (177). The resulting enriched methylated 
fraction and the total input fraction were then subjected to library 
amplification using the NEBNext amplification module according to the 
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manufacturer’s protocols, using 4 - 6 cycles for the total input, and 10 - 
12 cycles for the enriched methylated fractions. Library fragments that 
were between 200 - 300bp were size selected after agarose gel 
electrophoresis.  The libraries were then subjected to emulsion PCR and 
bead enrichment following the SOLiD emulsion PCR protocol (Life 
Technologies). The resulting beads were then deposited on the SOLiD 
flow cell and subjected to massively parallel 50bp single-read sequencing 
on a SOLiD v4.0 or 5500XL sequencer to achieve between 10 – 100 
million reads for each sample. Reads were aligned to the reference 
human genome (version hg18) using default settings in Bioscope v1.3 
software, with the exception of the bam output method, which was 
changed to alignment score. Methylated regions were identified as peaks 
of aligned sequencing tags using MACS v1.4 software (188-190), which 
allows identification of peaks after accounting for both global and local 
biases using the total input fraction. 
 For the array 500ng of material was provided to the Sidney Kimmel 
Comprehensive Cancer Center (SKCCC) Microarray core facility. Samples 
were prepared and methylation determined using the Infinium 
HumanMethylation450 BeadChip Kit (Illumina). Raw fluorescence data 
was provided to us by the core facility and processed internally. 
 
Analysis of MBD-Seq Data 




Processing and QC of Illumina 450K Methylation Array Data 
 Raw microarray data was preprocessed and beta values were 
obtained using the Minfi Bioconductor package with their recommended 
settings, including subset quantile normalization(182). All analysis was 
performed using the open source software R v3.0.2(165). 
 
Comparison of MBD-Seq and 450K Microarray Data 
 Beta values provided by the core facility were compared to beta 
values obtained from our own analysis using R v3.0.2(165). Comparison 
between sequencing and microarray data was performed using the 
Bioconductor packages Granges (191), IRanges (191), ggplot2(192), and 
vioplot (193) in R v3.0.2(165). Pearson correlation coefficients were 
calculated using R package Hmisc (194). 
   
Initial Analysis of the 450K Methylation Microarray Data Across All 
Samples. 
 Analysis of 450K microarray beta values was performed using R 
v3.0.2(165) and the following packages: ggplot2 (192), Hmisc (194), 
cluster (195), and gplots (196) 
. Sample 6058, tumor and normal, were removed due to suspicion they 
may have been interchanged. Analysis was performed only on probes 
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with CpG densities >0.025 within a 300bp window surrounding the 
probe location. 
 
Identification of a DNA Methylation Biomarker Panel with 450K 
Methylation Microarray Data 
 All analysis was performed in R v3.0.2(165) with packages Hmisc 
(194), cluster (195), and excel (Microsoft). Only probes with CpG 
densities >0.025 within a 300bp window surrounding the probe location 
were considered. Probes were ordered based on their standard deviation 
across all samples, and the top 300, 1000, or 5% (approximately 20,000) 
probes were analyzed. To determine a biomarker panel we calculated 
sensitivity and specificity for the top 5% most variable probes by 
comparing high grade and metastasis samples to low grade samples. The 
inverse comparison was also performed. We then eliminated all probes 
with a sensitivity<0.25 and specificity<0.9. The resulting panel was 
visualized using R v3.0.2 and significance determined using statistical 
tests Tukey’s Honest Significance Difference test and analysis of variance 
(ANOVA) test on the beta values binned into groups (metastasis, high 
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 Before 2000 chemotherapy, radiation and surgery constituted the 
majority of cancer therapy provided in the United States. In the mid 
2000’s there was a flurry of activity to find small molecule inhibitors of 
specific genomic mutations, such as BCR-Abl, EGFR and Her2. This was 
a consequence of the enormous efforts at Johns Hopkins, Harvard and 
other universities to obtain high coverage sequencing information on 
numerous cancer types. The flood of novel genetic information led to 
identification of numerous novel targets for pharmaceutical companies 
and biotech. Direct inhibition of these mutant proteins significantly 
abrogated many different diseases, offering a new treatment regimen for 
oncologists. Small molecule targeting was often simplified by the fact that 
the genomic alterations created disease specific pockets which normal 
tissue would not harbor(197). This avoided untoward side effects, 
allowing physicians to avoid dose limiting toxicities often seen with 
radiation or chemotherapy.  
 Every story has another side, though, and the bane of targeted 
therapy has and continues to be subsequent selection for a small 
molecule resistant tumor subtypes and regression (197-199). A cursory 
look through the literature shows that in the sea of people who have 
complete and maintained response to targeted therapy, there are oceans 
of patients who suffer recurrence (197-200). Efforts continue in this field 
to find novel, second generation small molecules, to overcome resistance 
or to combine with primary therapy to avoid resistance all together. 
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 As an alternative path to genetic therapy, in this thesis I describe 
targeting of another class of alterations that drive oncogenesis, 
epigenetics. As discussed many times here a number of existing groups 
investigate this problem, with a handful of FDA approved successes. We 
hoped to create an advantage for ourselves by solving the MBD2 crystal 
structure and using it for structure aided design. While this never 
materialized, we did successfully obtain diffracting crystals and collected 
enough data to generate reasonable electron density maps. Given 
previous difficulties by ourselves and others, finding suitable conditions 
for crystallizing a methyl binding domain family member in isolation for 
structure aided design may prove difficult. If a large and high affinity 
small molecule is found it may provide the required stability to produce 
diffraction capable crystals in the absence of DNA. 
 Our efforts to find a novel MBD2 small molecule were not as 
successful as we had originally hoped, but were also not futile. After a 
large HTS effort the lead biologically active compounds identified bound 
to DNA. Though they show specificity by changing chromatin at only 
methylated promoters, DNA binding small molecules are often difficult to 
develop and move into the clinic due to limiting toxicity (201, 202)(203). If 
these compounds are ever used in animals they will likely have to 
undergo significant improvement and structure optimization.  
 Three other small molecules were inactive in all of our assays 
except TR-FRET. KCC-131, KCC-107 and 127 may interact with DNA or 
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protein at high micromolar concentrations, but they may also interfere 
with the assay in some undetermined manner. Regardless, more work 
will be required to ferret out their target if they are going to move forward 
as a lead compound.  
 The final active small molecule, identified in the pilot screen, 
comes from a long and storied history as a therapeutic agent: the 
suramin derivative NF449. This anionic family is often found through 
HTS efforts. The most surprising result shown in this thesis is from the 
isothermal calorimetry data for this compound. NF449 is capable of 
specific, saturable inhibition of MBD2 by both the TR FRET assay and 
ITC. This hints its mechanism is not non-specific, like its structure and 
story in pubchem might suggest. Despite not showing any biological 
benefit in initial cell line screening we should seriously consider this as 
compound for what I refer to as “reverse pharmacophore identification;” 
in that instead of starting with a small compound with weak interaction 
and trying to build in sensitivity we have a large compound with 
moderate to weak interaction and need to shrink it down to the portions 
that interact with protein. The observation that NF449 is littered with 
carboxyl groups is also striking. The mechanism behind MBD2-MBD’s 
preference with this moiety would be very interesting to explain. Maybe 
our crystals in citrate, if somehow coordinated to the protein, will shed 
some light on this question. 
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 The final experiment chapter of my thesis presents the efforts I 
have undertaken to identify DNA methylation alterations tracking with 
prostate cancer aggressiveness. This is very much a work in progress, 
but has already shown tremendous promise. Based on the work here, 
and the group’s previously published data using the MBD2-MBD as a 
tool for enriching methylated DNA, I’m extremely confident the MBD-Seq 
method is accurately identifying methylated regions in the genome. 
Furthermore, preliminary analysis shows that we have identified 
candidate genomic regions with DNA methylation biomarkers which are 
associated with Gleason patterns and tumor stage. Once the sequencing 
data is properly normalized for inter sample comparisons, additional 
biomarkers should also be available given the unbiased nature of these 
data. Of course significant validation and development of a reproducible 
method for querying these regions will still be required.  
 I set out five and a half years ago to make a meaningful 
contribution to the scientific community through careful and diligent 
research while I earned a Ph.D. Using a baseball analogy, I don’t believe I 
hit a home run with the work I’ve accomplished but after suffering 
through a hurricane, two kids and a lot of headache I believe I’ve met the 
goal I set out at the start. I hope the legacy I’ve left behind in this work, 
in the Nelson and Yegnasubramanian labs, and in my publications will 





1. S. Choudhuri, From Waddington's epigenetic landscape to small 
noncoding RNA: some important milestones in the history of 
epigenetics research. Toxicology mechanisms and methods 21, 252 
(May, 2011). 
2. L. Van Speybroeck, From epigenesis to epigenetics: the case of C. 
H. Waddington. Annals of the New York Academy of Sciences 981, 
61 (Dec, 2002). 
3. A. H. Ting, K. M. McGarvey, S. B. Baylin, The cancer epigenome--
components and functional correlates. Genes & development 20, 
3215 (Dec 1, 2006). 
4. A. P. Moczek et al., The role of developmental plasticity in 
evolutionary innovation. Proceedings. Biological sciences / The 
Royal Society 278, 2705 (Sep 22, 2011). 
5. T. H. Scheike, K. K. Holst, J. B. Hjelmborg, Estimating heritability 
for cause specific mortality based on twin studies. Lifetime data 
analysis 20, 210 (Apr, 2014). 
6. J. B. Hjelmborg et al., The Heritability of Prostate Cancer in the 
Nordic Twin Study of Cancer. Cancer epidemiology, biomarkers & 
prevention : a publication of the American Association for Cancer 
Research, cosponsored by the American Society of Preventive 
Oncology,  (May 8, 2014). 
7. I. Locatelli, A. Rosina, P. Lichtenstein, A. I. Yashin, A correlated 
frailty model with long-term survivors for estimating the 
heritability of breast cancer. Statistics in medicine 26, 3722 (Sep 
10, 2007). 
8. I. Locatelli, P. Lichtenstein, A. I. Yashin, The heritability of breast 
cancer: a Bayesian correlated frailty model applied to Swedish 
twins data. Twin research : the official journal of the International 
Society for Twin Studies 7, 182 (Apr, 2004). 
9. W. F. Page, M. M. Braun, A. W. Partin, N. Caporaso, P. Walsh, 
Heredity and prostate cancer: a study of World War II veteran 
twins. The Prostate 33, 240 (Dec 1, 1997). 
10. N. V. Holm, M. Hauge, B. Harvald, Etiologic factors of breast 
cancer elucidated by a study of unselected twins. Journal of the 
National Cancer Institute 65, 285 (Aug, 1980). 
11. K. Murray, The Occurrence of Epsilon-N-Methyl Lysine in 
Histones. Biochemistry 3, 10 (Jan, 1964). 
12. E. L. Gershey, G. Vidali, V. G. Allfrey, Chemical studies of histone 
acetylation. The occurrence of epsilon-N-acetyllysine in the f2a1 




13. M. G. Ord, L. A. Stocken, Phosphate and thiol groups in histone f3 
from rat liver and thymus nuclei. The Biochemical journal 102, 631 
(Feb, 1967). 
14. U. Bedi, V. K. Mishra, D. Wasilewski, C. Scheel, S. A. Johnsen, 
Epigenetic plasticity: A central regulator of epithelial-to-
mesenchymal transition in cancer. Oncotarget 5, 2016 (Apr 30, 
2014). 
15. G. Zhang, S. Pradhan, Mammalian epigenetic mechanisms. IUBMB 
life 66, 240 (Apr, 2014). 
16. A. T. Annunziato, Assembling chromatin: the long and winding 
road. Biochimica et biophysica acta 1819, 196 (Mar-Apr, 2013). 
17. A. J. Bannister, T. Kouzarides, Regulation of chromatin by histone 
modifications. Cell research 21, 381 (Mar, 2011). 
18. C. Sawan, Z. Herceg, Histone modifications and cancer. Advances 
in genetics 70, 57 (2010). 
19. P. Mummaneni, S. S. Shord, Epigenetics and oncology. 
Pharmacotherapy 34, 495 (May, 2014). 
20. B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, R. Pazdur, 
FDA approval summary: vorinostat for treatment of advanced 
primary cutaneous T-cell lymphoma. The oncologist 12, 1247 (Oct, 
2007). 
21. StatBite: FDA oncology drug product approvals in 2009. Journal of 
the National Cancer Institute 102, 219 (Feb 24, 2010). 
22. A. Bird, The essentials of DNA methylation. Cell 70, 5 (Jul 10, 
1992). 
23. K. D. Robertson, P. A. Jones, DNA methylation: past, present and 
future directions. Carcinogenesis 21, 461 (Mar, 2000). 
24. A. M. Deaton, A. Bird, CpG islands and the regulation of 
transcription. Genes & development 25, 1010 (May 15, 2011). 
25. D. M. Messerschmidt, B. B. Knowles, D. Solter, DNA methylation 
dynamics during epigenetic reprogramming in the germline and 
preimplantation embryos. Genes & development 28, 812 (Apr 15, 
2014). 
26. J. M. Sun, V. A. Spencer, H. Y. Chen, L. Li, J. R. Davie, 
Measurement of histone acetyltransferase and histone deacetylase 
activities and kinetics of histone acetylation. Methods 31, 12 (Sep, 
2003). 
27. S. Kangaspeska et al., Transient cyclical methylation of promoter 
DNA. Nature 452, 112 (Mar 6, 2008). 
28. M. Okano, D. W. Bell, D. A. Haber, E. Li, DNA methyltransferases 
Dnmt3a and Dnmt3b are essential for de novo methylation and 
mammalian development. Cell 99, 247 (Oct 29, 1999). 
29. T. P. Jurkowski, R. Shanmugam, M. Helm, A. Jeltsch, Mapping the 
tRNA binding site on the surface of human DNMT2 
methyltransferase. Biochemistry 51, 4438 (Jun 5, 2012). 
231 
 
30. P. O. Esteve et al., Direct interaction between DNMT1 and G9a 
coordinates DNA and histone methylation during replication. 
Genes & development 20, 3089 (Nov 15, 2006). 
31. J. Song, O. Rechkoblit, T. H. Bestor, D. J. Patel, Structure of 
DNMT1-DNA complex reveals a role for autoinhibition in 
maintenance DNA methylation. Science 331, 1036 (Feb 25, 2011). 
32. J. Song, M. Teplova, S. Ishibe-Murakami, D. J. Patel, Structure-
based mechanistic insights into DNMT1-mediated maintenance 
DNA methylation. Science 335, 709 (Feb 10, 2012). 
33. E. Li, T. H. Bestor, R. Jaenisch, Targeted mutation of the DNA 
methyltransferase gene results in embryonic lethality. Cell 69, 915 
(Jun 12, 1992). 
34. J. E. Dodge, B. H. Ramsahoye, Z. G. Wo, M. Okano, E. Li, De novo 
methylation of MMLV provirus in embryonic stem cells: CpG 
versus non-CpG methylation. Gene 289, 41 (May 1, 2002). 
35. D. Meilinger et al., Np95 interacts with de novo DNA 
methyltransferases, Dnmt3a and Dnmt3b, and mediates epigenetic 
silencing of the viral CMV promoter in embryonic stem cells. EMBO 
reports 10, 1259 (Nov, 2009). 
36. X. Cheng, R. M. Blumenthal, Mammalian DNA methyltransferases: 
a structural perspective. Structure 16, 341 (Mar, 2008). 
37. T. Chen, Y. Ueda, S. Xie, E. Li, A novel Dnmt3a isoform produced 
from an alternative promoter localizes to euchromatin and its 
expression correlates with active de novo methylation. The Journal 
of biological chemistry 277, 38746 (Oct 11, 2002). 
38. S. K. Ooi et al., DNMT3L connects unmethylated lysine 4 of histone 
H3 to de novo methylation of DNA. Nature 448, 714 (Aug 9, 2007). 
39. D. Jia, R. Z. Jurkowska, X. Zhang, A. Jeltsch, X. Cheng, Structure 
of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA 
methylation. Nature 449, 248 (Sep 13, 2007). 
40. K. Hata, M. Okano, H. Lei, E. Li, Dnmt3L cooperates with the 
Dnmt3 family of de novo DNA methyltransferases to establish 
maternal imprints in mice. Development 129, 1983 (Apr, 2002). 
41. J. A. Law, S. E. Jacobsen, Establishing, maintaining and modifying 
DNA methylation patterns in plants and animals. Nature reviews. 
Genetics 11, 204 (Mar, 2010). 
42. R. Z. Jurkowska et al., Formation of nucleoprotein filaments by 
mammalian DNA methyltransferase Dnmt3a in complex with 
regulator Dnmt3L. Nucleic acids research 36, 6656 (Dec, 2008). 
43. H. Gowher, K. Liebert, A. Hermann, G. Xu, A. Jeltsch, Mechanism 
of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-
(cytosine-C5)-methyltransferases by Dnmt3L. The Journal of 
biological chemistry 280, 13341 (Apr 8, 2005). 
44. C. Holz-Schietinger, N. O. Reich, The inherent processivity of the 
human de novo methyltransferase 3A (DNMT3A) is enhanced by 
232 
 
DNMT3L. The Journal of biological chemistry 285, 29091 (Sep 17, 
2010). 
45. D. Bourc'his, G. L. Xu, C. S. Lin, B. Bollman, T. H. Bestor, Dnmt3L 
and the establishment of maternal genomic imprints. Science 294, 
2536 (Dec 21, 2001). 
46. K. E. Webster et al., Meiotic and epigenetic defects in Dnmt3L-
knockout mouse spermatogenesis. Proceedings of the National 
Academy of Sciences of the United States of America 102, 4068 
(Mar 15, 2005). 
47. R. Jaenisch, A. Bird, Epigenetic regulation of gene expression: how 
the genome integrates intrinsic and environmental signals. Nature 
genetics 33 Suppl, 245 (Mar, 2003). 
48. S. Laget et al., The human proteins MBD5 and MBD6 associate 
with heterochromatin but they do not bind methylated DNA. PloS 
one 5, e11982 (2010). 
49. R. R. Meehan, J. D. Lewis, S. McKay, E. L. Kleiner, A. P. Bird, 
Identification of a mammalian protein that binds specifically to 
DNA containing methylated CpGs. Cell 58, 499 (Aug 11, 1989). 
50. J. D. Lewis et al., Purification, sequence, and cellular localization 
of a novel chromosomal protein that binds to methylated DNA. Cell 
69, 905 (Jun 12, 1992). 
51. B. Hendrich, A. Bird, Identification and characterization of a family 
of mammalian methyl-CpG binding proteins. Molecular and cellular 
biology 18, 6538 (Nov, 1998). 
52. X. Nan et al., Transcriptional repression by the methyl-CpG-
binding protein MeCP2 involves a histone deacetylase complex. 
Nature 393, 386 (May 28, 1998). 
53. N. L. Adkins, P. T. Georgel, MeCP2: structure and function. 
Biochemistry and cell biology = Biochimie et biologie cellulaire 89, 1 
(Feb, 2011). 
54. P. A. Jones, D. Takai, The role of DNA methylation in mammalian 
epigenetics. Science 293, 1068 (Aug 10, 2001). 
55. L. S. Weaving, C. J. Ellaway, J. Gecz, J. Christodoulou, Rett 
syndrome: clinical review and genetic update. Journal of medical 
genetics 42, 1 (Jan, 2005). 
56. J. Guy, B. Hendrich, M. Holmes, J. E. Martin, A. Bird, A mouse 
Mecp2-null mutation causes neurological symptoms that mimic 
Rett syndrome. Nature genetics 27, 322 (Mar, 2001). 
57. S. H. Cross, R. R. Meehan, X. Nan, A. Bird, A component of the 
transcriptional repressor MeCP1 shares a motif with DNA 
methyltransferase and HRX proteins. Nature genetics 16, 256 (Jul, 
1997). 
58. N. Fujita et al., Methyl-CpG binding domain 1 (MBD1) interacts 
with the Suv39h1-HP1 heterochromatic complex for DNA 
233 
 
methylation-based transcriptional repression. The Journal of 
biological chemistry 278, 24132 (Jun 27, 2003). 
59. I. Ohki et al., Solution structure of the methyl-CpG binding domain 
of human MBD1 in complex with methylated DNA. Cell 105, 487 
(May 18, 2001). 
60. H. F. Jorgensen, I. Ben-Porath, A. P. Bird, Mbd1 is recruited to 
both methylated and nonmethylated CpGs via distinct DNA 
binding domains. Molecular and cellular biology 24, 3387 (Apr, 
2004). 
61. J. Berger, A. Bird, Role of MBD2 in gene regulation and 
tumorigenesis. Biochemical Society transactions 33, 1537 (Dec, 
2005). 
62. Y. Cai et al., The NuRD complex cooperates with DNMTs to 
maintain silencing of key colorectal tumor suppressor genes. 
Oncogene 33, 2157 (Apr 24, 2014). 
63. S. Yegnasubramanian, X. Lin, M. C. Haffner, A. M. DeMarzo, W. G. 
Nelson, Combination of methylated-DNA precipitation and 
methylation-sensitive restriction enzymes (COMPARE-MS) for the 
rapid, sensitive and quantitative detection of DNA methylation. 
Nucleic acids research 34, e19 (2006). 
64. J. C. Hansen et al., DNA binding restricts the intrinsic 
conformational flexibility of methyl CpG binding protein 2 (MeCP2). 
The Journal of biological chemistry 286, 18938 (May 27, 2011). 
65. J. Berger, O. Sansom, A. Clarke, A. Bird, MBD2 is required for 
correct spatial gene expression in the gut. Molecular and cellular 
biology 27, 4049 (Jun, 2007). 
66. B. Hendrich, J. Guy, B. Ramsahoye, V. A. Wilson, A. Bird, Closely 
related proteins MBD2 and MBD3 play distinctive but interacting 
roles in mouse development. Genes & development 15, 710 (Mar 
15, 2001). 
67. O. J. Sansom et al., Deficiency of Mbd2 suppresses intestinal 
tumorigenesis. Nature genetics 34, 145 (Jun, 2003). 
68. X. Le Guezennec et al., MBD2/NuRD and MBD3/NuRD, two 
distinct complexes with different biochemical and functional 
properties. Molecular and cellular biology 26, 843 (Feb, 2006). 
69. X. Nan, P. Tate, E. Li, A. Bird, DNA methylation specifies 
chromosomal localization of MeCP2. Molecular and cellular biology 
16, 414 (Jan, 1996). 
70. B. Hendrich et al., Genomic structure and chromosomal mapping 
of the murine and human Mbd1, Mbd2, Mbd3, and Mbd4 genes. 
Mammalian genome : official journal of the International Mammalian 
Genome Society 10, 906 (Sep, 1999). 
71. M. F. Fraga et al., The affinity of different MBD proteins for a 
specific methylated locus depends on their intrinsic binding 
properties. Nucleic acids research 31, 1765 (Mar 15, 2003). 
234 
 
72. K. L. Ho et al., MeCP2 binding to DNA depends upon hydration at 
methyl-CpG. Molecular cell 29, 525 (Feb 29, 2008). 
73. T. Lang, C. de Chastellier, Fluid phase and mannose receptor-
mediated uptake of horseradish peroxidase in mouse bone 
marrow-derived macrophages. Biochemical and ultrastructural 
study. Biology of the cell / under the auspices of the European Cell 
Biology Organization 53, 149 (1985). 
74. J. M. Cramer et al., Probing the dynamic distribution of bound 
states for methylcytosine-binding domains on DNA. The Journal of 
biological chemistry 289, 1294 (Jan 17, 2014). 
75. E. Wong et al., Mbd4 inactivation increases Cright-arrowT 
transition mutations and promotes gastrointestinal tumor 
formation. Proceedings of the National Academy of Sciences of the 
United States of America 99, 14937 (Nov 12, 2002). 
76. J. C. Shen, W. M. Rideout, 3rd, P. A. Jones, The rate of hydrolytic 
deamination of 5-methylcytosine in double-stranded DNA. Nucleic 
acids research 22, 972 (Mar 25, 1994). 
77. B. Hendrich, U. Hardeland, H. H. Ng, J. Jiricny, A. Bird, The 
thymine glycosylase MBD4 can bind to the product of deamination 
at methylated CpG sites. Nature 401, 301 (Sep 16, 1999). 
78. P. Wu et al., Mismatch repair in methylated DNA. Structure and 
activity of the mismatch-specific thymine glycosylase domain of 
methyl-CpG-binding protein MBD4. The Journal of biological 
chemistry 278, 5285 (Feb 14, 2003). 
79. C. B. Millar et al., Enhanced CpG mutability and tumorigenesis in 
MBD4-deficient mice. Science 297, 403 (Jul 19, 2002). 
80. H. N. Cukier et al., The expanding role of MBD genes in autism: 
identification of a MECP2 duplication and novel alterations in 
MBD5, MBD6, and SETDB1. Autism research : official journal of the 
International Society for Autism Research 5, 385 (Dec, 2012). 
81. S. R. Williams et al., Haploinsufficiency of MBD5 associated with a 
syndrome involving microcephaly, intellectual disabilities, severe 
speech impairment, and seizures. European journal of human 
genetics : EJHG 18, 436 (Apr, 2010). 
82. C. Bronner, G. Fuhrmann, F. L. Chedin, M. Macaluso, S. Dhe-
Paganon, UHRF1 Links the Histone code and DNA Methylation to 
ensure Faithful Epigenetic Memory Inheritance. Genetics & 
epigenetics 2009, 29 (Jan 14, 2010). 
83. G. V. Avvakumov et al., Structural basis for recognition of hemi-
methylated DNA by the SRA domain of human UHRF1. Nature 
455, 822 (Oct 9, 2008). 
84. A. Nishiyama et al., Uhrf1-dependent H3K23 ubiquitylation 
couples maintenance DNA methylation and replication. Nature 
502, 249 (Oct 10, 2013). 
235 
 
85. E. Citterio et al., Np95 is a histone-binding protein endowed with 
ubiquitin ligase activity. Molecular and cellular biology 24, 2526 
(Mar, 2004). 
86. B. Delatte, R. Deplus, F. Fuks, Playing TETris with DNA 
modifications. The EMBO journal 33, 1198 (Jun 2, 2014). 
87. S. K. Ooi, T. H. Bestor, The colorful history of active DNA 
demethylation. Cell 133, 1145 (Jun 27, 2008). 
88. R. R. Meehan, J. D. Lewis, A. P. Bird, Characterization of MeCP2, a 
vertebrate DNA binding protein with affinity for methylated DNA. 
Nucleic acids research 20, 5085 (Oct 11, 1992). 
89. H. F. Jorgensen, K. Adie, P. Chaubert, A. P. Bird, Engineering a 
high-affinity methyl-CpG-binding protein. Nucleic acids research 
34, e96 (2006). 
90. T. Baubec, R. Ivanek, F. Lienert, D. Schubeler, Methylation-
dependent and -independent genomic targeting principles of the 
MBD protein family. Cell 153, 480 (Apr 11, 2013). 
91. R. J. Klose et al., DNA binding selectivity of MeCP2 due to a 
requirement for A/T sequences adjacent to methyl-CpG. Molecular 
cell 19, 667 (Sep 2, 2005). 
92. F. Bedogni et al., Rett syndrome and the urge of novel approaches 
to study MeCP2 functions and mechanisms of action. Neuroscience 
and biobehavioral reviews,  (Mar 2, 2014). 
93. T. Clouaire, J. I. de Las Heras, C. Merusi, I. Stancheva, 
Recruitment of MBD1 to target genes requires sequence-specific 
interaction of the MBD domain with methylated DNA. Nucleic acids 
research 38, 4620 (Aug, 2010). 
94. C. Mayer-Jung, D. Moras, Y. Timsit, Effect of cytosine methylation 
on DNA-DNA recognition at CpG steps. Journal of molecular biology 
270, 328 (Jul 18, 1997). 
95. S. P. Chandler, D. Guschin, N. Landsberger, A. P. Wolffe, The 
methyl-CpG binding transcriptional repressor MeCP2 stably 
associates with nucleosomal DNA. Biochemistry 38, 7008 (Jun 1, 
1999). 
96. R. I. Wakefield et al., The solution structure of the domain from 
MeCP2 that binds to methylated DNA. Journal of molecular biology 
291, 1055 (Sep 3, 1999). 
97. I. Ohki, N. Shimotake, N. Fujita, M. Nakao, M. Shirakawa, Solution 
structure of the methyl-CpG-binding domain of the methylation-
dependent transcriptional repressor MBD1. The EMBO journal 18, 
6653 (Dec 1, 1999). 
98. J. Otani et al., Structural basis of the versatile DNA recognition 
ability of the methyl-CpG binding domain of methyl-CpG binding 
domain protein 4. The Journal of biological chemistry 288, 6351 
(Mar 1, 2013). 
236 
 
99. J. N. Scarsdale, H. D. Webb, G. D. Ginder, D. C. Williams, Jr., 
Solution structure and dynamic analysis of chicken MBD2 methyl 
binding domain bound to a target-methylated DNA sequence. 
Nucleic acids research 39, 6741 (Aug, 2011). 
100. N. Dephoure et al., A quantitative atlas of mitotic phosphorylation. 
Proceedings of the National Academy of Sciences of the United 
States of America 105, 10762 (Aug 5, 2008). 
101. P. V. Hornbeck et al., PhosphoSitePlus: a comprehensive resource 
for investigating the structure and function of experimentally 
determined post-translational modifications in man and mouse. 
Nucleic acids research 40, D261 (Jan, 2012). 
102. C. P. Tan, S. Nakielny, Control of the DNA methylation system 
component MBD2 by protein arginine methylation. Molecular and 
cellular biology 26, 7224 (Oct, 2006). 
103. K. Phillips, A. H. de la Pena, The combined use of the Thermofluor 
assay and ThermoQ analytical software for the determination of 
protein stability and buffer optimization as an aid in protein 
crystallization. Current protocols in molecular biology / edited by 
Frederick M. Ausubel ... [et al.] Chapter 10, Unit10 28 (Apr, 2011). 
104. C. Broennimann et al., The PILATUS 1M detector. Journal of 
synchrotron radiation 13, 120 (Mar, 2006). 
105. A. J. McCoy et al., Phaser crystallographic software. Journal of 
applied crystallography 40, 658 (Aug 1, 2007). 
106. G. M. Sheldrick, Experimental phasing with SHELXC/D/E: 
combining chain tracing with density modification. Acta 
crystallographica. Section D, Biological crystallography 66, 479 
(Apr, 2010). 
107. T. C. Terwilliger, J. Berendzen, Automated MAD and MIR structure 
solution. Acta crystallographica. Section D, Biological 
crystallography 55, 849 (Apr, 1999). 
108. T. C. Terwilliger, Maximum-likelihood density modification. Acta 
crystallographica. Section D, Biological crystallography 56, 965 
(Aug, 2000). 
109. W. Kabsch, Xds. Acta crystallographica. Section D, Biological 
crystallography 66, 125 (Feb, 2010). 
110. N. Wyhs, D. Walker, H. Giovinazzo, S. Yegnasubramanian, W. G. 
Nelson, Time-Resolved Fluorescence Resonance Energy Transfer 
Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG 
Binding Domain Protein 2. Journal of biomolecular screening,  (Mar 
7, 2014). 
111. S. B. Baylin, P. A. Jones, A decade of exploring the cancer 
epigenome - biological and translational implications. Nature 
reviews 11, 726 (Oct, 2011). 
112. A. Y. Lai, P. A. Wade, Cancer biology and NuRD: a multifaceted 
chromatin remodelling complex. Nature reviews 11, 588 (Aug). 
237 
 
113. E. E. Cameron, K. E. Bachman, S. Myohanen, J. G. Herman, S. B. 
Baylin, Synergy of demethylation and histone deacetylase 
inhibition in the re-expression of genes silenced in cancer. Nat 
Genet 21, 103 (Jan, 1999). 
114. J. M. Foulks et al., Epigenetic drug discovery: targeting DNA 
methyltransferases. J Biomol Screen 17, 2 (Jan). 
115. A. Mahindra et al., Latest advances and current challenges in the 
treatment of multiple myeloma. Nat Rev Clin Oncol 9, 135 (Mar). 
116. M. Rius, F. Lyko, Epigenetic cancer therapy: rationales, targets 
and drugs. Oncogene 31, 4257 (Sep 27). 
117. X. Lin, W. G. Nelson, Methyl-CpG-binding domain protein-2 
mediates transcriptional repression associated with 
hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. 
Cancer Res 63, 498 (Jan 15, 2003). 
118. L. K. Su et al., Multiple intestinal neoplasia caused by a mutation 
in the murine homolog of the APC gene. Science 256, 668 (May 1, 
1992). 
119. H. Bazin, E. Trinquet, G. Mathis, Time resolved amplification of 
cryptate emission: a versatile technology to trace biomolecular 
interactions. J Biotechnol 82, 233 (Jan, 2002). 
120. S. M. van den Wildenberg, B. Prevo, E. J. Peterman, A brief 
introduction to single-molecule fluorescence methods. Methods in 
molecular biology (Clifton, N.J 783, 81 (2011). 
121. K. M. Dawson, Activity of SC33428, a novel bishydrazone-bridged 
derivative of 4-demethoxydaunorubicin, against experimental 
tumors in mice. Cancer Res 43, 2880 (Jun, 1983). 
122. T. D. Shenkenberg, D. D. Von Hoff, Mitoxantrone: a new 
anticancer drug with significant clinical activity. Annals of internal 
medicine 105, 67 (Jul, 1986). 
123. T. Blumenthal, T. A. Landers, The inhibition of nucleic acid-
binding proteins by aurintricarboxylic acid. Biochemical and 
biophysical research communications 55, 680 (Dec 10, 1973). 
124. R. Hausmann, G. Schmalzing, P2X1 and P2X2 receptors in the 
central nervous system as possible drug targets. CNS & 
neurological disorders drug targets 11, 675 (Sep, 2012). 
125. S. Oka et al., NMR structure of transcription factor Sp1 DNA 
binding domain. Biochemistry 43, 16027 (Dec 28, 2004). 
126. M. Hulsmann et al., NF449, a novel picomolar potency antagonist 
at human P2X1 receptors. European journal of pharmacology 470, 
1 (May 30, 2003). 
127. S. El-Ajouz, D. Ray, R. C. Allsopp, R. J. Evans, Molecular basis of 
selective antagonism of the P2X1 receptor for ATP by NF449 and 
suramin: contribution of basic amino acids in the cysteine-rich 
loop. British journal of pharmacology 165, 390 (Jan, 2012). 
238 
 
128. R. A. North, Molecular physiology of P2X receptors. Physiological 
reviews 82, 1013 (Oct, 2002). 
129. G. Burnstock, Pathophysiology and therapeutic potential of 
purinergic signaling. Pharmacological reviews 58, 58 (Mar, 2006). 
130. M. Hohenegger et al., Gsalpha-selective G protein antagonists. 
Proceedings of the National Academy of Sciences of the United 
States of America 95, 346 (Jan 6, 1998). 
131. P. Krejci et al., NF449 is a novel inhibitor of fibroblast growth 
factor receptor 3 (FGFR3) signaling active in chondrocytes and 
multiple myeloma cells. The Journal of biological chemistry 285, 
20644 (Jul 2, 2010). 
132. R. D. Team, R: A Language and Environment For Statistical 
Computing. R Foundation For Statistical Computing {ISBN} 3-
900051-07-0,  (2011). 
133. J. H. Zhang, T. D. Chung, K. R. Oldenburg, A Simple Statistical 
Parameter for Use in Evaluation and Validation of High 
Throughput Screening Assays. J Biomol Screen 4, 67 (1999). 
134. S. Yegnasubramanian et al., DNA hypomethylation arises later in 
prostate cancer progression than CpG island hypermethylation 
and contributes to metastatic tumor heterogeneity. Cancer 
research 68, 8954 (Nov 1, 2008). 
135. M. J. Aryee et al., DNA methylation alterations exhibit 
intraindividual stability and interindividual heterogeneity in 
prostate cancer metastases. Science translational medicine 5, 
169ra10 (Jan 23, 2013). 
136. A. P. Feinberg et al., Personalized epigenomic signatures that are 
stable over time and covary with body mass index. Science 
translational medicine 2, 49ra67 (Sep 15, 2010). 
137. K. E. Schuebel et al., Comparing the DNA hypermethylome with 
gene mutations in human colorectal cancer. PLoS genetics 3, 1709 
(Sep, 2007). 
138. S. R. Floyd et al., The bromodomain protein Brd4 insulates 
chromatin from DNA damage signalling. Nature 498, 246 (Jun 13, 
2013). 
139. A. Muller, M. Florek, 5-Azacytidine/Azacitidine. Recent results in 
cancer research. Fortschritte der Krebsforschung. Progres dans les 
recherches sur le cancer 184, 159 (2010). 
140. M. L. Orta et al., 5-Aza-2'-deoxycytidine causes replication lesions 
that require Fanconi anemia-dependent homologous 
recombination for repair. Nucleic acids research 41, 5827 (Jun, 
2013). 
141. A. Gnyszka, Z. Jastrzebski, S. Flis, DNA methyltransferase 
inhibitors and their emerging role in epigenetic therapy of cancer. 
Anticancer research 33, 2989 (Aug, 2013). 
239 
 
142. J. M. Mehnert, W. K. Kelly, Histone deacetylase inhibitors: biology 
and mechanism of action. Cancer J 13, 23 (Jan-Feb, 2007). 
143. C. P. Miller, M. M. Singh, N. Rivera-Del Valle, C. A. Manton, J. 
Chandra, Therapeutic strategies to enhance the anticancer efficacy 
of histone deacetylase inhibitors. Journal of biomedicine & 
biotechnology 2011, 514261 (2011). 
144. F. Carrier, Chromatin Modulation by Histone Deacetylase 
Inhibitors: Impact on Cellular Sensitivity to Ionizing Radiation. 
Molecular and cellular pharmacology 5, 51 (Jan 1, 2013). 
145. J. Yoo, J. H. Kim, K. D. Robertson, J. L. Medina-Franco, Molecular 
modeling of inhibitors of human DNA methyltransferase with a 
crystal structure: discovery of a novel DNMT1 inhibitor. Advances 
in protein chemistry and structural biology 87, 219 (2012). 
146. W. S. Xu, R. B. Parmigiani, P. A. Marks, Histone deacetylase 
inhibitors: molecular mechanisms of action. Oncogene 26, 5541 
(Aug 13, 2007). 
147. A. Fischer, F. Sananbenesi, A. Mungenast, L. H. Tsai, Targeting the 
correct HDAC(s) to treat cognitive disorders. Trends in 
pharmacological sciences 31, 605 (Dec, 2010). 
148. M. Yoshida et al., Histone deacetylase as a new target for cancer 
chemotherapy. Cancer chemotherapy and pharmacology 48 Suppl 
1, S20 (Aug, 2001). 
149. S. R. Haynes et al., The bromodomain: a conserved sequence found 
in human, Drosophila and yeast proteins. Nucleic acids research 
20, 2603 (May 25, 1992). 
150. P. Filippakopoulos et al., Histone recognition and large-scale 
structural analysis of the human bromodomain family. Cell 149, 
214 (Mar 30, 2012). 
151. C. H. Arrowsmith, C. Bountra, P. V. Fish, K. Lee, M. Schapira, 
Epigenetic protein families: a new frontier for drug discovery. 
Nature reviews. Drug discovery 11, 384 (May, 2012). 
152. M. Rosner, M. Hengstschlager, Targeting epigenetic readers in 
cancer. The New England journal of medicine 367, 1764 (Nov, 
2012). 
153. C. Dhalluin et al., Structure and ligand of a histone 
acetyltransferase bromodomain. Nature 399, 491 (Jun 3, 1999). 
154. C. W. Chung, A. W. Dean, J. M. Woolven, P. Bamborough, 
Fragment-based discovery of bromodomain inhibitors part 1: 
inhibitor binding modes and implications for lead discovery. 
Journal of medicinal chemistry 55, 576 (Jan 26, 2012). 
155. P. Bamborough et al., Fragment-based discovery of bromodomain 
inhibitors part 2: optimization of phenylisoxazole sulfonamides. 
Journal of medicinal chemistry 55, 587 (Jan 26, 2012). 
156. P. Filippakopoulos et al., Selective inhibition of BET 
bromodomains. Nature 468, 1067 (Dec 23, 2010). 
240 
 
157. E. Nicodeme et al., Suppression of inflammation by a synthetic 
histone mimic. Nature 468, 1119 (Dec 23, 2010). 
158. I. A. Asangani et al., Therapeutic targeting of BET bromodomain 
proteins in castration-resistant prostate cancer. Nature,  (Apr 23, 
2014). 
159. J. E. Delmore et al., BET bromodomain inhibition as a therapeutic 
strategy to target c-Myc. Cell 146, 904 (Sep 16, 2011). 
160. O. Y. Mian et al., Methyl-binding domain protein 2-dependent 
proliferation and survival of breast cancer cells. Molecular cancer 
research : MCR 9, 1152 (Aug, 2011). 
161. S. N. Krishna et al., A fluorescence-based thermal shift assay 
identifies inhibitors of mitogen activated protein kinase kinase 4. 
PloS one 8, e81504 (2013). 
162. K. Peltonen et al., A targeting modality for destruction of RNA 
polymerase I that possesses anticancer activity. Cancer cell 25, 77 
(Jan 13, 2014). 
163. Y. Chi, K. Gao, H. Zhang, M. Takeda, J. Yao, Suppression of cell 
membrane permeability by suramin: involvement of its inhibitory 
actions on connexin 43 hemichannels. British journal of 
pharmacology,  (Mar 18, 2014). 
164. W. Y. Bolton E, Thiessen PA, Bryant SH, PubChem: Integrated 
Platform of Small Molecules and Biological Activities. Chapter 12 In 
Annual Reports in Computational Chemistry (American Chemical 
Society, 2008), vol. 4. 
165. R. C. T. (2013). (Vienna, Austria, 2013). 
166. M. C. Haffner et al., Androgen-induced TOP2B-mediated double-
strand breaks and prostate cancer gene rearrangements. Nature 
genetics 42, 668 (Aug, 2010). 
167. W. G. e. a. Nelson. M. D. Abeloff, Ed., Clinical Oncology (Elsevier 
Churchill Livingstone, Philadelphia, PA, ed. 3rd, 2004). 
168. A. S. Donn, C. S. Muir, Prostatic cancer: some epidemiological 
features. Bulletin du cancer 72, 381 (1985). 
169. R. Etzioni et al., Overdiagnosis due to prostate-specific antigen 
screening: lessons from U.S. prostate cancer incidence trends. 
Journal of the National Cancer Institute 94, 981 (Jul 3, 2002). 
170. R. R. Gatling, Prostate carcinoma: an autopsy evaluation of the 
influence of age, tumor grade, and therapy on tumor biology. 
Southern medical journal 83, 782 (Jul, 1990). 
171. P. C. Walsh, T. L. DeWeese, M. A. Eisenberger, Clinical practice. 
Localized prostate cancer. The New England journal of medicine 
357, 2696 (Dec 27, 2007). 
172. B. A. Morris, J. D. Robinson, E. Piall, G. W. Aherne, V. Marks, 
Proceedings: Development of a radioimmunoassay for morphine 
having minimal cross-reactivity with codeine. The Journal of 
endocrinology 64, 6P (Jan, 1975). 
241 
 
173. D. Hanahan, R. A. Weinberg, The hallmarks of cancer. Cell 100, 57 
(Jan 7, 2000). 
174. Z. Chen, L. Wang, Q. Wang, W. Li, Histone modifications and 
chromatin organization in prostate cancer. Epigenomics 2, 551 
(Aug, 2010). 
175. S. Yegnasubramanian, W. G. Nelson, in DNA Methylation, 
Epigenetics and Metastasis, M. Esteller, Ed. (Springer publishers, 
The Netherlands, 2005),  pp. 45-79. 
176. J. G. Herman, S. B. Baylin, Gene silencing in cancer in association 
with promoter hypermethylation. The New England journal of 
medicine 349, 2042 (Nov 20, 2003). 
177. S. Yegnasubramanian et al., Chromosome-wide mapping of DNA 
methylation patterns in normal and malignant prostate cells 
reveals pervasive methylation of gene-associated and conserved 
intergenic sequences. BMC genomics 12, 313 (2011). 
178. D. Serre, B. H. Lee, A. H. Ting, MBD-isolated Genome Sequencing 
provides a high-throughput and comprehensive survey of DNA 
methylation in the human genome. Nucleic acids research 38, 391 
(Jan, 2010). 
179. S. Yegnasubramanian et al., Hypermethylation of CpG islands in 
primary and metastatic human prostate cancer. Cancer research 
64, 1975 (Mar 15, 2004). 
180. J. D. Brooks et al., CG island methylation changes near the GSTP1 
gene in prostatic intraepithelial neoplasia. Cancer epidemiology, 
biomarkers & prevention : a publication of the American Association 
for Cancer Research, cosponsored by the American Society of 
Preventive Oncology 7, 531 (Jun, 1998). 
181. M. C. Haffner et al., Tracking the clonal origin of lethal prostate 
cancer. The Journal of clinical investigation 123, 4918 (Nov 1, 
2013). 
182. M. J. Aryee et al., Minfi: a flexible and comprehensive Bioconductor 
package for the analysis of Infinium DNA methylation microarrays. 
Bioinformatics 30, 1363 (May 15, 2014). 
183. A. R. Rao, H. G. Motiwala, O. M. Karim, The discovery of prostate-
specific antigen. BJU international 101, 5 (Jan, 2008). 
184. J. B. Eifler et al., An updated prostate cancer staging nomogram 
(Partin tables) based on cases from 2006 to 2011. BJU international 
111, 22 (Jan, 2013). 
185. M. Darshan et al., Biobanking of derivatives from radical 
retropubic and robot-assisted laparoscopic prostatectomy tissues 
as part of the prostate cancer biorepository network. The Prostate 
74, 61 (Jan, 2014). 
186. W. Liu et al., Copy number analysis indicates monoclonal origin of 




187. S. Yegnasubramanian, Preparation of fragment libraries for next-
generation sequencing on the applied biosystems SOLiD platform. 
Methods in enzymology 529, 185 (2013). 
188. Y. Zhang et al., Model-based analysis of ChIP-Seq (MACS). Genome 
biology 9, R137 (2008). 
189. J. Feng, T. Liu, Y. Zhang, Using MACS to identify peaks from ChIP-
Seq data. Current protocols in bioinformatics / editoral board, 
Andreas D. Baxevanis ... [et al.] Chapter 2, Unit 2 14 (Jun, 2011). 
190. J. Feng, T. Liu, B. Qin, Y. Zhang, X. S. Liu, Identifying ChIP-seq 
enrichment using MACS. Nature protocols 7, 1728 (Sep, 2012). 
191. M. Lawrence et al., Software for computing and annotating 
genomic ranges. PLoS computational biology 9, e1003118 (2013). 
192. H. Wickham. (Springer, NY, 2009). 
193. D. Adler. (2005). 
194. F. J. Harrell, C. Dupont, e. al, F. E. H. Jr, Ed. (2014). 
195. M. Maechler, P. Rousseeuw, A. Struyf, M. Hubert, K. Hornik. 
(2014). 
196. Gregory R. Warnes et al. (2014). 
197. J. Zhang, P. L. Yang, N. S. Gray, Targeting cancer with small 
molecule kinase inhibitors. Nature reviews. Cancer 9, 28 (Jan, 
2009). 
198. G. Qu et al., Combination of BIBW2992 and ARQ 197 is effective 
against erlotinib-resistant human lung cancer cells with the EGFR 
T790M mutation. Oncology reports 32, 341 (Jul, 2014). 
199. L. Formisano et al., Epidermal growth factor receptor activation 
modulates Src-dependent resistance to lapatinib in breast cancer 
models. Breast cancer research : BCR 16, R45 (May 5, 2014). 
200. C. N. Sternberg, D. P. Petrylak, R. A. Madan, C. Parker, Progress in 
the treatment of advanced prostate cancer. American Society of 
Clinical Oncology educational book / ASCO. American Society of 
Clinical Oncology. Meeting 34, 117 (2014). 
201. L. H. Hurley, DNA and its associated processes as targets for 
cancer therapy. Nature reviews. Cancer 2, 188 (Mar, 2002). 
202. R. Palchaudhuri, P. J. Hergenrother, DNA as a target for 
anticancer compounds: methods to determine the mode of binding 
and the mechanism of action. Current opinion in biotechnology 18, 
497 (Dec, 2007). 
203. K. Gurova, New hopes from old drugs: revisiting DNA-binding 









9993 Sherwood Farm Rd 
Owings Mills, MD 21117 






Doctor of Philosophy  Johns Hopkins School of Medicine  June 2014  
  Department of Pharmacology and Molecular Sciences 
 
 
Bachelor of Science (BS) Massachusetts Institute of Technology June 2005 
    Chemical Engineering/Minor in Spanish 
 
 
Academic Research Experience: 
Johns Hopkins School of Medicine-Department of Pharmacology             Baltimore, MD 
Candidate for Ph.D.  Mentor: Dr. William G Nelson 8/2008-Present 
 
Graduate student in the lab of Dr. William Nelson and Dr. Srinivasan 
Yegnasubramanian studying methylated DNA reader proteins. 
 Characterized the biophysics of the MBD2 protein’s interaction with methylated 
DNA by solving the x-ray crystallography structure and through biochemical assays 
such as ITC, fluorescence polarization, thermal melt analysis, and point mutation 
studies 
 Established and maintained collaborations with principle investigators in other 
fields at our institution to bring the techniques of x-ray crystallography and 
pathology to our lab 
 First to apply Time Resolved Fluorescence Energy Transfer (TR-FRET) Technology to 
monitor DNA-protein interactions. Utilized this novel technology to assemble a HTS 
assay to find small molecule inhibitors of our epigenetic reader protein 
 Co-authored a funded R03 grant through the NCI to cover expenses for applying our 
TR FRET HTS assay to their 370,000 compound small molecule library. 
Collaborated with medicinal chemistry and HTS departments at the Scripps 
Institute® to complete the screen. 
 Validated 2 compounds from the HTS screen as able to relieve epigenetic repression 
in multiple cancer cell line models. Manuscript describing the screen and validation 
of these compounds in progress 
 Utilized a novel methylated DNA precipitation strategy with next generation 
sequencing to analyze the prostate cancer methylome for signatures that could 
improve prognosis during biopsy. 
 Authored and awarded a 3-year grant to cover salary and travel related to my work 
with the prostate cancer methylome analysis 
 Served as a peer mentor for the medical school graduate students from 2010-2014, 
assisting more than 200 students in their transition between undergraduate and 




 From 2009-2014 I was responsible for managing 20-40 prospective students each 
year during our department’s interview weekend for the first of three days they were 
visiting Johns Hopkins.  




Massachusetts Institute of Technology                               Cambridge, MA 
BS in Chemical Engineering     Mentor: Dr. Daniel I.C. Wang                8/2001-6/2005 
Received a Bachelor of Science in Chemical Engineering and a minor in Spanish studies 
in June 2005.  
 Chemical Engineering Project Lab- In a small group successfully engineered an 
incubator capable of hypoxic tissue culture growth under sterile conditions. Applied 
incubator to determine the optimal growth conditions for mouse embryonic stem 
cells 
 Biological Engineering Laboratory Course- Expressed, purified and confirmed 
presence of a protein of interest in bacterial and mammalian systems 
 Undergraduate Research Opportunities Program (UROP)-Worked in the 
Biotechnology Process Engineering Center (BPEC) under Dr. Peng Jiao and Dr. 
Daniel I.C. Wang. Successfully engineered a bacterial line with a modular coding 




Ambergen Incorporated                         Watertown, MA 
Research Associate  Supervisor: Dr. Christopher Sears       12/2007-8/2008 
 
Project leader investigating novel means of determining prognosis in colorectal cancer 
(CRC) via a gene expression platform.  
 Analyzed and transitioned gene expression microarray data into a biomarker panel 
for prognosis 
 Designed and implemented a reproducible RNA extraction protocol from paraffin 
tissue after overcoming numerous technical issues related to nucleic acid damage 
from fixing process and age (patent pending) 
 Successfully created a real time PCR based panel for the biomarkers discovered in 
microarray analysis and applied it to a large validation set of RNA extracted from 
FFPE tissue 
 Worked with principle investigator and CSO to guide overall project design in 
meetings and via written progress reports 
 
 
Dana Farber Cancer Institute-Harvard Medical School        Boston, MA  
Research Technician Supervisor: Dr. Levi Garraway & Matthew Meyerson  Full Time 
9/2006-12/2007 
 
Technician in a lab focused on the genomic understanding of melanoma, lung and 
prostate cancer.  
 Independently designed and executed experiments related to confirming whole 
genome sequencing study results from senior lab members using Sequenome® 
technology 
 Helped expand a mass spectrometry based high throughput assay (Oncomap) from 
covering a few hundred to over a thousand known point mutations and applied it to 





MIT Nuclear Research Reactor Lab                         Cambridge, MA 
Senior Reactor Operator/Supervisor         Supervisor: Edward Lau         4/2002-8/2008 
 
Nuclear Regulatory Commission (NRC) licensed reactor supervisor for this 5 megawatt 
research reactor.  
 NRC Licensed Reactor Operator 2002-2004. 
 NRC Licensed Senior Reactor Operator-Supervisor 2004-2008. 
 Responsible for all aspects of the 5MW nuclear reactor while on duty including 
supervision and calculation of startup conditions, monitoring systems for abnormal 
indications and radiation levels.  
 Maintained ultimate responsibility for deciding appropriate responses to 
problems/alarms 
 Maintained expert knowledge of all emergency protocols and procedures in case of 
catastrophic disaster. Had this occurred the supervisor on duty acts as the initial 
incident commander 
 Interacted regularly with other public entities (fire, EMS and police department staff) 
to prepare for incidents 
 Supervised >20 reactor operators to ensure safe operation of the reactor 
 Maintained extensive knowledge of radiation safety and methods for working in high 
radiation fields 
 Regularly assisted lab engineers with routine maintenance of mechanical and 




Clinical Work Experience: 
 
Bel Air Volunteer Fire Company                    Bel Air, MD             
Paramedic  Supervisor: Loren Anderson                      5/2011-Present 
Work as a paid employee for this volunteer service that covers 911 emergencies in the 
town of Bel Air in Harford County Maryland.  
 
Liberty Road Volunteer Fire company                   Randallstown, MD  
Paramedic  Supervisor: James Fulton                9/2010-2/2014 
 
Cataldo Ambulance Service Inc                 Somerville, MA           
Paramedic  Supervisor: Human Resources Department          6/2002-8/2008 
Served in a high public visibility position as ice/court paramedic for two professional 
sports teams (Boston Celtics and Boston Bruins). This required providing medical care 
and transport to players, coaches and league officials while also managing the attention 






Owings Mills Volunteer Fire Company Owings Mills, MD  4/2009-Present 
 Perform the duties of a Paramedic as a volunteer for the fire company’s ambulance 
 
Volunteer EMT-Basic and Chief of MIT-EMS  Cambridge, MA          9/2001-8/2008                                                             
Co-founder and previous chief of the MIT Ambulance Service. Was responsible for 
overseeing all aspects of this basic life support transporting ambulance including 
operations, clinical care and training. Managed between 40-60 EMT providers. Served 
246 
 
as lead contact for MIT administration and other city emergency services (fire, police, 
etc) 
 
New Milford Community Ambulance Corporation, New Milford, CT         6/2001-6/2003 
 
 
Professional Societies:  
Society of Hispanic Professional Engineers Member/Treasurer         2003-2005 
Served as treasurer in 2004. Authored quarterly budget requests for funding from the 
Institute and managed all assets of approximately $2000-$5000. Responsible for 
approving all expenditures and reimbursements. Invested significant time as a 
volunteer in the Jamaica Plains area of Boston working with more than 10 
underprivileged children assisting them with their studies and preparation for the SAT. 
 
Society for Advancement of Chicanos and Native Americans in Science  
Member    2010-Present 





Wyhs N, Walker D, Yegnasubramanian S, Nelson WG. Time Resolved Fluorescence 
Resonance Energy Transfer assay for Discovery of Small molecule Inhibitors of Methyl-
CpG Binding Domain Protein 2.  
J Biomol Screen. 2014 Mar 7. [Epub ahead of print]. 
 
Darshan M, Zheng Q, Fedor HL, Wyhs N, Yegnasubramanian S, Lee P, Melamed J, 
Netto GJ, Trock BJ, De Marzo AM, Sfanos KS. Biobanking of derivatives from radical 
retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate 
cancer biorepository network. Prostate. 2013 Sep 21. 
 
Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler 
W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, 
Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers 
WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial 




Wyhs N, Walker D, Yegnasubramanian S, Nelson WG. Development of a High 
Throughput Small Molecule Discovery Assay for the Epigenetic Target Methyl-CpG 
Binding Domain 2. Invited Presentation at: Prostate Specialized Programs of Research 




Wyhs N, Giovinazzo H, Walker D, Yegnasubramanian S, Nelson WG. Identification of 
Novel Small Molecule Inhibitors of the Epigenetic Reader Protein MBD2. Poster 
Presentation: AACR 105th Annual Conference; 2014 Apr; San Diego, CA. 
 
Wyhs N, Reichert Z, Yegnasubramanian S, Nelson WG. Biophysical Characterization of 
Methyl-CpG Binding Domain 2 Protein. Poster Presented At: Prostate Specialized 







Department of Defense Prostate Cancer Research Program Prostate Cancer Pre-Doctoral 
Training Award        8/2011-8/2014 
Authored and awarded grant worth approximately $100,000 covering my full stipend, 
health insurance and travel expenses. 
 
Undergraduate Leadership Award       5/2005  
Awarded by the Public Service Center to one undergraduate representing inspiration 
and dedication towards community service. 
 
President’s Call to Service Lifetime Achievement                 12/2005 
Awarded by MIT Emergency Medical Service and the President’s Council for 
volunteering over 4000 hours. 
 
Citizen Recognition Award         6/2004  
Highest citizen medal awarded by MIT Police Department for outstanding work for the 
MIT community and public safety. 
 
William L. Stewart, Jr. Award         5/2003  
Recognized for outstanding contributions by an individual student or student 
organization to extracurricular activities. 
 
Multi-Cultural Community Service Award        5/2003 
Awarded by the office of Minority Education for great contributions to the community. 
 
 
Skills and Other Certifications:  
Proficient in Spanish 
Excellent knowledge of excel, word, power point, and basic computer skills. Experienced 
with matlab and R programming languages. 
Hobbies include scuba diving, racquetball, tennis and hiking. 
 
 
 
 
